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SUMMARY
This thesis has been mainly concerned with the determination 
of the overall urinary excretion and the characterization of the 
neutral urinary metabolites of dexamethasone, testosterone,
1-dehydrotestosterone and 19-nortestosterone after intramuscular 
administration to castrated horses (ponies and thoroughbreds).
The percentages of the free and the conjugated steroids were 
determined after solvent extraction and Sephadex LH-20 column 
chromatography. The urinary steroids were extracted by Amberlite 
XAD-2 and separated into glucuronides and sulphoconjugates by 
Sephadex LH-20 chromatography. After enzyme hydrolysis and 
solvolysis respectively, the freed steroids were fractionated on 
Kieselgel H columns and after derivatization as their trimethylsilyl 
ethers or methoxime-trimethylsilyl ethers, were analysed by combined 
gas chromatography-mass spectrometry. The metabolites of 
dexamethasone were identified by microchemical reactions and thin- 
layer chromatography.
Results of the analysis have shown that in general the pathways 
of biotransformation (Phase I and Phase II) of these steroids in the 
equine castrate were qualitatively similar to those previously 
reported for other species. However, the quantitative differences 
in the excretion and relative importance of these pathways are 
attributed to the effects of species difference and the structural 
modification of the steroids. Epimerization at C-17 with stereo­
selective conjugation to glucuronic acid, stereo-selective reduction 
of the A -3-oxo group with the formation of 38,5a-isomer, stereo­
selective conjugation of the 17$-hydroxyl group to sulphuric acid 
and the hydroxylation at C-16 were major transformations observed 
for the anabolic steroids. 6-Hydroxylation and reduction of the 
20-ketone were the major transformations for dexamethasone.
On the basis of the results obtained from this work it is now 
possible to develop specific gc-ms methods to confirm the administration 
of these steroids to horses.
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CHAPTER I
GENERAL INTRODUCTION
1.1 STEROIDS : Their occurrence and significance
A very large group of organic compounds occurring widely in 
animals and plants contain the sterane (III) ring system, which is 
the fully saturated analogue of cyclopentanophenanthrene (II).
These compounds, referred to as the 'steroid' group, are biologically 
derived from six isopentenyl pyrophosphate units (I) and contain 
various modifications of the sterane ring system. The three cyclo- 
hexane rings are designated A, B, C and the cyclopentane ring is 
the D ring (III).
(II) Cyclopentanophenanthrene (III) STERANE 
(Perhydrocyclopentanophenan
Some biologically important groups of substances containing the sterane
ring are sterols, bile acids, the hormones of the adrenal cortex and
sex glands and drugs related to them, the D group of vitamins, cardiac
glycosides (saponins), sapogenins and the arthropod moulting hormones.
C~CH2~  CH2-  0-P206H3
(I) Isopentenyl pyrophosphate
Cholesterol (IV) is the principal sterol of animal tissues and 
has not yet been found in plant tissues.
<HO
(IV) CHOLESTEROL
The de novo synthesis of cholesterol from acetate with the aid of 
acetyl coenzyme A and its foie as a precursor in the biosynthesis 
of the steroid hormones by the endocrine glands is well established.
The steroid hormones are grouped according to their ‘parent 
hydrocarbon and comprise the pregnanes (V) (progestagens and cortico­
steroids), androstanes (VI) (male sex hormones) and oestranes (VII) 
(female sex hormones). Because these compounds possess biochemical, 
clinical and therapeutic significance, their analysis in biological
samples is of considerable interest. The chemical structures of 
most naturally occurring steroids have already been elucidated and 
the pathways for their total synthesis established. An immense 
amount of effort has also been directed towards the syntheses of
(V) PREGNANE (VI) ANDROSTANE (VII) OESTRANE
hormone analogues in the hope that the pharmacological actions would 
be modified, and in favourable examples, the less desirable effects 
suppressed and the more desirable ones enhanced. Many compounds and 
modifications have been synthesised, formulated and tested for this 
purpose, and a variety of pharmaceutical preparations are now available 
for therapeutic use. The steroid hormones relevant to the work described 
in this thesis are the corticosteroids, the androgens and their synthetic 
analogues. A brief review of these steroids, their biotransformation, 
excretion and methods of determination, mainly in the urine, is presented 
below.
1.2. The corticosteroids:
In the vertebrates, corticosteroids are produced by the adrenal 
glands and have profound effects on many metabolic processes. The 
physiological activity of the corticosteroids is related to the intro­
duction of the following groups on the basic C^^-pregnane (V) series:
(a) an a,£-unsaturated ketone group on C-3 (b) a hydroxyl or carbonyl 
group at C-ll (c) a carbonyl group at C-20 adjacent to the primary 
hydroxyl group at C-21 (d) an a-hydroxyl group at C-17. Although each 
of the above substituents are not present in all adrenal steroids, it 
is through variations in one or more of these functional groups that 
different biological activity is conferred on the various compounds.
A convenient, though often misleading, classification of cortico­
steroids gives two main groups: (1) Glucocorticoids which influence
carbohydrate and protein metabolism and have anti-inflammatory effects.
The principal ones are cortisol, cortisone, 11-deoxycortisol, 21-deoxy- 
cortisol, corticosterone and 11-dehydrocorticosterone. (2) Mineralo- 
corticoids which regulate electrolyte balance, especially those of Na+ 
and K+. To this group are assigned aldosterone and 11-deoxycorticosterone. 
The distinction between these two categories is by no means absolute and 
their physiological effects often overlap. The structural formulae of 
some adrenal corticosteroids are shown in Fig. 1, and the major cortico­
steroids present in some animal species are shown in Table 1. Other 
steroid groups produced by the adrenals in some vertebrate species include 
androgens, oestrogens and progestational hormones.
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Fig.I. Structural formulae of some naturally occurring corticosteroids.
Table I. Distribution of adrenal corticosteroids in animals.*
Animal
Corticosteroids
Corticosterone Cortisol Cortisone Aldosterone DOC®
Man y A y v/
Rhesus monkey y y y v/
Rat y y
Rabbit y y
Guinea Pig y y y y
Cat y y
Dog y y
Sheep y y y
Cattle y y y y
Horse y y y
Aves (class) ✓: y
Reptiles (class) y
* Adapted from Sandor et al. (1976) 
© DOC = deoxycorticosterone 
f y. = principal glucocorticoid
Adrenal corticosteroids have been used in medical therapy for 
some time. Because of their important role in the regulation of 
intermediary metabolism, changes in circulating levels of these 
steroids brought about either by disease states or therapeutic 
administrations show pronounced physiological effects. For various 
types of hypoadrenalism, e.g. acute or chronic Addison's disease, 
congenital adrenal hyperplasia (21-hydroxylation defect) and 
panhypopituitarism, replacement steroid therapy is essential to 
maintain normal physiologic state. However, where functional adrenal 
tissue is present, a variety of side-effects and complications such as 
increased catabolism of proteins, increased urinary excretion of 
nitrogen, urea and ketone bodies, hyperglycemia, water retention, 
hypocalcemia and ulcerogenesis may arise during prolonged steroid 
therapy.
Lymphoid tissue exhibits a great sensitivity to glucocorticoids; 
neoplastic lymphoid tissue appears to be inhibited by corticosteroid 
therapy. Another effect of corticosteroid therapy is the relief of 
various conditions associated with tissue inflammation, collagen 
disorders and allergic reactions. Since these disorders may be caused 
by a variety of agents, it is likely that corticosteroids modify not 
the agent but the tissue reactivity to the agents.
Cortisone was first shown to be beneficial in the treatment of 
rheumatoid arthritis (Hench et al. 1949). However, the undesirable side- 
effects observed during therapy led to development of therapeutic agents 
with fewer side effects than occur with the naturally occurring steroids. 
Numerous analogues have been synthesised and tested biologically. Amongst 
the modifications introduced were a double bond at C-l, halogenation at 
C-6 and or C-9, alkylation at CA£, C-6 and C-16, hydroxylation at C-16 
and the formation of a cyclic ketal at the C-16,17 positions. Esteri- 
fication of the analogues prolongs the duration of the pharmacologic 
effects. Although separation of the beneficial anti-inflammatory and 
immunosuppressant effect from the glucocorticoid activity was largely 
unsuccessful, the synthesis of compounds with little or no mineralo- 
corticoid properties represents an important therapeutic advance. These 
efforts have also allowed some deductions concerning the structure-activity 
relationships which are summarised in Table 2. The structural formulae 
of some synthetic corticosteroids are shown in Fig. 2.
Table 2 Structure-activlty relationships of some synthetic 
analogues of corticosteroids.
Substituent
Cortisone
(
11-ketone decreases glucocorticoid 
activity
Prednisone A^ -ll-r ketone slight increase in gluco­
corticoid activity, increased 
AI effect,decreased sodium 
retention
Prednisolone A'*', 11-hydroxy same as above
6a-methyl- and
9a-fluoro-
prednisolone
A'*’, 6a-methyl 
9a-fluoro
sodium retention eliminated, 
increased glucocorticoid 
potency and AI effect.
Dexamethasone
Betamethasone
Triamcinolone
a\  9a-fluoro, 
16-methyl (a or 3) 
16a-hydroxy
as above
Triamcinolone-
acetonide
cyclic ketal at 
*"16-17
as above
Fludrocortisone
2-methylcortisol
9a-fluoro
2a-methyl
greatly increased sodium 
retention, very small increase 
in glucocorticoid and AI effect
© AI = anti-inflammatory
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Fig.2. Structural formulae of some synthetic glucocorticosteroids.
1.3. The androgens and anabolic steroids;
The androgens are secreted mainly by the testes and to a small 
extent by the adrenal cortex. They exert significant control over the 
development of male reproductive organs, the secondary sexual 
characteristics at puberty and also show a generalised anabolic effect 
causing increased protein formation, particularly of muscle and bone.
The androgens are characterised by the presence of functional 
substituents such as the a,/3-unsaturated ketone group on C-3 and the 
17^-hydroxy group on the basic Clg-androstane (VI) series. However, the 
structural requirements for anabolic activity are quite different and 
need not necessarily involve the substituent groups demanded by the sex- 
associated activity (Kochakian 1975).
The most potent naturally occurring androgen, testosterone, is 
produced in males by the testes and in females, small amounts are produced 
by the ovaries. In addition, the testes also produce other androgenic 
compounds, oestrogens and progestagens. Dehydroepiandrosterone and 
small amounts of other androgens are also produced by the adrenal cortex.
The structural formulae of some natural androgens are shown in Fig. 3.
The metabolites of testosterone also exhibit physiological effects at 
cellular level (Baulieu 1970).
Androgens are used in the treatment of male hypogonadism, dwarfism 
and breast cancer. The anabolic effects are used therapeutically to 
accelerate recovery from debility, osteoporosis and nephrosis. Muscular 
development is enhanced by anabolic agents and they have been used to 
promote performance of athletes, racehorses and racing dogs. However, the 
undesirable androgenic side-effects have led to the development of drugs 
with high anabolic and reduced androgenic activity. Anabolic steroids 
are broadly classified into two large groups : (a) androstane derivatives 
and (b) 19-norandrostane (estrane) derivatives. Each group includes:
(i) steroids having a free or esterified 17/1-hydroxy group and (ii) steroids 
having a 17/l-hydroxy-17a-alkyl group. The 17a-alkylated compounds are used 
mainly for oral administration.
Some other modifications include the introduction of double bonds at 
C—1, C-9 and C-ll, methyl groups at C-l, C-2 or C-7, halogenation at C-4 
or C-9 and the replacement of the carbon atom at with oxygen. Ester-
ification of the 17/1-hydroxy group with long chain fatty acids prolongs the 
duration of the pharmacological effects. The structural formulae of some
TESTOSTERONE ANDROSTENEDIONE
H
DIHYDROTESTOSTERONE
O
HO
ANDROSTERONE
O
ANDROSTANEDIOL DEHYDROEPIANDROSTERONE
Fig. 3. Structural formulae of some naturally occurring androgens
synthetic anabolic agents are shown in Fig. 4.
1.4. Biotransformation of steroids :
1.4.1. Glucocorticosteroids :
The biotransformation of endogenous glucocorticoids has been studied 
in almost all species and tissues and in health and disease. It has also 
been comprehensively reviewed (Cope 1972, Edwards and Landon 1976,
Kime 1978, Riad-Fahmy et al. 1979).
Deactivation of the natural corticosteroids is brought about by 
reduction and oxidation including carbon-bond cleavage. Liver is the 
major site of catabolism of steroids and the enzymes concerned are 
located in the sub-cellular fractions. The major pathways of cortisol 
metabolism in man are illustrated in Fig. 5. Reductive metabolism occurs
4
mainly at the A -3-oxo group, with the formation of isomers of tetrahydro 
derivatives, and to a lesser extent at C-20. In oxidative metabolism, 
dehydrogenation occurs at C-ll, hydroxylation occurs mainly at C-6 but 
can also occur at C-l, C-2, C-15 and C-18 and cleavage removes the side 
chain at C-17 to produce the 11-oxygenated 17-oxosteroids. The isolation 
and identification of a new class of acidic metabolites of cortisol 
characterised by the 21-oic acid group has recently been reported in man 
(Bradlow et al. 1973). The major proportion of the metabolites of 
cortisol in man are excreted as conjugates of glucuronic acid and a 
minor proportion as sulphoconjugates (Kornel and Saito 1975, Kornel and 
Miyabo 1975). Extra-hepatic catabolism of glucocorticosteroids has been 
reported to occur in the lung (Sowell et al. 1971), skin (Hsia and Hao 
1966), eye (Ono et al. 1973), pituitary (Brown et al. 1957) and kidney 
(Ganis et al. 1956).
The biotransformation of synthetic glucocorticoids has been studied 
mainly in the rodent and to a lesser extent in man, monkey, dog, horse 
and pig. Some general aspects of the metabolism of systemically given 
glucocorticoids has been reviewed by Seutter (1975). A direct comparison 
of the metabolism of these steroids is difficult because of the effects of 
factors such as the differences in species, dose and mode of administration 
methods of analysis and the nature and degree of substitutents present 
on the molecule. However, as a generalization, the qualitative and
QH
O
1-DEHYDR0TEST0STER0NE
OH
19-N0RTEST0STER0NE
CH.
O
C ]
METHANDIENONE 17a-METHYLTEST0STER0NE
TRIENBOLONE OXANDROLONE
Fig. 4. Structural formulae of some synthetic anabolic steroids
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Fig. 5. Catabolism ofcortisol and cortisone. '
(from Kime 1978)
quantitative differences in the metabolic transformations between the 
natural glucocorticoids and their synthetic analogues are attributed 
to the structural modifications. For the analogues where modifications 
are limited to rings A and/or B (e.g. double bond at Gct~ and/or
9a-fluro groups and the 6a-methyl group) metabolism proceeds 
qualitatively in a manner similar to the endogenous steroids by reduction 
and oxidation including hydroxylation and carbon-bond cleavage (Caspi and 
Pechet 1958, Vermeulen 1959, Bush and Mahesh 1964, Buhler et al. 1965).
The more potent analogues (e.g. dexamethasone, betamethasone, 
triamcinolone and its acetonide) where modifications are present on ring 
D as well as on rings A and B, metabolism proceeds mainly by hydroxylation 
at C-6 and reduction at C-20. The oxidations at C-ll and C-17 have been 
found to be relatively minor pathways in the catabolism of these compounds 
in the rat, dog, monkey and man (Butler and Gray 1970, Haque et al. 1972* 
English et al. 1975, Kupfer and Partridge 1970, Murphy et al. 1964,
Florini et al. 1961, Mineo 1976, Kripalani et al. 1975). A systematic 
study of the metabolic fate of a number of synthetic glucocorticoids 
(having substituents present on rings A, B and D) has been reported in the. 
rat (Mineo 1976, Mineo et al. 1978). Their results have been summarised 
and presented in Table 3.
For the 6a-fluoro-17-deoxy steroids (e.g. fluorocortolone and 
fluocinonide) reduction of the dienone group in the A-ring and defluor­
ination at C-6 followed by hydroxylation at the C-63 position have been 
reported in man and the rat (Gerhards et al. 1971, Takahashi 1972, Kono 
et al. 1973) and at C-6a position in the ram (Lambe 1978). 17a-Hydroxyl- 
ation of 17-deoxymethasone has been reported in the rat by Hyashi et al. 
(1974), 63-hydroxylation in both the rat and dog and 7a-hydroxylation 
in the rat only (Hbrnke et al. 1980).
The in vivo and in vitro oxidation of the primary hydroxyl group 
at C-21, leading to the formation of the 21-oic acid metabolites of some 
synthetic glucocorticoids, has also been reported in man (Gerhards et al. 
1971) and in animals (Gordon and Morrison 1978). A 63-hydroxy-21-oic 
acid metabolite of deoxymethasone has been identified in the dog (HOrnke 
et al. 1980).
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The increased biological potency of the glucocorticoid anaologues 
over cortisol has been attributed to their slower metabolism and 
excretion, decreased binding to plasma proteins and a greater affinity 
for the binding sites in target organs (Glenn et al. 1957, Vermeulen 
1959, Florini and Buyske 1959, Fotherby and James 1972, Mineo 1976, 
Panaretto and Wallace 1978). Extra-hepatic catabolism of synthetic 
corticosteroids has been reported to occur in the skin (Tauber and 
Toda 1976); eye (Sugar et al. 1972, Yamauchi et al. 1975), lung 
(Hartiala et al. 1976), salivary gland (Murphy et al.1964), placenta 
(Blandford and Murphy 1977, Anderson et al. 1977) and the kidney 
(Hayashi et al. 1974).
1.4.2. Androgens and anabolic steroids :
The biotransformation of androgens is more .complex because of the
interconversions and transformations of the metabolites at cellular
level. Liver is again the major site of catabolism and the enzymes
concerned are located in the subcellular fractions (Baulieu 1970,
Baulieu and Robel 1970). Deactivation of the androgens (Fig.5) is
4
brought about mainly by the reduction of the A -3-oxo group with the 
formation of isomeric dihydro and tetrahydro metabolites. In oxidative 
metabolism, dehydrogenation occurs at C-17 and hydroxylation on the 
steroid nucleus can occur at C-2, C-6, C-7, C-15, C-16, C-18 and C-19; 
hydroxylation at C-19 has been shown to be a biosynthetic step in the 
formation of estrogens (Bedrak and Samuels 1969). In vivo epimerization 
of the 17yS-hydroxy group of testosterone has been reported to occur in 
man (Brooks and Giulaini 1964, Wilson and Lipsett 1966), in the bovine 
male castrate (Martin 1966) and in vitro in the rat liver homogenate 
(Kochakian et al. 1952). Conjugation with glucuoronic and sulphuric 
acids occurs mainly at the C-3 and C-17 hydroxyl groups. The major 
extrahepatic site of catabolism is the intestine, but it also occurs in 
the skin, muscle, prostate, brain, placenta and foetal tissues (Baulieu 
and Robel 1970).
The biotransformation of synthetic anabolic steroids has been
studied mainly in man and to a lesser extent in the rodent, rabbit,
steers and the marmoset monkey. In man, the metabolism of androstanes
and estranes proceeds via oxidation of the 17y$-hydroxy group to form the
417-oxosteroids and the reduction of the A -3-oxo group to form the isomeric
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5 a/5£ tetrahydro metabolites in the ratio of 1:1 (Engel et al. 1958).
However, where a 17a-alkyl substituent was present, oxidation of the
l^S-hydroxyl group was inhibited (Levedahl and Samuels 1950, Quincy
and Gray 1967), the ratio of the 5a/5/i tetrahydro metabolites was
altered to about 10:1 (Rongone and Segaloff 1962, Caspi et al. 1965)
and metabolism proceeded mainly by hydroxylation at C-6 (Dtlrbeck and Bilker
1980).
For 4-chlorotestosterone reduction of the 3-oxo group has been 
reported (Castegnaro and Sala 1961). However, where an additional double 
bond in the A-ring and a 17a-methyl group were also present on the 
molecule, (4-chloro-17a-methyl-l-dehydrotestosterone) metabolism proceeded 
via hydroxylation at the 6/3 and 16yi-hydroxy positions and the metabolites 
were excreted in the urine mainly as their glucuronides (Schubert and 
Schuman 1970, Schubert and Wehrberger 1970).
Where the carbon atom in the A-ring (C-2) was replaced with oxygen 
(e.g. Oxandrolone) reduction of the 3-oxo group was inhibited and the 
principal metabolite in the urine was identified as 16yS-hydroxy oxandrolone 
excreted as the glucuronide conjugate (Karim et al. 1973). Where the 
oxygen atom at C-3 was absent (e.g. Orabolin; 17a-ethyl-17</3-hydroxyestra-
4-ene) metabolism proceeded via oxygenation at C-3 with the formation of
4
the A -3-oxo group (17a-ethyl-1^3-hydroxyestra-4-.ene-3-one;Nilevar) and 
the subsequent reduction of the a ,y3-unsaturated ketone to give isomers 
of tetrahydro Nilever in both man and the marmoset monkey. Hydroxylation 
of the 17a-ethyl side chain leading to the formation of an isomer of 
19-nor-17a-pregnanetriol as the major metabolite occurred only in man, 
wheareas hydroxy-Nilever and hydroxytetrahydro Nilever were formed in 
both man and the marmoset monkey (Ward et al. 1977a).
Epimerization of the secondary 17/S-hydroxyl group has been observed 
in the rabbit (Templeton and Kim 1977) and horse (Houghton 1977), and 
of the tertiary 1^-hydroxy group (e.g. methandienone) in man (Macdonald 
et al. 1971, Dtlrbeck and Bilker 1980).
The substituents at C-2, C-4, C-17, the removal of the angular 
methyl group and the conjugated dienone group in the A-ring all cause 
a decrease in the aromatisation of the synthetic anabolic steroid to 
estrogens (Townsley and Brodie 1970).
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The very short half-lives of the natural hormones probably 
account for the lack of their pharmacological effect when given 
orally. More pharmacologically effective preparations of the natural 
hormones are made by intramuscular injections as aqueous suspensions 
or as oily solutions of their esters so that the injectate forms a 
depot from which there is a continuous release of the active compound 
into circulation. This approaches the normal situation of a continuous 
release of steroid from the endocrine gland. After de-esterification 
of this type of compound,metabolism appears to proceed by the normal 
pathways. However for effective oral activity, structural modifications 
are made to the molecule in order to delay its normally rapid metabolism. 
In doing so, alterations in the relative importance of different 
metabolic pathways also occur (Brotherton 1976).
1.5. Excretion of steroids:
The different end products of steroid catabolism are usually made 
more water-soluble by conjugation with polar acidic substances before 
they are eliminated from the organism. The main methods of conjugation 
in the vertebrates are the formation of glycosides of glucuronic acid 
or half esters of sulphuric acid. However, other unusual metabolic 
conjugates of steroids are formed and their excretion and metabolic 
significance havebeen reviewed by Layne (1970).
Endogenous steroids and their synthetic analogues are excreted, 
almost completely, in both urine and faeces mainly as the conjugates and 
in small amounts as free steroids. Steroid metabolites excreted in 
the faeces can arise from the unabsorbed drug after oral administration 
or from their biliary secretion. After biliary secretion into the 
intestine, steroids can be reabsorbed and pass into systemic circulation 
(Hyde and Williams 1957). This enterohepatic recirculation is 
reflected in the smaller amounts of the steroid metabolites found in 
the faeces than initially found in bile (Wyngaarden et al. 1955).
Because excretion is the end compartment of a process that starts 
with biosynthesis or administration and continues through absorption,
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distribution and metabolism in the various body tissues, it follows that 
factors affecting any of these compartments may qualitatively and quantit­
atively affect the excretion of the metabolites. Factors affecting the 
excretion of neutral steroids, specially in the urine, have been reviewed 
by Vestergaard (1978). It has also been reported that in man, renal 
clearances of steroid glucuronides are high, but those of their sulphates 
are low; the latter are mainly eliminated faecally (Hellstrom et al. 1969, 
Bongiovanni and Eberlein 1957).
1.5.1 Excretion of qlucocorticosteroids and their metabolites:
The route of excretion of glucocorticosteroids varies with the
nature of the steroid and the species. Although the adult human excretes
steroid metabolites mainly via the urine,’ fecal excretion during the first
few months of life is about the same level as urinary excretion (Gustafsson
et al. 1968). This is probably related to the high neonatal sulphatase
activity. In man about 75-95% of the administered cortisol metabolites
are rapidly excreted in the urine and about 5-10% in faeces (Fukushima et
al. 1960, Lindblom 1973, Heilman et al. 1954). However, after oral
administration, 20% of the metabolites were excreted in faeces (Cope 1964).
The main metabolites of corticosterone in man are excreted in the urine
(80% in 24 h) and to a lesser extent in the faeces (13-15%). The major
proportion of the metabolites of endogenous corticosteroids are excreted
in human urine as glucuronides and a very small proportion as sulpho-
conjugates (Kornel and Saito 1975). The excretion of cortisol metabolites
in the female baboon was found to be very similar to man (Pepe and
Townsley 1974, Setchell 1976) with 80% of the dose excreted in the urine
within 48 h. The majority of the urinary metabolites (50-55%) were
conjugated with glucuronic acid, about 13-15% appeared as unconjugated
materials and less than 10% was found in the sulphate fraction. After
14administration of C-corticosterone, the percent excretion in urine and 
faeces for different species was - rodents (30% and 70%), dogs (55% and 
32%) and cats (mostly in faeces).
For the synthetic corticosteroids, after oral administration of 
prednisolone to man, almost 90% of the dose was excreted in the urine 
within 48 h (Sandberg and Slaunwhite 1957, Vermeulen 1959). However,
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increasing substitution of the steroid molecule results in a slower 
and less complete urinary excretion and an increase in the excretion 
of unconjugated metabolites (Slaunwhite and Sandberg 1961, Butler and 
Gray 1970, Haque et al. 1972, Sterjenholm and Katz 1975).
After intramuscular administration of prednisolone to rats, about 
50% of the activity was excreted in the faeces and 26% in the urine in 
24- h. Again increasing substitution leads to a slower and less complete 
fecal excretion of the synthetic glucocorticoids in this species 
(Takahashi et al. 1972, Baldratti et al. 1973, English et al. 1975,
Kripalani et al. 1975, Mineo 1976 and 1978). Faecal excretion has 
also been shown to be the major route of elimination of synthetic 
glucocorticoids in the dog and monkey (Kripalani et al. 1975, Martin 
et al. 1975) while the urinary excretion route is favoured ,in sheep 
(Leish and Panaretto 1978, Lambe et al. 1978).
1.5.2. Excretion of androgens, anabolic steroids and their metabolites:
The route of excretion of the androgens and anabolic steroids varies 
with the compound and species. In man about 70-90% of the metabolites 
of radioactive testosterone or androstenedione are excreted in the 
urine within 48 h (Sandberg and Slaunwhite 1956, Zumoff et al. 1971) 
and about 10% in the bile of which half is reabsorbed (Martin et al.
1965). Of the injected dehydroepiandrosterone only about 50% is recovered 
in the urine (Slaunwhite et al. 1967). A major proportion of the 
metabolites of testosterone excreted in the urine are conjugated with 
glucuronic acid. The urinary clearance of androgen glucuronosides is 
high and hence their concentration in plasma is extremely low; the 
reverse is true for androgen sulphates (Vermeulen 1979). After 
administration of testosterone, the urinary excretion of the metabolites 
is favoured in the guinea pig (Burnstein et al. 1955) while the fecal 
excretion is the major route in the rat (Ashmore et al. 1953, Gustafsson et al. 
1968), rabbit'(Taylor and Scratchard 1967), cat (Archer et al. 1965) and 
the bovine male castrate (Gassner et al. 1960).
For the synthetic analogues, after oral administration of testosterone 
undecanoate to man, 40% of the dose was rapidly excreted in the urine 
mainly as conjugates; only 50% of the dose was recovered in the urine 
after 1 week (Horst et al. 1976). Similarly, after oral administration
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of 17a-methyltestosterone (Quincy and Gray 1967), oxandrolone 
(Karim et al. 1973) and a number of 1-dehydroandrostenes (Galletti 
and Gardi 1971), between 4-0-50% of the administered dose was excreted 
in the urine, mainly in the form of conjugated metabolites. However 
very little or no conjugation of the urinary metabolites of methane- 
dienone (173-hydroxy-17a-methylandrost-l,4-diene-3-one) has been 
reported in man (Macdonald et al. 1971, Dtlrbeck et al. 1978,
Frischkorn and Frischkorn 1978) thus reflecting the effect of structural 
substituents on metabolism and excretion.
After intramuscular administration of testosterone oenanthate 
to steers (Gassner et al. 1960) and trienbolone acetate to barren cows 
(Pottier et al. 1975), greater than 80% of the radioactivity was excreted 
in the faeces over a 10-day period. After oral administration of 
17a-methyltestosterone to normal rats, 57-90% of the metabolites were 
excreted in the faeces. However when the bile duct was ligated, 
greater than 90% of the metabolites were excreted in the urine thus 
showing almost complete absorption of the compound from the gastro­
intestinal tract and subsequent excretion into the faeces via entero- 
hepatic circulation. (Hyde et al. 1954-)
1«6. Analysis of steroids in urine:
A variety of techniques are now available for the qualitative 
and quantitative determination of hormonal steroids in biological fluids 
and other preparations. These techniques and their underlying principles 
have been adequately described in a number of articles and text books 
(Eik-Nes 1970, Heftman 1973, Loraine and Bell 1976, Gttrdg and Szasz 
1978, Gray and Oames 1979). The rapid developments in methodology for 
the analysis of hormonal steroids in urine has recently been reviewed by 
Vestergaard 1980).
The analytical procedures described in this thesis can be broadly 
divided into three main groups:
1) Hydrolysis
2) Isolation (including extraction and purification)
3) Determination (sometimes combined with separation)
Although no clear distinction exists between these groups, each 
of these is briefly discussed below.
(1) Hydrolysis of steroids : Steroids are excreted in the urine both
as free (unconjugated) steroids and in the form of conjugates (mainly 
glucuronides and sulphates). Because the analysis of intact steroid 
conjugates presents great difficulties, hydrolysis has been a necessary 
step in almost all work on the extraction and estimation of hormonal 
steroids. Hydrolysis methods therefore must achieve a complete hydrolysis 
of both the major conjugate groups. The vigorous,non-selective 
hydrolysis of urinary steroids by boiling in presence of N-HC1 has 
long been known to be unsatisfactory. It causes decomposition of cortico­
steroids and even the stable C-18 and C-19 steroids are known to produce 
artifacts of dehydration and substitution (Edwards et al. 1953). The 
gentler, relatively selective enzymatic methods do not necessarily 
hydrolyse all conjugated material (Mauvais-Oarvis and Baulieu 1965, 
Vestergaard 1978) and the optimal conditions for complete enzymatic 
hydrolysis of steroid conjugates in buffered urine vary according to the 
type of enzyme preparation and the nature of urine samples.
In an attempt to find mild methods for the extraction and estimation 
of steroids, Edwards et al. (1953) saturated the urine with ammonium 
sulphate^then extracted the conjugated steroids using a mixture of ether- 
ethanol(3:l, v/v); oxidative elimination of the glucuronide conjugates 
was then carried out using the sodium bismuthate procedure (Norymberski 
et al. 1953). Periodic acid has also been used for the oxidative 
elimination of the glucuronide moiety.
Mild acid-catalysed hydrolysis of steroid conjugates at, or near, room 
temperature has also been extensively studied because it cleaves conjugates 
with less artifact formation. Hydrolysis of conjugates by merely standing 
in acidified aqueous solutions has been reported for the hydrolysis of 
aldosterone-18-glucuronide (Dyrenfurth and Venning 1957) and the enol 
glucuronide of androstenedione (Wakabayashi et al. 1961). Solvent-catalysed 
hydrolysis of the urine or a conjugate extract acidified to pH 1 has proved 
to be a useful and popular method for analysis of steroid sulphates . 
Continuous ether solvolysis (Rivera et al. 1967) or static solvolysis using 
conjugate extracts dissolved in acidified (pH 1) organic solvents have been 
described (Burnstein and Lieberman 1958, Kornel 1965, Vihko 1966).
(2) Isolation of steroids : Solvents of different polarities are
generally used for the selective extraction of unconjugated steroids 
from aqueous samples. Recently, the neutral non-ionic Amberlite resins 
(e.g. XAD-2; Bradlow 1968 and 1977) have been shown to be very efficient 
for the extraction of steroids (free and conjugated) from the urine.
These procedures also serve as the initial step in the purification and
concentration of steroids from urine.
With the development of different procedures of chromatography such 
as adsorption and partition chromatography which include column, paper, 
thin layer (tic), gas-liquid (glc) and high performance liquid chromatography 
(HPLC) it became easier not only to separate complex mixtures of steroids, 
but at the same time, when properly undertaken, to give some indication 
about the structural identity of the substances. These techniques have 
been reviewed by Bush (1961), Neher (1964-), Lisboa (1969) and Gdrflg and 
Szasz (1978). Reduction in the complexity of the steroid extracts is 
achieved by careful selection of organic solvent systems, adsorbents, 
gas chromatographic phases and solvent/gas flow rates. Depending on the
analysis procedure chosen,a combination of some of these purification
/
procedures is frequently necessary in order to obtain extracts of 
sufficient purity for quantification and structural elucidation.
(3) Determination of steroids: The individual steroids or groups of
structurally similar steroids can be qualitatively or quantitatively 
determined by selecting an appropriate method. The classical methods 
were based on colorimetry which was the most sensitive procedure at that 
time. Important methods belonging to this group (Table 4-) include the 
method of Kober (1931) for determination of oestrogens, Zimmerman 
(1935) for 17-oxosteroids and Porter and Silber (1950) for gluco­
corticoids.
The reaction of m-dinitrobenzene with 17-oxosteroids was the 
earliest colorimetric method for urinary androgens. The earliest 
procedure for measuring urinary corticosteroids was described by Porter 
and Silber(1950). Since the reagent acts only with the 'dihydroxyacetone' 
side chain, this method measures only cortisol, cortisone, 11-deoxycortisol 
and their tetrahydro metabolites. A variation on this procedure was 
introduced by Norymberski et al. (1953) which measures the so-called 
117-oxogenic1 steroids which possess 17a-20-diol, 17a,20,21-triol or 
17a,21-diol-20-one side chains. These compounds undergo oxidation with 
sodium bismuthate resulting in side chain cleavage and formation of the 
corresponding 17-oxosteroids. Thus an analysis of the 17-oxosteroid
Table 4. Principal colour reactions in steroid analysis
Name of 
reaction
Substrate Reagent Product and 
max.absorption
Kober oestrogens hydroquinone oxidised form
m  aqueous 515-520 nm
H2so^
Zimmerman 17-oxosteroids m-dinitro- 
benzene in 
alkali
(
(
(
NO
520 nm
Porter-Silber 17a,21-diol- 
-20-ones
phenylhydra- 
zine in 
aqueous 
H2so4
phenylhydrazone 
410 nm
Tetrazolium 20,21-ketols Blue
tetrazolium
formazan 
525 nm
content in urine prior to and after bismuthate oxidation affords an 
estimate of these types of adrenal steroids. A further improvement of 
this approach is described by Appleby et al. (1955) where sodium boro- 
hydride reduction precedes bismuthate oxidation. Here the 21-deoxy-20, 
17-ketols are first reduced to 17a,20-diols and therefore, also 
undergo oxidative cleavage to the 17-oxosteroids. Furthermore the 
endogenous 17-oxosteroids are reduced to 17-hydroxysteroids so that 
the final Zimmerman reaction measures only the 17-hydroxycorticosteroids. 
Selective degradations of the various corticosteroid side chains are 
described in a paper by Norymberski (1971).
Ultra-violet spectrometry may be used to quantify steroids
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possessing a suitable chromophore, the A -3-one being the commonest
system. For fluorimetric assays, strong acids or alkali are used to
1 4induce fluorescence with steroids possessing the A -3-oxo, A -3-oxo 
and A^^-3-oxo chromophore (Mattingly 1962, Korenmannl963). While 
the smallest amount of a steroid determined by colorimetry is usually 
about 2-5 vg> as little as 0.1 can be determined by the most 
sensitive fluorimetric methods. Optical methods have often been combined 
with tic separation and this combination has been used in the screening 
and detection of synthetic steroids (Bishara and Oakovljevic 1970,
Dalmau et al. 1973, Byrne et al. 1977, Verbeke 1979).
HPLC is a special branch of column chromatography in which the 
mobile phase is passed down the column under high pressure. The use of 
much smaller particles,of the adsorbent or support increases column 
efficiency and resolution and as a result analysis time can be considerably 
reduced relative to classical column chromatography. The application of 
HPLC to the analysis of steroids has been adequately dealt with by Siggia 
and Dishman (1970) and Fitzpatrick (1978). Detection and quantitation 
of steroids is achieved by fluorimetry or UV spectrometry. Difficulties 
encountered in glc such as low volatility and thermal instability of 
steroids do not affect HPLC which combines the advantages of gas 
chromatography and tic with rapid separation and quantitation (0.01 - 
1 jjig) of steroids. HPLC has been used for separation and quantification 
of synthetic and natural steroids (Satyaswaroop et al. 1977, Tsuei et 
al. 1978, Frischkorn and Frischkorn 1978, Rose and Ousko 1979, Peterson 
et al. 1980).
T he introduction of glc in steroid analysis occurred in 1960 and 
since then has become a standard technique for the determination of 
steroids (Eik-Nes and Horning 1968, Reimendal and SjOval 1971, Clark 
and Wotiz 1973). Glc provides a method for the separation of compounds 
of a volatile mixture according to their relative distribution between 
a stationary liquid phase and a mobile gas phase. The sensitivity of 
the method depends on the type of detector employed - flame ionization 
(0.01 jig), electron capture (0.0001 jug) or a mass spectrometer (0.01 yg). 
The resolution of complex mixtures depends on the sample preparation, 
type of column (packed or open tubular), and the packing material 
(stationary phases) used. Generally incomplete resolution necessitates 
some pre-separation by other chromatographic methods prior to glc.
Modern glc systems allow separation of compounds isothermally or by 
programming at pre-selected rates. Accurately determined retention data 
are of great value in the characterization of steroids and permit the 
determination of total steroid profiles of urine extracts in clinical 
disorders (Horning et al. 1969, Van de Calseyde et al. 1972).
Although some free steroids can be chromatographed, chemical deri­
vatives such as acetates, methyl esters, trimethylsilyl ethers (TMS; 
Luukkainen et al. 1961), Q-methyloxime trimethylsilyl ethers (M0-TMS; 
Gardiner and Horning 1966) and 0-isopropylidenedioxy derivatives 
(Adlercreutz et al. 1967) are necessary to overcome the problems 
associated with the low volatility and high polarity of steroids. Cortico­
steroids with the C-17 side chain undergo thermal decomposition on glc 
columns (VandenHeuvel and Horning 1960). To stabilize the side chain, 
various derivatives such as acetonides (Bailey 1967), cyclic boronates 
(Anthony et al. 1969) siliconide-dimethylsilyl ethers (Kelly 1969) and 
M0-TMS (Thenot and Horning, 1972a and b) are used. For steroids without 
natural electrophores a variety of halogen-substituted reagents are 
used to prepare electron-capturing derivatives (Blau and King 1977,
Poole, et al. 1,980).
The integration of gas chromatography with mass spectrometry made 
possible the analysis of steroids in the low nanogram range and resulted 
in the most powerful technique available for structural elucidation of 
steroids in biological materials. Accounts of the principles and
practice of gc-ms are available in a number of text books and reviews 
(Roboz 1968, Waller 1972, McFadden 1973, Lawson 1975, Horning et al. 
1978, Setchell 1979) as are general surveys of mass spectra of steroids 
(Brooks and Middleditch 1973, Spiteller-Friedmann and Spiteller 1969, 
Zaretskii 1976).
Several distinct types of mass spectrometers are available. They 
all possess sample inlet systems, an ionization chamber (ion source), a 
mass analyser (mass filter), an ion detector and means of displaying 
and recording the mass spectra. The major difference in these instru­
ments is the method by which positive ions are separated in the mass 
analyser, most instruments incorporate either magnetic deflection or 
a quadrupolemass filter. A sample introduced into the ion-source of 
the mass spectrometer is bombarded with high-energy electrons (70 eV) 
which cause fission of the chemical bonds to produce positively charged, 
negatively charged or neutral species. The location of the initial 
positive charge on the molecule generally directs subsequent frag­
mentation resulting in the formation of ions which are characteristic 
of that compound. Steroids have been most commonly analysed as their 
TMS or MO-TMS derivatives; these substituted groups lend not only 
thermal stability but also direct the fragmentations during mass 
spectrometric ionization processes. Modes of fragmentation of steroids 
and their derivatives under different forms of ionization (electron 
impact, chemical ionization, field desorption, negative ionization, 
etc.) are quite complex as indicated by the detailed studies of 
Budzikiewicz (1972), Von Unruh and Spiteller (1970a, b and c) and 
Michnowicz and Munson (1972, 1974).
With the adaptation of computers for acquisition and reduction 
of gc-ms data, it is now possible to analyse complex mixtures using 
rapid scanning techniques. During each gc-ms run, the changes in the 
intensity of each ion in the chosen mass range is recorded with the 
scan number as a function of time. The data is stored on magnetic discs 
or tapes. A computer controlled gc-ms system has two general modes of 
operation - (i) continuous repetitive measurement of spectra between 
selected mass range (e.g. 50-500 amu) at fixed time intervals during a 
gc-ms run, (ii) selected ion monitoring of predetermined ion/ions by
rapid switching between the m/z values at fixed time intervals (some­
times called mass-fragmentography). The second mode of operation 
increases the sensitivity of the chromatographic analysis by increasing 
the integration time on the fixed masses, thus enhancing the signal- 
to-noise ratio.
The capabilities of mass spectrometry are being extended by the 
use of capillary column gc (Begue et al. 1979, Lisboa et al. 1979, 
VandenHeuvel and Zweig 1980), combined HPLC-ms (McFadden et al. 1976) and 
by negative ion-chemical ionization ms (Hunt and Crow 1979). The technique 
of combined gc-ms has been applied in this thesis to study the metabolism 
of some steroids in the cross-bred gelded horse.
1.7. Purpose of the present study:
1.7.1. The doping of race horses :
In horse racing, doping is generally deemed to be the administration 
of substances other than normal nutrients that could affect the perform­
ance of a horse at the time of racing (Clarke and Moss 1977). Very 
often, the small amounts of "prohibited substances" detected in post­
race "dope" tests are the residues of drugs used in veterinary therapy.
The Rules of Racing in Britain are unequivocal on this subject. For a 
horse to win, it must demonstrate genuine superiority unaided by 
any medication which can cover an inherent weakness in the animal.
Much speculation now centres on the detection of steroid hormones 
(both natural and synthetic) which are used as therapeutic agents in 
veterinary medicine. These fall into two main classes - the glucocorti- 
costeroids and the anabolic steroids. The pharmacology and the use of 
steroids in equine therapy have been reviewed by Tobin (1978, 1979).
Some of the synthetic corticosteroid and anabolic steroid preparations 
and formulations available for veterinary use are listed in Table 5.
They differ with regard to their dose, potency, route of administration, 
therapeutic uses and the duration of their therapeutic effects.
1.7.2. Detection and identification of administered steroids and their 
metabolites in horse body fluids:
The practice of administration of steroids to horses has led to 
the development of several methods for the determination of these drugs 
and their metabolites in horse body fluids.
Table 5 Synthetic corticosteroids and anabolic steroids available for 
veterinary use*
CORTICOSTEROIDS
Betamethasone
Betamethasone-21-sodium phosphate
Dexamethasone
Dexamethasone-21-acetate
Dexamethasone-21-isonicotinate
Dexamethasone-21-phenylpropionate
Dexamethasone-21-sodium phosphate
Flumethasone
9a-Fluroprednisolone-21-acetate
Methylprednisolone-21-acetate
Paramethasone-21-acetate
Prednisolone
Triamcinolone
ANABOLIC STEROIDS
Boldenone undecylenate 
Nandrolone cyclohexylpropionate 
Nandrolone laurate 
Nandrolone phenylpropionate 
Testosterone phenylpropionate 
Trienbolone acetate
* Adapted in part from Chapman (1979)
a) Detection of synthetic corticosteroids : The detection and
identification of several synthetic corticosteroids added to horse 
urine at a level of 21ig/ml was described by Moss and Rylance (1966).
After ethyl acetate extraction, the extract was analysed by tic in 
different solvent systems, the steroids located under UV light at 254 nm 
or using chromogenic spray and identified from their R^ values. A 
radioimmunoassay (RIA) method capable of detecting the urinary 
excretion of several proprietary corticosteroids after intramuscular 
administrations to experimental horses has been reported by Chapman et 
al. (1977). RIA has also been used to detect low levels of dexamethasone 
(5-10 ng/ml) in the plasma and urine of thoroughbred horses after 
administration of proprietary preparations of dexamethasone (Seawright 
et al. 1980). The authors measured serial plasma and urine levels of 
dexamethasone and cortisol in horses over a period of 60-120 h after 
single intravenous administrations of dexamethasone-21-sodium phosphate 
and single intramuscular injections of dexamethasone-21-isonicotinate or 
dexamethasone-21-trimethylacetate.
The biotransformation of orally administered prednisolone to 
horses has also been studied by tic and chromogenic spray detection 
(Moss and Rylance 1967). The unconjugated metabolites excreted in 
urine were identified as prednisolone, prednisone, 203-dihydropredni- 
solone, 203-dihydroprednisone and cortisol. Cortisol was not detected 
in pre-administration urine samples from the experimental animals or in 
random samples obtained from other horses. A similar pattern of 
metabolites was also identified in horse urine after oral administration 
of prednisone and intramuscular injection of prednisolone trimethylace­
tate.
b) Detection of synthetic anabolic steroids : A sensitive RIA screen­
ing technique for the detection of unconjugated urinary excretion 
products after intramuscular administrations of a number of synthetic 
anabolic steroid preparations to horses has been described by Jondorf 
(1977) and Oondorf and Moss (1978).
The biotransformation of intramuscularly administered 19-nortest- 
osterone to horses has been studied by isotope labelling and combined 
gc-ms (Houghton 1977, Houghton and Dumasia 1980). The excretion of
radioactivity was virtually complete in 36 h with 70% of the dose
being excreted in the urine; less than 10% of the urinary radioactivity
was present in the unconjugated fraction. After mixed enzyme hydrolysis
of the urine, the neutral metabolites were purified by silica gel column
chromatography and seven different metabolites of 19-nortestosterone
14were identified by gc-ms. After the administration of 19-nor- C-
14testosterone laurate ester, the C activity in the urine could be 
detected for over two weeks (Houghton 1976). A specific combined gc-ms 
method to identify estrane-3,17-diol, the major metabolite of 
19-nortestosterone in horse urine was developed by Houghton et al.(1978).
1.7.3. The present study:
In order to implement effectively the rules governing the use of 
drugs in racing it is essential to detect and confirm the administration 
of exogenous steroids in horse body fluids. Therefore, a knowledge of 
the pharmacokinetic parameters such as the metabolism and excretion 
rates of these steroids is necessary in order to establish a sound 
scientific and legal basis to detect and control the use of these drugs. 
Moreover in cases where the administered steroid is extensively 
metabolised before excretion, biotransformation studies can prove useful 
in determining a suitable analyte to detect and confirm its use (Houghton 
et al. 1978, Dtlrbeck et al. 1979).
As is the case for naturally occurring steroids, synthetic steroid 
drugs undergo extensive metabolism prior to excretion (Vermeulen 1959, 
Butler and Gray 1970, Ward et al. 1975 and 1977b, Dtlrbeck and BUker, 1980). 
Since species difference is an important factor affecting the metabolism 
and excretion of drugs, it is essential to study the metabolism and 
excretion of these steroids in the horse before sensitive methods can be 
developed for their detection.
In view of the above the biotransformation and urinary excretion of 
dexamethasone, testosterone and 1-dehydrotestosterone and their radio­
labelled analogues were studied in cross-bred gelded horses after intra­
muscular administration of the steroids. The percentage of administered 
radioactivity excreted in the urine was determined by scintillation
counting. Various methods including Amberlite XAD-2 and solvolysis were 
used for the extraction and hydrolysis of steroid conjugates.Separation 
and purification of the urinary metabolites was carried out using 
Sephadex LH-20 and Kieselgel H column chromatography, tic and HPLC. 
Following the formation of suitable derivatives the metabolites were 
identified by microchemical reactions or combined gc-ms. A study of 
the phase II metabolism of 19-nortestosterone in the horse was also 
carried out, using methods developed during this work, in order to 
establish the pathways of biotransformation of anabolic steroids in the 
horse.
CHAPTER II
MATERIALS AND METHODS
2.1 MATERIALS
a) Steroids:
Dexamethasone, testosterone, 1-dehydrotestosterone, 19-nortest- 
osterone, 5a-androstane-3a,170-diol, 5a-androstane-30,170-diol, 
50-androstane-3a,170-diol, 50-andrqstane-30 »173-diol, 3a-hydroxy-5a- 
androstan-il7-one, 3a-hydroxy-53-androstan-17-one, 33-hydroxy-5a- 
androstan-17-one and 30-hydroxy-50-androstan-17-one were purchased 
from Sigma London Chemical Co. 63-Hydroxybetamethasone was a gift 
from Dr.Phillips of Glaxo Laboratories, Greenford, Middlesex; 
5a-estrane-30,173-diol, 5a-androstane-3a,17a-diol, 5a-androstane-3/J, 
17a-diol, 50-androstane-3a,17a-diol and 53-androstane-33,17a-diol were 
gifts from Professor D.N.Kirk, M.R.C. Steroid Reference Collection^
30,16a-dihydroxy-50-androstan-17-one and 30,170-dihydroxy-5a-androstan- 
16-one were gifts from Professor Dr.G.Spiteller, University of Bayreuth 
West Germany and 5a-estrane-3a,170-diol, 50-estrane-3a,170-diol, 
50-estrane-30,170-diol, 3a-hydroxy-5a-estran— 17-one and 3a-hydroxy- 
50-estran-17-one were gifts from Organon, Oss, Netherlands.
Dexamethasone (specific activity 25 Ci/mmol), 
[l,2-(n)-3H] -1 -dehydrotestosterone (specific activity 33 Ci/mmo^,
(4- ^C)testosterone (specific activity 53.5 Ci/mmol), ^H-n-hexadecane 
and ^^C-n-hexadecane were purchased from Radiochemical Centre, Amersham 
19-Nor(4-^4C)testosterone was purchased from CEA, France (specific 
activity 40-50 Ci/mol).
The radioactive and chemical purities of the steroids were checked 
by tic in various solvent systems. A typical histogram showing the 
radiochemical purity of dexamethasone is illustrated in
Fig.7. The average radiochemical purities of the labelled steroids
determined in three solvent systems are given below:
[l,2-(n)-^H dexamethasone (S-l, S-4 and S-10) 98.1%
£l,2-(n)-3H -1-dehydrotestosterone (S-l, S-7 & S-8) - 97.1%
(4-^C)testosterone (S-l, S-2 and S-3) 96.5%
The solvent systems are described on page 42.
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Unlabelled dexamethasone
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A typical histogram showing the radiochemical purity 
of [l,2-(n)-3pT] Dexamethasone on tic.
Adsorbent: Silica gel S1 F 0.25 mm thick
i. o
Solvent system: chloroform - dichloromethane
ethanol (8:1:1, v/v/v)
d ). ucner cnemicais ;
Sephadex LH-20 was purchased from Pharmacia Fine Chemicals, London; 
Amberlite XAD-2 resin, acetic anhydride, sodium bismuthate and sodium 
sulphate were purchased from BDH Chemicals Ltd., Poole, Dorset; sodium 
borohydride, 2,5-diphenyloxazole (PPO), l,4-bis-[2-(5-phenyloxazolyl]- 
benzene (POPOP) and p-toluene sulphonic acid were obtained from Sigma 
Chemical Co; N,0-bis-(trimethylsilyl)-acetamide and trimethylchlorosilane 
were obtained from Pierce and Warriner (U.K.) Ltd., Chester; methoxyamine 
hydrochloride was obtained from Eastman Kodak Ltd., Kirkby, Liverpool; and 
Kieselgel H nach Stahl from Anderman & Co. Ltd., East Molesey, Surrey. 
Helix pomatia digestive juice (Industrie Biologique Francaise) was 
obtained from Uniscience Ltd., Cambridge and contained a minimum of 
100,000 Fishman units of $ -glucuronidase and 1,000,000 Roy units of aryl 
sulphatase per ml. Silica Gel S13F for tic was purchased from Whatman Ltd. 
Maidstone, Kent and a-butyl P.B.D. from Ciba Laboratories, Horsham, Sussex. 
The placebo oily solution ^ containing a mixture of benzyl alcohol (10%, v/v) 
and cresol (0.3%, v/v) in arachis oil] used in the administration of 
anabolic steroids was donated by Intervet Laboratories, U.K.
Analytical grade organic solvents were obtained from either BDH Ltd. 
or Hopkins & Williams Ltd. Pyridine was refluxed over K0H, redistilled 
and stored in well stoppered dark bottles. Hexane, ethyl acetate, 
1,2-dichloroethane, dichloromethane, chloroform?acetone and methanol were 
all redistilled before use.
Scintillant solutions used during the study were:
i) Bray's scintillant which was prepared as described by Bray (1960)
ii) RIA LUMA scintillant (purchased from LKB Ltd., Selsdon, Surrey).
iii) Triton:toluene scintillant which was prepared by dissolving 
a-butyl P.BD. scintillator (8.0 g) in a mixture of Triton X-100 - 
toluene (1:1 v/v, 2L).
Sodium acetate buffer (0.2M; pH 4.5) was prepared by mixing 
CH COONa . 3H Q solution (0.2M; 49 ml) with glacial acetic acid solution
J  C*
(0.2M; 51 ml).
c) Instruments :
Melting points were determined on a Koffler microheating stage and 
are uncorrected. Ultra-violet spectra were recorded in methanol on a 
Pye Unicam SP 8000 spectrometer. Infra-red spectra were recorded as KBr 
discs on a Pye Unicam SP 200 Spectrometer.
2.2 METHODS
2.2.1. Animals; steroid administrations; collection of blood and urine:
Cross-bred gelded male ponies, aged between 7-12 years were used 
in this study. The animals were individually housed in metabolism 
stalls specially constructed to restrict too much movement. They were 
allowed free access to food (corn and hay) and to water at all times. 
During experiments, the animals were removed from the stalls and 
exercised once a day.
Intramuscular administrations of a mixture of known amounts of 
chemically pure labelled and unlabelled steroids were made at single 
sites in the neck using a 16-guage needle (Monoject 200 Luer). After 
each injection, the swabs, needles, syringe and vials were thoroughly 
washed in methanol and the radioactivitiy in the combined washes was 
determined. The individual dose administered to each animal was 
calculated by subtracting the recovered activity from that originally 
present in the vial.
Timed sequential blood samples were collected from an indwelling 
polythene cannula (Braunula No.2 Luer; Armour Pharmaceutical Co.Ltd., 
Eastbourne, Sussex) inserted into the jugular vein using a local 
anaesthetic (xylocaine 2% with adrenaline 1:80,000; Astra Chemicals Ltd., 
Watford). Blood samples (10 ml) were aspirated in special syringes 
(Monovettes) containing potassium ethylenediaminetetraacetate (EDTA) or 
collected in tubes containing lithium-heparin (Seward Laboratories, 
London). The tubes were centrifuged at 1500 rpm for 5 min and the 
plasma was aspirated into polythene vials. Aliquots (2 x 1 ml) were 
removed for radioactivity measurements and the remainder stored at -20°C 
for repeat analysis if necessary. In order to prevent clotting of blood 
in the cannula, sterile trisodium citrate (3.8% w/v aqueous) or heparin 
(20 units/ml) in sterile sodium chloride (0.9%w/v; Boots Co.Ltd., 
Nottingham) was injected into the cannula after collection of each 
blood sample, the anticoagulant being removed by discarding the first 
few ml of blood before collection of the next sample.
Urine samples were collected by means of a specialised harness made 
of a moulded latex funnel to which a length of polythene tube was 
attached. This harness was secured to the hindquarters of the.horse
in such a way that the funnel was directly under the penis to catch 
voided urine. During the day urine samples were collected in individual 
1 gallon plastic bottles. Overnight samples were collected on a modified 
fraction collector using 1 litre capacity plastic containers moving round 
at the rate of one pot per hour. All naturally voided urine samples were 
collected up to 48 h after the treatment or longer if necessary. The 
volume of each urine sample was measured, aliquots removed for analysis 
and the rest of the urine sample then stored at -20°C until required for 
further analysis.
2.2.2. Liquid scintillation counting:
A packard Tricarb Liquid Scintillation Spectrometer (Model 3320) 
with a Teletype (Model 33) printer terminal was used. Determinations 
were carried out in polythene vials (Kontron Instruments Ltd., St.Albans, 
Herts.),using 10 ml of scintillant solutions. Optimal discriminator
voltages, gain settings, and counting efficiencies were determined for
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each scintillant using either H-n-hexadecane or C-n-hexadecane as
standard isotopes. Quench correction curves were determined by the
channels ratio method using separate sets of quenched standards prepared
using normal horse urine, horse plasma or halogenated organic solvents
as quenching agents. A typical quench correction calibration curve for
the tritium isotope is illustrated in Fig. 8. The slope was calculated
from linear regression analysis and the constants to fit the equation
y = mx + c were determined. Quench correction curves were periodically
checked for their reproducibility. Calculations were carried out on a
programmable Wang desk-top calculator using either manual or paper-tape
input and the results expressed as disintegrations per min (dpm). For
the determination of radioactivity in experimental samples, duplicate
aliquots of plasma (1.0 ml) and urine (0.1 ml) were used.
2.2.3. Extraction procedures:
a) Amberlite XAD-2 extraction
Urinary steroids (free and conjugated) were extracted and concentrated 
using the neutral resin Amberlite XAD-2 (Bradlow 1968). The resin was 
washed with methanol, acetone and water before being used for the first 
time. Measured aliquots of the urine were passed down a glass column (diam. 
30 mm) containing Amberlite XAD-2 resin (1 g resin per ml urine). After 
the urine had passed through (flow rate about 2 ml per min), the resin..
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Fig. 8. Quench correction calibration curve 
Conditions: Polyethylene vials
3
H-n-hexadecane Standard
RIA LUMA Scintillant (10 ml)
• n = 5 repeat 10 min counts 
Instrument : Packard Tricarb 3320
Analyser Settings: e Ae
Red Channel 50 - 1000
Green Channel 50 - 210
Gain 65%
was washed with deionised water ( 2 x 1  vol) and the total aqueous eluates 
were discarded. The resin . retains steroids and large organic 
molecules while inorganic salts and water pass through. The 
material retained on the resin was then eluted with methanol 
(3 x 1 vol) and the combined methanol eluates were .taken down.'to dryness 
under reduced pressure. When smaller volumes (10 ml) of urine were 
analysed, a column (diam. 15 mm) containing 5g resin was used. The 
resin was used repeatedly for extractions with further water and 
methanol washes in between each use to remove any traces"of radioactive 
material retained from the previous run.
b) Solvent extraction
Aliquots of urine (before and after hydrolysis) were extracted 
with organic solvents (dichloromethane or ethyl acetate, 2 x 2  vol ).
A measured portion of the combined organic phase was removed for the 
determination of radioactivity. The remainder of the organic phase 
was washed with NaOH (0.1N or 1.0N) until neutral, then with saturated 
NaCl solution and the aqueous phases were discarded. An aliquot of the 
organic phase (containing the neutral steroids) was again removed for 
the determination of radioactivity. In the dexamethasone study, 
alkaline washes of the solvent extracts were omitted because of the 
susceptibility of the C-17 side chain to alkaline degradation (Monder 
and Bradlow 1977).
2.2.4. Fractionation of steroids from urine:
a) Total urinary radioactivity
The cumulative percentage of the administered dose excreted in the 
whole urine was determined from the total amount of radioactivity present 
in each sample.
b) Unconjugated steroids
Urinary samples were extracted with organic solvents ( 2 x 2  vol) 
before any form of hydrolysis treatment to extract the unconjugated 
(free) steroids. After measuring the volumes, aliquots of the organic 
solvent were removed for radioactivity determination. Where necessary, 
the fraction was washed with alkali (NaOH, 0.1N) and aliquots were again 
taken for the determination of radioactivity.
c) Conjugated steroids
Three methods were used in this study to hydrolyse the steroid 
conjugates present in urine:
i) Hot acid hydrolysis: To aliquots of urine, conc.HCl (15 ml/
100 ml urine) was added and the mixture boiled under reflux for 
30-40 min. After cooling, the freed steroids were extracted with 
ethyl acetate (2 x 2 vol ). After measuring the volumes,aliquots 
were removed for radioactivity determination. Both glucuronides 
and sulphoconjugates are hydrolysed by this procedure.
ii) Enzyme hydrolysis: Before hydrolysis treatment, urine extracts
were dissolved in acetate buffer (0.2M, pH 4.5) and the neat urine 
samples were adjusted to pH 4.5 with cone HC1. Helix pomatia enzymes 
at a concentration of 500 Fishman units of 3 -glucuronidase and 
5000 Roy units of aryl sulphatase per ml original urine were added, the 
mixture incubated at 37°C for 36-48 h, the freed steroids extracted with 
ethyl acetate and the radioactivity determined as described.
iii) Solvolysis: Ethyl acetate was shaken in a separating funnel
with 2M h 2S04 (Vihko 1966). After separation, the aqueous phase was 
discarded and the acidified ethyl acetate (50 ml) was added to an 
Erlenmeyer flask containing the urine extract dissolved in methanol 
(1 - 2 ml). After incubation for 24 h at 37°C, the solvent was washed 
with IN NaOH until neutral, with saturated NaCl solution, dried over 
anhydrous Na2S04 and taken to dryness under reduced pressure. This
procedure hydrolyses pnly the sulphoconjugated steroids.
d) Non-extractable steroids
The aqueous phase remaining after the various hydrolysis treatments 
and extraction procedures was measured and the radioactivity determined 
by counting 0,1 ml aliquots. This fraction was not processed further.
2.2.5. Separation and purification of urinary steroids:
a) Thin layer chormatography (tic)
Tic plates were prepared in an automatic level setting plate 
spreader using silica gel S13F (35g) shaken with deionised water (70 ml).
The slurry was spread over five clean dry glass plates (20 x 20 cm).
When dry, the plates were heated in an oven at 110°C for 1 h and stored 
in a dessicator until used. Plates of 0.25 mm thickness were used for 
analytical work and 0.5 or 1.0 mm thickness for preparative scale work.
Samples (urine or plasma extracts) were dissolved in a few drops of 
methanol and applied as spots or streaks about 2 cm above the bottom 
edge of the plate using a fine capillary tube. The reference compounds 
were applied in adjacent lanes. During application, a stream of warm 
air was directed over the plate to facilitate evaporation of the solvent and to 
minimise spreading and overloading of the extracts.
Various solvent systems were used during the course of the study 
and are listed below. Solvent systems were prepared freshly each time 
and allowed to equilibrate for at least 30-60 min in covered glass 
tanks lined with chromatography paper. In general, the solvent front 
was allowed to travel about 15-17 cm up the plate. Solvent systems used
were (v/v):-
S-l Ethyl acetate
S-2 Chloroform - ethyl acetate (1:1)
S-3 Chloroform - methanol (4:1)
S-4 Chloroform - dichloromethane - ethanol (8:1:1)
S-5 Ethyl acetate - dichloromethane - ethanol (55:35:10)
S-6 Chloroform - cyclohexane - ethanol (5:1:1)
S-7 Chloroform - ethanol (19:1)
S-8 Cyclohexane - ethyl acetate (6:4)
S-9 Chloroform - ethanol - water (70:30:2)
S-10 Chloroform - dioxan - water (2:1:1)
S-ll Cyclohexane-dichloromethane-acetone-ethyl acetate (7
After development of the chromatograms, the reference cdmpdunds were
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located by short wave UV light at 254 nm (A -3-oxo chromophore) or by 
spraying with alkaline blue tetrazolium reagent (Recknagel and Litteria 
1956). The radioactive areas in the extracts were located by trans­
ferring sequential cm bands of the tract from the plate directly into 
scintillation vials. After addition of methanol (0.5 ml) and scintillant 
(10 ml), the vials were counted in the liquid scintillation spectrometer.
Recovery of the radioactive metabolites from the silica gel 
was carried out by scraping the appropriate area into a stoppered 
tube. After addition of methanol, the tubes were stoppered, shaken 
for several minutes, centrifuged and the methanol aspirated with 
a pasteur pipette. After two further extractions, the combined 
methanol extracts were taken down to dryness under nitrogen and 
aliquots were removed for determination of recovery. Total recoveries 
ranged between 85-90% for the extraction, of, steroids from the .silica gel.
b) Silica gel column chromatography
After hydrolysis of the conjugates, the crude urine extracts 
containing the free steroids were fractionated by column chromatography 
using Kieselgel H-60 as adsorbent. The columns were prepared as 
follows:-
A stoppered glass column (diam. 15 mm) with a sintered glass frit 
was half filled with hexane. The column bed was layered with 3 mm of 
acid washed sand. A slurry of Kieselgel H-60 (5 g) in hexane was 
poured into the column and packed under gentle pressure to obtain even 
sedimentation. A further 3 mm of sand was layered on top of the packed 
column to prevent disturbance of the silica gel when loading. The 
column was then equilibrated with at least 50 ml of the solvent system to 
be used for :'eluting the steroid metabolites. The urinary extract was 
carefully applied on top of the silica gel using minimal volume of the 
solvent mixture and after topping up the column with the eluant, the 
flow-rate was maintained by gentle pressure applied at the top of the 
column. Fractions (3ml or 5 ml) were collected using an automatic 
fraction collector and aliquots of each fraction were taken for the 
determination of radioactivity.
c) High performance liquid chromatography (HPLC):
An Applied Chromatography Systems (Model 750/03) twin-headed 
reciprocating pump was used with detection at 244 nm by a Cecil CE 212 
variable wavelength UV monitor fitted with an 8 yl flow-through cell and 
a Servoscribe (Model I.S.RE 541.2) potentiometric recorder operating at 
10 mv. Chromatographic separations were carried out using stainless 
steel columns (250 x 4.5 mm) containing 5 ym silica (Partisil-5, Whatman, 
Maidstone, Kent). A 20 yl syringe loading loop injector (Rheodyne Model 
7120) was used to inject the samples onto the column. The solvent 
mixture (hexane-dichloromethane-ethanol-glacial acetic acid,
13:6:1:0.1, v/v/v/v) was used as the mobile phase for chromatography 
at a flow rate of 2.5 ml/min, which produced a pressure drop of 
100 bars.
d) Sephadex LH-20 column chromatography
Sephadex LH-20 was allowed to swell overnight in excess solvent. 
Chromatography was carried out in glass columns fitted with glass 
stopcocks. A glass bead or glass frit layered with 3mm of acid washed 
sand was used as the bed support. The Sephadex slurry was added to 
the column and allowed to settle by gentle pressure to obtain even 
sedimentation. Care was taken to avoid air bubbles being trapped in 
the gel. A piece of filter paper held in place with washed glass wool 
was placed on top of the column to prevent the gel from floating in 
the solvent. About 50 ml of solvent was passed through to equilibrate 
each column before use. The urinary extract was dissolved in the solventf 
applied to the surface of the gel and the chromatographic separation was 
carried out at a flow rate of approximately 0.5 ml/min. Fractions of 
the eluate (3 ml or 5 ml) were collected using an automatic fraction 
collector and aliquots of each fraction were taken for the determination 
of radioactivity.
2.2.6. Preparation of steroid derivatives:
(A) The following selective chemical reactions were used for the 
synthesis and characterization of the various metabolites of dexamethasone
(i) Acetylation: The primary and secondary hydroxyl groups were
selectively acetylated by reaction with acetic anhydride in pyridine,in 
the dark,for 16 h at room temperature. The 11)3 and 17a-hydroxyl groups 
were not esterified by this method.
(ii) Hydrolysis of acetates: The C-21 acetate group was readily
hydrolysed under mild conditions using potassium carbonate (2.0% w/v) in
aqueous methanol at room temperature for 1 h.
(iii) Reduction (Norymberski and Woods 1955) : Reduction of the C-ll
and C-20 ketones to the corresponding secondary alcohols was carried out 
using sodium borohydride in methanol at 0°C for 20 min. No reduction of 
the a,3 -unsaturated 3-oxo group was observed under these conditions.
(iv) Oxidation of the C-17 side chain : This reaction was carried 
out using the sodium bismuthate oxidation procedure described by 
Bailey (1964) to yield the 17-ketone.
(v) Oxidation of the secondary alcohol groups (Bush 1961): Secondary 
alcohols were oxidised to the corresponding ketones using chromium 
trioxide in glacial acetic acid. The reaction was carried out in the 
dark at room temperature for 30 min.
(B) The following derivatives were used for the gc-ms analysis of 
anabolic steroids:
(i) Preparation of 0-methyloxime derivatives (MO) : The condensation 
of the carbonyl groups with methoxyamine hydrochloride was carried out 
according to the method described by Fales and Luukkainen (1965).
Aliquots of samples (urine extracts or reference steroids) were trans­
ferred to screw-capped vials. After removal of the solvent under 
nitrogen, the residues were dissolved in a solution of methoxyamine 
hydrochloride in dry redistilled pyridine (8% w/v, 0.1 ml). ’ After 
mixing the contents on a whirlimixer, the reaction was allowed to 
proceed overnight at room temperature. The pyridine was removed under 
nitrogen at 40°C and the residual material was then silylated.
(ii) Preparation of trimethylsilyl ethers (TMS): Aliquots of the samples 
(urine extracts, reference steroids or the MO-derivatives) were transferred 
to screw-capped vials. After removal of the solvent, N-0-bis(trimethyl- 
silyl)-acetamide (BSA; 0.1 ml) and trimethylchlorosilane (TMCS: 0.025 ml) 
were added and the vial closed carefully. The contents were mixed on a 
whirlimixer for 10-15 sec and the reaction was allowed to proceed at
60°C for 2 h. The solvents were gently removed under N2 at 40°C and the
residue taken up in hexane. TMS-ethers were found to be stable for at
least 3 days in hexane solution.
(iii) Preparation of 0-isopropylenedioxy trimethylsilyl ethers (acetonide 
- TMS ethers) (Bailey 1967): Aliquots of the fractions isolated from
silica gel columns were made anhydrous by evaporation to dryness from
acetone-benzene mixture (1:1 by.voli) . The residues were taken up in
dry acetone (2 ml) containing p-toluene sulphonic acid (2 mg). After the 
addition of fused anhydrous CaCl2 (50 mg), the reaction mixture was
thoroughly shaken for 4 h at room temperature. After centrifugation, 
the supernatent was removed and evaporated to dryness under N2 at 
40°C. The residue was taken up in benzene (10 ml), washed with 
NaOH (IN, 1 x 2  ml), water (2 ml), dried over anhydrous NagSO^ and 
evaporated to dryness under Ng. The residual material was silylated 
as described above.
2.2.7 Gas-liquid chromatography (glc):
Analytical glc was carried out on a Perkin Elmer Model F-17 gas 
chromatograph fitted with dual flame ionization detectors. Coiled 
glass columns (2m x 6.4 mm o.d., 2mm i.d.) packed with 1.5% OV-1 
on AW-DCMS Gas Chrom Q (100-120 mesh) were used with N2 as the carrier 
gas (flow rate 20 ml/min). Samples for glc were dissolved in hexane and 
aliquots ranging from l-5yl in volume were injected using a Hamilton lOyl 
syringe. The injection port heaters were maintained at 200°-225°C and 
the oven was temperature programmed from 180°-260°C at 2°/min. The 
retention times of the reference compounds and urinary metabolites were 
recorded as distance in cm from the time of injection to the top of the 
steroid peak.
2.2.8 Combined gas-chromatography mass spectrometry (gc-ins):
A Finnigan 4000 series automated gas chromatograph mass spectrometer 
interfaced with a Model 6110 data system for data acquisition and reduction 
was used in this study (Finnigan Corp., Sunnyvale, California). The gas 
chromatograph (Model 9610) was interfaced to the dual source (EI-CI) 
quadrupole mass spectrometer via a single stage glass jet separator.
The glc and mass spectrometry conditions used during the study are 
tabulated below:-
Column 1.8 m x 6.4 mm o.d., 2 mm i.d. coiled glass
Support AW-DMCS Gas Chrom Q, 100-120 mesh
Phase 1.5% 0V-1
Operating temp. programmed from 180° to 260°C at 5°/min
Carrier gas Helium
Flow rate 20 ml/min at room temp.
Ionising voltage 70 eV
Separator and 
transfer line 250 C
temperature
Ion source temp. 240°c
When used in the repetitive scan mode, mass spectra of the glc 
effluent were continuously recorded at 3 sec intervals to cover a 
mass range between 50-600 amu. When used in the selected ion 
monitoring (SIM gc-ms) mode, four ions (m/z values) characteristic 
of the compound under investigation were continuously monitored 
during a glc run within a switching cycle of 1-2 sec.
Chemical ionisation mass spectrometry (CI-MS) was carried out
using either methane or ammonia as the reagent gas. In this mode the
use of an ionised reactant gas (e.g. methane) at high pressure (around
1 Torr.) usually results in either a proton transfer or a hydride
abstraction from the compound under investigation resulting in easily
+ +identifiable quasi molecular ions (M - 1) . Because very little 
internal energy is imparted to the ion produced, it undergoes little, 
if any, further fragmentation.
Data processing: During operation, the data acquired by the
computer is stored on a cartridge disc and each scan is automatically 
assigned a spectrum number. After completion of each glc run, the raw 
data was processed via the computer and plots of the reconstructed ion 
current (RIC) and mass chromatograms obtained. Mass spectra of the 
compounds were obtained after subtraction of the background noise and 
hard copy output of the processed data was plotted directly using the 
Zeta plotter (Zeta Research Inc. U.S.A.).
Characterization of steroid derivatives by mass spectrometry: In 
general, the ions present at m/z 73 and 75 in the mass spectra of most 
steroid TMS derivatives are formed by fragmentation of the trimethyl- 
silyl groups and carry a high ion current relative to the other ions 
in the spectrum yet yield virtually no structural information. For 
this reason, all mass spectra presented in this thesis have been 
normalized using the most abundant ion above mass 100 and plotted from 
m/z 100 upwards.
The TMS derivatives of steroid hydroxyl groups are characterized
+ + 
by the loss of methyl (M.-15) and trimethylsilanol (M.-90) moieties
from the molecular ion. Where more than one hydroxy group is present,
successive losses of methyl and trimethylsilanol moieties may be observed.
The TMS derivatives of steroids containing the 17-hydroxy group show a
base peak at m/z 129 arising from charge retention of a fragment 
containing the carbon atoms at C-15, C-16, C-17 and the trimethylsilanol 
group. The corresponding ion at (m T-129) is not observed in the spectra 
of these steroids.
The O-methyloximes (of monoketones) are distinguished by their odd 
molecular weights and show weak ions for the loss of a methyl group 
(M.-15) and methoxy radical (M.-31). For the MO-TMS derivative an.additional 
loss of 90 amu (M-121)* due to a trimethylsilanol group is indicative of 
a monohydroxy-monoketo compound.
Isomeric steroids like testosterone/epitestosterone, androstanediols, 
androsterone/etiocholanolone etc. give rise to similar mass spectra and 
only their glc properties provide essential distinction.
The origin of and the structural information obtained from the 
fragment ions observed in the mass spectra of the steroids identified in 
this thesis will be discussed in the appropriate chapters.
CHAPTER III
METABOLISM OF DEXAMETHASONE
3.1 INTRODUCTION
Dexamethasone (9a-fluoro-16a-methyl-ll^, 17a,21-trihydroxypregna 
-l,4-diene-3,20-dione) is one of several potent synthetic glucocorticoids 
available to the equine practitioner. Besides the parent steroid, at 
least seven derivatives (C-21 esters) are sold for veterinary use in 
the United Kingdom. Although it is widely used for its anti-inflammatory 
and anti-rheumatic properties, little attention has been given to its 
biotransformation in the horse.
The general aspects of the metabolism and excretion of synthetic 
glucocorticosteroids have been described in Chapter I. The metabolism 
of dexamethasone has previously been studied in man (Haque et al. 1972), 
in sheep (Leish and Panaretto 1978) and in the rat (English et al. 1975, 
Mineo 1976 and 1978). After intravenous administration of radiolabelled 
dexamethasone,plasma levels and urinary excretion of radioactivity have 
been studied in man and sheep, but the pathways of biotransformation and 
the identity of the metabolites have not yet been elucidated. After oral 
administration of H-dexamethasone to rats (English et al. 1975)> tissue 
distribution and urinary expretion of radioactivity was monitored and 
unchanged dexamethasone (I), 6-hydroxydexamethasone (V) and 20-dihydro- 
dexamethasone (VI) WdYe,. identified as unconjugated metabolites in
3
the urine. Similarly after intramuscular administration of H-dexa­
methasone to rats, Mineo (1976 and 1978) identified unconjugated unchanged 
dexamethasone (I), 11-dehydrodexamethasone (III), 6-hydroxydexamethasone 
(V) and 20-dihydrodexamethasone (VI) in the urine. However, all of these 
studies have indicated that dexamethasone is extensively metabolised to 
polar compounds which are excreted in the urine mainly in the unconjugated 
form.
In the present study the metabolism and urinary excretion of tritium 
labelled dexamethasone in the horse was investigated. Since the therapeutic 
dose of dexamethasone for a horse (body weight about 400 kg) is only about 
25 mg, the concentrations of the drug and its metabolites in body fluids 
are quite small. Since corticosteroids are unsuited to glc because of
their low volatility and thermal instability, the isolation and 
identification of the urinary metabolites was based on radiotracer 
methods. Sephadex LH-20 and silica gel tic were used to purify and 
isolate the radioactive metabolites and selective microchemical 
reactions were used to characterize the functional groups present 
on the metabolites. In a subsequent study a large dose of the drug 
(250 mg) was administered to three horses in an attempt to isolate 
sufficient amounts of pure metabolites for identification by mass 
spectrometry using direct insertion probe. Due to the insolubility 
of dexamethasone in saline this large dose had to be administered in 
the form of an aqueous suspension and the results obtained were very 
different from the therapeutic dose study.
3.2 EXPERIMENTAL
3.2.1. Preparation and characterization of reference compounds 
from dexamethasone:
All reference compounds were prepared from dexamethasone using 
standard methods as’ described by Butler and Gray (1970) and their 
purity was checked by tic using four different solvent systems 
(Table 6).
(a) 17-oxo-dexamethasone (II):
Oxidation of dexamethasone with sodium bismuthate gave the 
corresponding 17-oxo-steroid (9a-fluoro-16a-methyl-ll/J-hydroxyandrosta- 
1,4-diene-3,17-dione). The crude product was purified by preparative 
tic and gave an analytically pure sample, m.p. 239°-240°C. The mass 
spectrum of the compound (Fig. 9) showed ions at m/z 312 (M^-HF)
and m/z 122 (A ring). The product was less polar than dexamethasone 
on tic (Table 6) and gave a negative blue tetrazolium reaction 
indicating loss of the side chain. .
(b) 11-dehydrodexamethasone (III):
It was found necessary to protect the C-17 side chain by acetylation 
prior to oxidation of the 11/3-hydroxyl group. Oxidation of dexamethasone 
-21-acetate in glacial acetic acid with aqueous chromium trioxide 
(0.4 g %, w/v) for 30 min gave the corresponding 11-keto compound,
(9a-fluoro-16a-methyl-17a-hydroxy-21-acetoxypregna-l,4-diene-3,11,20 
-trione), yield 91%, m.p. 179°-180°C. Saponification of the acetate 
using aqueous KgCO^ (2.0 g %, w/v) at room temperature gave 11-dehydro
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Fig. 9. Mass spectrum of 17-oxo-dexamethasOne (9a-fluoro-16a- 
methyl-113-hydroxyandrosta-l,4-diene-3,17-dione) 
synthesised from authentic dexamethasone.
dexamethasone. The product, recrystallized from aqueous methanol 
(yield 90%, m.p. 198°-200°C), was less polar than dexamethasone on 
tic (Table 6) and gave a positive blue tetrazolium reaction. The 
mass spectrum of the compound (Fig. 10) showed a base peak at 
m/z 121 which is characteristic of corticosteriods with 1,1-oxo- 
function (Urich et al.. 1980) and a molecular ion m/z 390. The 
identification of the other ions is given in.Fig. 10).
(c) 20-dihydrodexamethasone (VI):
Stereospecific sodium borohydride reduction of dexamethasone 
gave the 20-dihydro product (9a-fluoro-16a-methyl-ll/£,17a,20,21- 
tetrahydroxypregna-1,4-diene-3-one). The crude product recrystallized 
twice from an ethyl acetate-cyclohexane mixture gave an analytically 
pure sample, m.p. 138°-140°C. UV analysis showed an absorption maximum 
at 242 nm. Infra red analysis (KBr disc) showed absorption bands at 
2.89 ym and 3.39 ym (OH). The mass spectrum of the compound (Fig.11) 
showed a base peak at m/z 122 and fragment ions at m/z 374 (M?-HF),
333(M*- loss of C^q , C21 side chain) and 315 |flf!-(H:L0+ C^side
chain)J . The product was more polar than dexamethasone on tic 
(Table 6).
Table 6.
-f .■■■■■■■■■ 
systems -
System
No
dexamethasone 11-dehydro-
dexamethasone
17-oxo-
dexamethasone
20-dihydro­
dexamethasone
S— 1 0.42. 0.55 0.62 0.18
S— 4 0.40 0.57 0.64 0.22
S— 5 0.45 0.56 0.69 0.20
S— 6 . 0.48 0.62 0.70 0.26
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Identification of ions from Ring D and side chain
Ion Species 
(m/z)
Loss in amu 
from molecular ion 
(Mt -)
Route of formation
)
372 18 Loss of H^O
360 30 Loss of CH20
331 59 Loss of CH^COO*
330 60 Loss of CH3C00H
313 77 Loss of CH^COO* plus H20
254 136 Loss of C._ plus side chain 16 1 /
and HF
239 151 Loss of C15> C , C1?, plus side 
chain and HF
Fig.10. Mass spectrum of 11-dehydrodexamethasone (9a-fluoro-16a-methyl- 
17a, 21-dihydroxypregna-l,4—diene-3,11,20-trione) synthesised 
from authentic dexamethasone.
wmasmaaaamto-.._
Re
l.
 
In
te
ns
it
y(
%)
100
l u  ii. lit., iii' .
315
t L,
54
374 
(M — HF) +
100 200
m/z
300 400
Fig. 11. Mass spectrum of 20-dihydrodexamethasone (9a-fluoro-16a-methyl- 
ll$,17a,20,21-tetrahydroxypregna-l,4-diene-3-one) synthesised 
from authentic dexamethasone.
3.2.2 Administration to animals and collection of blood and urine
samples:
Intramuscular administrations of a mixture of the labelled and 
unlabelled drugs were made to crossbred gelded horses at single sites 
in the neck. The weights of the animals, the dosages and the vehicle 
used for the injection for each experiment are given in Table 7»
Table 7.
3
Administration of H-dexamethasone to horses
Expt.No. Animal Body 
Weight(Kg)
Dose injected 
yCi/kg yg/kg
Vehicle used
Low dose
9/74
41/75
Caspar
Nimrod
288
360
1.4
0.7
86 ) 
83 |
dissolved in 10% 
ethanol in saline 
(10 ml)
High dose 
10/78 
13/78 
14/78
Pedro
Caspar
Percy
390
390
236
0.64
0.69
1.1
640 ) 
640 J 
1016 )
emulsified in 
0.5% Tween-80 
in saline 
(10 ml)
The housing of animals and the collection of sequential timed
blood and urine samples have been described (Section 2.2.1. Chapter II).
Urine samples were collected up to 96 h after administration and aliquots
' 3
(0.1 ml x 2) from each specimen were taken to determine total H excreted. 
Sequential blood samples were collected up to 24 h and aliquots of the 
plasma (1 ml x 2) were counted for H activity. Blood samples were not 
collected for expt. 9/74.
3.2.3. Extraction of unconjugated steroids from plasma:
Plasma samples (0-8 h, expt. 41/75) were pooled, the volume made
up to 100 ml with deionised water and the unconjugated steroids extracted
with dichloromethane-ethanol (9:1, v/v; 200 ml). The organic phase was 
dried over anhydrous Na2S04and taken down to dryness under reduced
pressure. Tic of the extract was carried out using system S-4; 
dexamethasone, 11-dehydrodexamethasone and 20-dihydrodexamethasone 
were used as reference compounds.
3.2.4. Distribution of radioactivity in crude urine fractions:
Low dose study: Individual urine samples voided during the first 24 h
after administration were analysed as follows:-
(a) Non-conjugated steroids : Aliquots of each urine (2 x 10 ml) 
were extracted twice with 2 volumes of ethyl acetate. A measured 
portion of the combined ethyl acetate was removed for the measurement 
of radioactivity.
(b) Conjugated steroids : Nitrogen was bubbled through the residual 
urine after extraction of unconjugated steroids to remove any dissolved 
ethyl acetate. The urine was then hydrolysed with Helix pomatia mixed 
enzyme preparation at pH 4.8 for 36-48 h at 37°C and the freed steroids 
were again extracted with ethyl acetate ( 2 x 2  vol). An aliquot of the 
combined ethyl acetate was taken for measurement of radioactivity.
High dose study:
(a) Samples (50 ml; 0 - 24 h pooled urine) from each experiment were 
first extracted with ethyl acetate (as above) to remove the unconjugated 
steroids. After enzyme hydrolysis of the residual urine, the freed 
steroids were again extracted with ethyl acetate. Duplicate aliquots
of the unconjugated and conjugated steroid extracts and of the residual 
urine after extraction were taken for measurement of radioactivity.
(b) Samples (50ml; 0-24 h pooled urine) from each experiment were 
first adjusted to pH 4.0 with conc. HCl and the unconjugated steroids 
were extracted with ethyl acetate as before.
3.2.5. Isolation and identification of urinary metabolites:
Low dose study: Samples (50 ml) of pooled urine from the first 24 h
of collection after administration were processed as shown in the 
flow diagram (Fig. 12). Radioactive fractions resolved by Sephadex 
LH-20 column chromatography were pooled and the solvent taken down to 
dryness. Further purification of the individual fractions was carried
Mixed
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(elution vol):
Solvent removed:
Metabolites
eluted:
URINE (0-24- h sample, 50 ml)
I
enzyme hydrolysis (Helix pomatia) 
pH 4.8, 37°C, 48 h
1
Amberlite XAD-2 resin. (50 g)
r
1
Resin
i
deionised water wash 
(2 x ,50 ml )
Resin
Radioactivity eluted with methanol (3 x 50 ml) 
combined methanol taken to.dryness
i
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Eluted with dichlormethane-methanol 
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1
(1-25)
Tic
(26-50) (51-100) (101-150) Methanol
wash
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Identification by microchemical reactions and tic
Fig.12. Flow diagram for the isolation and identification of urinary 
metabolites after administration of therapeutic doses of 
^H-dexamethasone.
out by tic using solvent systems S-ll and S-4. The radioactive 
metabolites were isolated from the tic plates and then derivatized 
by the microchemical reactions described by Butler and Gray (1970).
The values of the underivatized metabolites and their oxidation, 
reduction and acetylation products were then determined in at least 
two solvent systems (S-l and S-4).
High dose study: Very little radioactivity was excreted in the urine 
in experiments 13/78 and 14/78 and they were not analysed further.
The 24 h urine collection from expt. 10/78 was processed further for 
identification of the metabolites.
Samples (50 ml; 0-24 h pooled urine) were adjusted to pH 4 with 
conc. HCl and the unconjugated steroids extracted with ethyl acetate. 
The ethyl acetate was reduced to dryness and the residue chromato­
graphed on a Sephadex LH-20 column as described (Fig. 12). Only one 
radioactive fraction (elution volume between 26-50 ml) was resolved. 
After removal of the solvent, the residue was dissolved in methanol 
(100 yl) and aliquots (10 yl) were further purified by HPLC. The 
HPLC conditions have been described in Chapter II (section 2.2.5.c). 
Timed fractions (every 2 min) of the eluate from the HPLC 'column were 
collected for each run. Aliquots of each fraction were taken for the
3
determination of H activity. Fractions containing the radioactive 
metabolite were pooled and the solvent taken to dryness. The residue 
containing the purified metabolite was analysed by chemical ionization 
mass spectrometry using direct insertion probe.
After 150 ml of the solvent mixture had passed down the Sephadex
LH-20 column, the radioactivity retained on the gel was eluted with
methanol. The methanol was removed under reduced pressure
and the residual material was methylated with diazomethane.in ether
(10 ml). The ether was evaporated to dryness and the methylated
extract was applied to a Kieselgel column (5.0 g; column diam. 1.5 cm)
and eluted with dichloroethane-ethanol 98:2 v/v. Fractions (60 x 3 ml)
3were collected and the H activity determined. Fractions comprising 
resolved metabolites were pooled and after removal of the solvent the 
residues were analysed by electron impact and chemical ionization mass 
spectrometry, using direct insertion probe.
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3.3 RESULTS .
3.3.1. Radioactivity in plasma:
3The levels of H in plasma for expts. 41/75 and 10/78 are shown
3
in Fig. 13. The levels of H-activity were low, reaching a maximum 
between 1-2 h and declining gradually over a period of 24 h after 
administration. Only 65% of the radioactivity in the plasma (0 - 8 h 
pool; expt. 41/75 ) was present in the unconjugated fraction. Tic of 
the extract (in system S-4) showed that the major band of radioactivity 
had the same R^ value as authentic dexamethasone (Table 8).
Table: 8
Tic of unconjugated radioactivity extracted from 0-8 h pooled plasma 
(Expt. 41/75).
-  , . -
% H extracted % of plated dpm present in various sections
Extract from plasma origin = 20 dihydro = Std.dexa- = 11-dehydro-
-dexamethasone methasone dexamethasone 
std
Plasma spiked 
with 3H- 
Dexamethasone
96.5 1 - 85.0 1.2
Plasma pool 
expt. 41/75
65 8.4 5.8 70.1 3.4
3.3.2. Excretion and distribution of radioactivity in crude urine and urine 
fractions:
3(a) Low dose : Urinary excretion of H is shown in Fig. 14. Between
50-60% of the administered dose was excreted during 96 h, excretion 
being virtually complete in the first 36 h. The distribution of radio­
activity in the various crude fractions in the first 24 h is shown in
3 . . .
Fig. 15 and the percentages of H present in the various fractions
for both the experiments are given in Table 9.
1400
1200
1000aaxs
coam
*.'800
a
u<d
a
>>-p
•H
>
•H
■pocO
O•H
T3
cOa
600 .
400
200
4 6 8 10
Time after administration (h)
12
▲
— i
24
3Fig.13. Plasma concentration of H after intramuscular administration of 
JjL,2-(n)- h ]Dexamethasone.
A Expt. 41/75 
• Expt. 10/78
0 20 40 60 80
Time a f t e r  a d m in is tr a t io n  (h )
100
F ig .  14 U r in a ry  e x c re t io n  o f  r a d io a c t iv i t y  a f t e r  in tra m u s c u la r
3
a d m in is tr a t io n  o f  ( 1 ,2 - n -  H)dexamethasone to  two 
horses ( Low Dose : 25 mg ) .
Cu
mu
la
ti
ve
 
p
e
r
c
e
n
t
a
g
e
.o
f 
H 
ex
cr
et
ed
 
in 
ur
in
e
20 - (A)
10 *
30 -
(B)
20 -
10 *
10 15 20 25
Time after administration (h)
Fig. 15. Distribution of urinary radioactivity in the crude ethyl
acetate extracts during the first 24 h after administration 
of [l,2-( n)-^HlDexamethasone
A: Expt. 9/74 B: Expt. 41/75
• Unconjugated fraction 
O Conjugated fraction
■ Unextractable fraction
Table 9
The excretion and distribution of radioactivity in the urine and in the
unconjugated, conjugated and unextractable fractions of the 24 h sample
3after intramuscular administration of H-dexamethasone (expressed as % 
of total dose).
Expt.
No.
Percentage total 
dose excreted-
Fractionation of 
24 h pool into
Total dose 
recovered
in 24 h in 96 h Uncon- Con­
jugated jugated
Unextr­
actable
9/74 40.2 51.5 26.5 7.8 4.2 38.5
41/75 56.0 61.0 36.0 13.3 5.0 54.3
These results indicate that about 65% of the urinary radioactivity 
was excreted in the unconjugated and 20-22% in the conjugated form. The 
apparently linear rate of excretion of the unconjugated fraction
(Fig.15(A);expt. 9/74) could only occur if the fraction contained one
single component which was excreted in the urine via an active and saturated
secretory process thus reflecting true excretion of the compound. However,
as has been subsequently shown, this is not the oc^ se for this fraction and 
therefore the result could only be considered fortuitous. In Fig. 15 (B) 
(expt. 41/75) the apparent delay in the excretion of radioactivity in the 
urine could have been caused by a delay in the absorption of the drug 
after administration. Since the first urine sample was voided 9.5 h after 
injection the slow excretion into urine could not be determined. However, 
once absorbed from the site of administration the radioactivity was rapidly 
excreted in thq urine. A similar delay in the absorption and urinary 
excretion of radioactivity after i.m. administration of prednisolone to 
horses, due presumably to an inadvertent injection into fatty tissue has 
been reported by Moss and Rylance (1967).
3(b) High dose; The urinary excretion of H is shown in Fig. 16. The
3
discrepancy in the excretion of H between expts. 10/78 and 13 and 14/78
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is difficult to explain. For the three experiments, the percentage of 
the total dose excreted in the first 24 h and in the unconjugated and 
enzyme hydrolysed urinary extracts is given in Table 10. It can be 
seen that the percentages of the dose extracted by ethyl acetate from 
the urine samples adjusted to pH 4 without hydrolysis and also after 
enzyme hydrolysis treatement (at pH 4.8) are virtually identical. This 
indicates that the material which is extracted from the urine is of an 
ionic (acidic) nature and not water soluble steroid conjugates, which 
cannot be extracted from the urine by organic solvents before hydrolysis 
of the conjugate moiety or saturation of the urine with ammonium sulphate.
Table 10.
Percentage of the total dose excreted in the 24 h pooled urine sample and 
in the urinary fractions after administration of a high dose (250 mg) of 
dexamethasone.
Expt. 
No.
Total dose 
excreted 
in 24 h
Unconjugated 
fraction ex­
tracted at 
urine pH 8.6 
before 
hydrolysis.
Unconjugated 
fraction ex­
tracted at 
urine pH 4.0 
before 
hydrolysis
Total radio­
activity ex­
tracted from 
urine after 
enzyme 
hydrolysis 
treatment.
Unextract- 
able from 
urine
10/78
%
65.0
%
7.8
%
45.0
%
45.0
%
20.0
(12.0)* (69.0) (69.3) (30.7)
13/78 9.5 2.0 6.0 6.1 3.5
(22.0) "(63.0) (64.9) (35.7)
14/78 13.0 2.6 8.4 8.1 4.8
(20.0) (65.0) (65.0) (37.0)
* Figures in parenthesis indicate % of total urinary radioactivity extracted 
with ethyl acetate after different treatments.
5.3.3. Isolation and identification of urinary metabolites:
(a) Low dose : The elution of reference steroids from Sephadex LH-20
columns under standard chromatographic conditions is shown in Fig.17.
For the urine extract four major fractions were resolved using 150 ml of the
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eluant; a fifth fraction was eluted with methanol (Fig. 1.7).. The radioactive 
fractions containing partially resolved metabolites were pooled, the 
solvent removed and the radioactive residues from each fraction were 
further analysed and purified by tic.
Fraction 1 (elution vol. 0-25 ml) contained 16% of the urinary 
activity and was further resolved by tic (system S-ll) into two 
radioactive metabolites. Metabolite la had an Rp value of 0.39 
corresponding to that of authentic 17-oxo-dexamethasone (II).
Metabolite lb had an Rp value of 0.29 corresponding to. that of 
11-dehydrodexamethasone (III).
Fraction 2 (elution vol. 26-50 ml) contained 17.5% of the urinary 
activity and was also resolved by tic (system S-4) into two radioactive 
metabolites. Metabolite 2a had an Rp value of 0.41 corresponding to 
that of standard dexamethasone (I). The second metabolite (2b) had an 
Rp. value of 0.51.
Fraction 3 (elution vol. 51-100 ml) contained 12% of the urinary 
activity. Tic of this fraction (system S-4) showed a major band of 
radioactivity (metabolite 3) having an Rp value of 0.19 corresponding 
to that of authentic 20-dihydrodexamethasone (VI).
Fraction 4 (elution vol. 101-150 ml) also contained 12% of the 
urinary activity. Tic of this fraction (system S-4) showed a major 
band of radioactivity (metabolite 4) having an Rp value of 0.25.
(Authentic 6^-hydroxybetamethasone had an Rp value of 0.26 in this 
system).
Fraction 5, eluted with methanol, and containing 25% of the urinary 
activity,was not examined further.
The six radioactive metabolites described above were isolated from tic.
The identification and characterization of the individual compounds was 
carried out on aliquots of each metabolite using the microchemical 
reactions as described by Butler and Gray (1970). The Rp values of the 
underivatised steroids and their oxidation, reduction and acetylation 
products were determined in two solvent systems SI and S4 (Tables 11 and 
12).Tests were run in parallel with authentic reference compounds and 
their Rp values were compared with the urinary metabolites. 6yS-Hydroxyr
betamethasone (authentic sample obtained from Glaxo Labs.) was used as 
a reference compound to determine the identity of the 6-hydroxylated 
metabolites. This compound has previously been used to identify 
6/8-hydroxydexamethasone in rat urine (English et al. 1975).
Table 11*
Thin-layer chromatography of dexamethasone metabolites isolated from 
horse urine. System S-l (ethyl acetate)
Metabolites and Chemical modifications
Reference Compounds. None Oxidation Reduction Acetylation
Metabolite la 0.61 0.63 0.39 0.59
17-oxo-dexamethasone 0.63 0.62 0.40 0.61
Metabolite lb 0.57 0.70 0.42 0.69
11-dehydrodexamethasone 0.57 0.71 0.44 0.70
Metabolite 2a 0.41 0.62 0.19 0.62
dexamethasone 0.40 0.63 0.18 0.64
Metabolite 2b 0.52 0.51 0.28 0.61
6-hydroxy-17-oxo-betamethasone 0.53 0.53 0.28 0.63
Metabolite 3 0.17 0.62 0.18 0.60
20-dihydrodexamethasone 0.19 0.62 0.18 0.62
Metabolite 4 0.25 0.50 0.11 0.62
6-hydroxybetamethasone 0.26 0.51 0.14 0.64
Table 12.
Thin-layer chromatography of dexamethasone metabolites isolated from 
horse urine. System S-4 (Dichloromethane-chloroform-ethanol, 8:1:1, v/v/v)
Metabolites and Chemical modifications
Reference Compounds. None Oxidation Reduction Acetylation
Metabolite la 0.62 0.61 0.43 0.64
17-oxo-dexamethasone 0.63 0.62 0.42 0.62
Metabolite lb 0.56 0.69 0.34 0.71
11-dehydrodexamethasone 0.59 0.70 0.36 0.74
Metabolite 2a 0.40 0.63 0.20 0.67
dexamethasone 0.42 0.62 0.22 0.68
Metabolite 2b 0.51 0.52 0.27 0.67
6-hydroxy-17-oxo-betamethasone 0.50 0.50 0.29 0.66
Metabolite 3 0.20 0.60 0.20 0.61
2 0-dihydrodexamethasone 0.21 0.62 0.20, 0.62
Metabolite 4 0.26 0.51 0.09 0.67
6-hydroxybetamethasone 0.28 0.51 0.10 0.70
(b) High dose : The ethyl acetate extract of the 0-24 h pooled urine sample,
isolated at pH 4.0, was fractionated by Sephadex LH-20 column chromatography. 
Only one fraction (elution volume between 25-50 ml) containing about 5% of 
the urinary radioactivity (3.9% of total dose) was resolved by chromatography 
under standard conditions. After removal of the solvent, the residue from 
this fraction was further purified by HPLC and was found to contain only 
one radioactive metabolite having a retention time corresponding to that of 
authentic dexamethasone (I) under the experimental conditions used. This 
radioactive metabolite was confirmed as the parent drug (dexamethasone) by 
direct probe inlet CI-MS using methane as the reagent gas. The Cl mass 
spectra of authentic dexamethasone and of the urinary metabolite are shown 
in Fig. 18 and Fig.19.
The polar material (containing about 60% of the urinary activity or 40% of 
the dose) was eluted from the Sephadex LH-20 column with methanol, and 
after removal of the solvent, the residue was methylated with diazomethane. 
Silica column chromatography of the methylated extract resolved three
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Fig. 19. Methane Cl - mass spectrum of dexamethasone isolated from 
horse urine after administration of high dose.
radioactive metabolites representing 2.8%, 13.6% and 18.5% of the 
administered dose. Because of the degradation of the C-17 side chain 
during analysis by electron impact and methane-CI mass spectrometry, 
the molecular weights and the absolute identification of the structures 
of these acidic metabolites could not be determined.
3.4 DISCUSSION
After intramuscular administration of a therapeutic dose of
3 2
H-dexamethasone to cross-bred gelded horses, H-levels in plasma were
3
low. Peak concentrations of the H-activity in plasma were obtained 
between 1-2 h after administration. Similar results were obtained by 
Mineo (1976) after i.m. injections of a number of different synthetic 
analogues to rats. About 65% of the radioactivity in the 0-8 h pooled 
plasma sample was present in the unconjugated form. Between 40-50% 
of the administered radioactivity was rapidly excreted in the urine in 
the first 24 h and a total of 50-60% of the dose was excreted during 
the first 96 h after administration. Although the fecal excretion of 
radioactivity was not measured, the above results indicate that the 
excretion of administered dexamethasone in the horse is intermediate 
between man with a predominantly urinary route of excretion (Haque et 
al. 1972, Brooks et al. 1977) and the rat which shows a mainly fecal 
route of excretion (Rice et al. 1974). Greater than 60% of the radio- 
activity in the 24 h urine collection was excreted in the unconjugated 
form. The relatively small proportion of the metabolites excreted as 
conjugates could be attributed to the absence of A-ring reduction 
(Glenn et al. 1957, Florini et al. 1961).
After initial mixed enzyme hydrolysis treatment on aliquots of 
the 24 h urine collection, the radioactivity was extracted by Amberlite 
XAD-2 resin. After removal of the solvent, the radioactive metabolites 
present in thevextract were separated and purified by Sephadex LH-20 
column chromatography and tic. Identification of the metabolites was 
based upon tic data for each compound and also the change in value 
of the product following selective microchemical transformations - 
acetylation, oxidation and reduction of each metabolite. These tests 
were run in parallel with the corresponding derivatives of the reference
compounds and the chromatographic evidence is presented in Tables 
11 and 12. Using this technique, in addition to dexamethasone,
five radioactive metabolites were identified from the 0-24 h urine 
collection accounting for 57.5% of the urinary activity (Fig. 20) .
The main metabolic pathways were hydroxylation at C-6 and reduction 
at C-20, with oxidation at C-ll and C-17 being relatively minor 
routes. The polar material (fraction 5) which was retained on the 
Sephadex LH-20 column and accounted for 25% urinary activity was 
not analysed further at this stage. However from subsequent studies 
using a large dose of dexamethasone it was found that this fraction 
accounted for more than 60% of the urinary activity and contained 
polar unidentified C-21-acidic metabolites of dexamethasone. Since 
this fraction (Fraction 5; low dose study) was isolated from urine 
extracted at pH 4.5 (following enzyme hydrolysis treatment) it is 
possible that it could contain some acidic metabolites.
Because of the insolubility of large amounts of dexamethasone in. 
ethanol-saline (1:9, v/v) the large dose was administered as an 
aqueous suspension. In experiments 13/78 and 14/78, the slow urinary 
excretion of radioactivity after intramuscular administration suggests 
a slower rate of absorption from the site of administration. These 
results agree well with the slow delivery of drugs into the systemic 
circulation from micronised suspensions which are formulated as long- 
acting preparations. In expt. 10/78 the rapid absorption and 
excretion of 65% of the administered dose in the urine in the first 
24 h after administration is difficult to explain. Because the plasma
3
H levels after administration were low, it is unlikely,to be due to 
the steroid being injected inadvertently into a vein.
For the three experiments, about 20% of the urinary radioactivity 
could be extracted from the 0-24 h urine sample (average pH 8.5) before 
any form of hydrolysis treatment. However, greater than 60% of the 
urinary radioactivity could be extracted from the urine after acidifi­
cation of the sample to pH.4.0 without enzyme:hydrolysis treatment and 
also after mixed hydrolysis treatment at pH 4.8 followed by incubation 
at 37°C for 48 h. This result suggested that the radioactive 
metabolites were excreted in the urine not as the water soluble steroid
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Fig. 20. Urinary metabolites of dexamethasone in the horse.
conjugates but in the form of ionisable acidic compounds which could 
not be extracted into the organic solvents from an alkaline solution 
(i.e. horse urine).
Studies on the isolation and identification of the urinary 
metabolites after administration of the large dose were carried out 
on the 0-24 h urine sample from experiment 10/78 only because it 
contained a large proportion of the administered dose. Purification 
of the unconjugated steroids extracted from the urine at pH 4 by 
Sephadex LH-20 column chromatography resolved only one radioactive 
fraction accounting for about 5% of the urinary activity. This fraction 
was further purified by HPLC and the isolated radioactive metabolite was 
identified as the parent drug dexamethasone by methane CI-MS using 
direct insertion probe. The base peak at m/z 333 £(M + l)+-6o| in the 
mass spectrum of the compound (Fig.19) is derived from the loss of
the C__, C0„ side chain. The polar material which was retained on the
20 21 ^
Sephadex LH-20 column was eluted with methanol and accounted for 60% of
the urinary radioactivity (40% of the administered dose). After
methylation with diazomethane, this material was chromatographed on a 
Kieselgel H column and three radioactive fractions were isolated. The 
absolute identities of these methylated acidic metabolites could not be 
obtained due to lack of authentic reference steroids and because of the 
degradation of the side chain at C-17 during mass spectrometric analysis 
using both El and Cl modes.
It is known that the structural modifications of the synthetic 
glucocorticoids make these compounds poor substrates for hepatic enzyme 
systems responsible for the catabolism of endogenous glucocorticoids.
The reductive catabolism of the A-ring is inhibited due to the presence 
of the l,4-diene-3-one and the 9ct-fluoro groups (Glenn et al. 1957,
Butler and Gray 1970). However complete reduction of the A ring has been 
reported after.administration of prednisolone in man (Caspi and Pechet 
1958, Vermeulen 1959), after administration of fluorocortolone to man 
(Gerhards et al. 1971, Kono et al. 1973) and ram (Lambe et al. 1978) and 
after administration of fluocinonide to rats (Takahashi 1972). The 
majority of the synthetic glucocorticoids are metabolised by the reduction 
of the ketone at C-20 and hydroxylation at C-6. However, these pathways
are relatively slow (Bush and Mahesh 1964) and due to the lipophilic 
nature of these compounds they are slowly excreted from the body. 
Furthermore, synthetic corticosteroids have a lesser capacity for 
conjugation due to the stability of the A-ring.
After the administration of a therapeutic dose of 
dexamethasone to horses, the metabolism proceeded via the reduction of 
the ketone at C-20 and hydroxylation at C-6 and the relatively minor 
pathways of oxidation at C-ll and C-17 and the majority of the 
biotransformation products were excreted in the urine in the unconjugated 
form. These findings compare well with the pathways of catabolism of.' 
betamethasone (the 16y3-methyl isomer) in man (Butler and Gray 1970) and 
those of a number of synthetic glucocorticoids in the rat (Mineo 1976). 
However after the administration of a large dose, the constraints 
imposed by the structural modifications on the pathways of biotransformation 
contributed to the induction of an alternate pathway leading mainly to the 
formation of the highly polar water soluble acidic metabolites of 
dexamethasone in order to facilitate the rapid elimination of the drug 
from the body. This formation of the C-21 acidic metabolites of 
dexamethasone marks a new pathway for the biotransformation and 
elimination of this drug in the horse. The C-21 oxidation of cortisol 
in man was first reported by Bradlow et al. (1973) and the mechanism of 
the formation of C-21-acidic metabolites has been described in subsequent 
publications (Monder et al. 1975, Zumoff et al. 1977, Monder et al. 1980). 
The C-21 acidic metabolites of synthetic glucocorticoids like prednisolone 
(Lee 1977), fluorocortolone (Laurent et al. 1975), halcinonide (Kripalani . 
et al. 1977), triamcinolone acetonide (Gordon and Morrison 1978) and 
17-deoxydexamethasone (Hbrnke 1980) have also been isolated and identified 
from both in vivo and in vitro studies in animals. Recently a gc-ms 
method for the identification of cortolic acids has been reported by 
Shackleton et al. (1980).
CHAPTER IV
METABOLISM OF TESTOSTERONE
4.1 INTRODUCTION
Testosterone (l7|3-hydroxyandrost-4-ene-3-one), the natural 
male testicula,r androgen is also a potent anabolic agent. Its use, 
however, is limited because of its androgenic side effects. The 
anabolic effect induced by the administration of testosterone is 
not immediately apparent, but manifests itself after the majority 
of the effective dose has been metabolised and excreted (West et
al. 1951)*
The metabolism.of testosterone has been extensively studied 
both in vivo and in vitro in man and several animal species and 
many excellent' accounts of its metabolism are available (Dorfman 
and Ungar 1965, Baulieu and Robel 1970, Wilson 1975, Ismail 1976, 
Kochakian and Arimasa 1976, Vermeulen 1979)* Testosterone is 
metabolised by several enzymes such as the ^-reductases, hydro- 
xysteroid oxidoreductases and ring hydroxylases present in the 
liver and most other tissues. Degradative metabolism involves 
saturation of the A ring to form 5<x and 5|3 compounds, reduction 
of the 3-oxo group and oxidation of the 17(3-hydroxy group. Although 
liver is the major site for degradative metabolism, considerable 
extrahepatic and peripheral interconversion of androgens also occurs 
in vivo. Once secreted into general circulation, testosterone can 
serve as a precursor both for oestrogen formation and for the bio­
synthesis of 5a-reduced steroids that are in themselves potent 
androgens. Therefore, an insight into androgen physiology is difficult 
due to the complexity of its catabolism and the actions of the meta­
bolites at cellular level. Conjugation occurs mainly in the liver 
with glucuronic and sulphuric acids * The glucuronides are rapidly 
excreted at rates approaching the glomerular filtration rates 
whereas the sulphoconjugates are cleared very slowly through the 
proximal tubules (Hellstrom et al. 1969, Vermeulen 1979)*
The major urinary metabolites of testosterone in man are the 
isomers of 3-hydroxy-androstan-17-one (androsterone/etiocholanolone), 
5-androstane-3,17~diol, and small amounts of dihydrotestosterone and
and androstenedione (Baulieu and Robel 1970). The hydroxylation of 
testosterone at C—6, C—7 and C—16 positions and the excretion of 
conjugated hydroxyke tonic steroids in urine is a minor path­
way in man. The mechanism of aromatization and the formation of 
oestrogens from C-19-hydroxy percursor steroids has been reviewed 
by Engel (1973).
In the present study* the metabolism and urinary excretion 
of (4-14C) testosterone after intramuscular administration to two 
cross-bred gelded horses was investigated. After hydrolysis and 
extraction of the steroids from the 0-24 h urine collection, the 
neutral metabolites were isolated and after further purification 
they were identified by gc-ms. Due to lack of authentic reference 
compounds, the stereochemistry of some of the metfi/bolites could 
not be established.
4.2 EXPERIMENTAL
4.2.1. Administration to animals and collection of blood and urine 
samples?
Bfefore administration of the drug, urine samples from each 
animal were collected as control specimens. Intramuscule,r adminis­
trations of a mixture of the labelled and unlabelled steroids were 
made to the two horses at single sites in the neck. The dose was 
dissolved in ethanol (0.3 ml) to which was added arachis oil (8.0 ml) 
containing benzyl alcohol (10$ v/v) and cresol (0.3$ v/v). The 
weights of the animals and the doses are given in Table 13.
Table 13 .
Administration of (4-^C) testosterone to horses
Expt. No. Animal
Body Dose prepared Dose
injected
/^uCi)
/ffA gWeight
(kg)
(^CjjuCi unlabelled(mg)
1/77 PEDRO 382 25.03 150 22.0 34 6
13/77 NIMROD 378 22.68 150 21.6 375
The housing of animals and the collection of sequential timed 
blood and urine samples have been described (Section 2.2.1. Chapter II).
Urine samples were collected upto 200 h after administration and 
aliquots (0*1 ml x 2) from each specimen were taken to determine 
the total excreted. Sequential blood samples were collected 
upto 24 h and the plasma (l ml x 2) counted for activity#
4*2.2. Extraction of uncon.jugated steroids from plasma:
Plasma samples (0-8 h, expt l/77) were pooled (approx. 60 ml), 
the volume made upto 100 ml with deionised water and the unoonjugated 
steroids extracted with ethyl acetate (l x 500 ml). The ethyl 
aoetate was washed with HaOH (0.1 N, 2 x 100 ml), then with brine, 
dried over anhydrous Na^SO^ and taken down to dryness under reduced 
pressure. Tic of the extract was carried out using system S-3; 
androstenedione, testosterone and 5ct--androstane-3(3,17f3*-diol were 
used as reference compounds.
4*2.3* Distribution of radioactivity in crude urine fractions:
Samples (50 ml; 0-24 h pooled urine) from each experiment 
were processed as shown in the flow diagram (Fig . 21) in order 
to determine the percentages of non-conjugated, conjugated and 
unextractable "^C. Aliquots of the urine and ethyl acetate were 
removed at each stage for scintillation counting to determine the 
percentage of present in the various fractions.
4*2*4* Isolation of the neutral metabolites:
(a) Total enzyme hydrolysis : Samples (50 ml; 0-24 h pooled urine) 
from each experiment were adjusted to pH 4*8 and incubated with 
Helix pomatia digestive juice (0.25 ml) at 37°C for 48 h. After 
hydrolysis, the urine was extracted with ethyl acetate (2 x 100 ml). 
The ethyl acetate w. s washed with NaOH (0.1 N, 2 x ^0 ml), then with 
brine, dried over anhydrous Na^SO^ and taken down to dryness under 
reduced pressure at 40°.
(b) Acid hydrolysis of the residual urine s After mixed enzyme 
hydrolysis treatment and extraction of the freed steroids, the 
volume of the residual urine was /adjusted to $0 ml with deionised 
water and oonc. HC1 (7.5 ml) was added. The mixture was boiled 
under reflux for 1 h, cooled and the neutral extract was isolated 
by solvent extraction as described above.
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Fig* 21. .Flow diagram for the isolation of neutral urinary
14-extracts after administration of C-testosterone.
(from Houghton and Dumasia 1979)
(c) Total acid hydrolysis : Samples (50 ml; 0-24 h pooled urine)
from each experiment were hoiled under reflux with conc. HC1 (7*5 ml) 
for 1 h and the neutral extract was isolated as described above#
4»2#5»* Studies on the steroid conjugates:
(a) Extraction and fractionation of conjugates i Samples (50 ml;
O-24 h pooled urine) from each experiment were passed down a 
column containing Amberlite XAD-2 resin (Bradlow 1968)# After the 
urine had passed down the column, the resin was washed with deionised 
water (2 x 50 ml) an& fhe radioactivity retained on the resin was 
eluted with methanol (3 x 50 ml)# The combined methanol washings 
were taken down to dryness under reduced pressure at 40°* ®ie 
residual material was dissolved in chloroform - methanol (l:l, v/v;
2 ml) made 0.01 M with respect to EFaCl and fractionated on a 
Sephadex LH-20 column (10.0 g; column diam# 20 mm) prepared in and 
eluted with the same solvent mixture (Vihko 1966, Eriksson and 
Grtistafsson 1970)* Fractions (30 x 5 ml) were collected and any 
material retained on the gel was eluted with methanol. An aliquot 
(0#1 ml) of each fraction was taken to determine the total radio­
activity. Fractions comprising the resolved radioactive peaks 
were combined and the solvent removed under reduced pressure at 
40°.
(b). Hydrolysis of the steroid conjugates isolated by Sephadex 
LH-20 chromatography s The fraction containing the glucuronic acid 
conjugates was dissolved in 0.2 M sodium acetate buffer, pH 4*5 (50 ml) 
and incubated with Helix pomatia digestive juice (0.25 ml) at 37°
for 48 h. After hydrolysis treatment the neutral extract containing 
the aglycones was isolated as described.
The fraction containing the sulphuric acid conjugates was 
dissolved in methanol (l.O ml) and solvolysed at 37° for 24 h in 
ethyl aoetate (50 ml) acidified with 2M H^SO^. After solvolysis 
treatment, the ethyl ac-r-tate was washed with aqueous saturated NaHCO^
solution until alkaline, then with brine, dired over anhydrous Na^SO^ 
and taken down to dryness to give the neutral extract.
(c) Standardisation of Sephadex LH-20 column chromatography*
l^Nortestosterone (l mg), testosterone glucuronide (Na salt)
(l mg) and androsterone sulphate (Ha salt) (l rag) were added to 
an Amberlite XA2>-2 extract of a pre-administration urine sample 
(50 ml) and the extract was chromatographed on a Sephadex LH-20 
column, using the above conditions. The glucuronide and sulphate 
fractions were isolated and after hydrolysis, an aliquot (l/6 of 
each fraction was derivatised (MO-TMS) and analysed by gc-ms.
4*2.6. Fractionation of the neutral steroid metabolites by 
Kieselgel H' column chromatography :
The neutral extracts were fractionated on Kieselgel HI 
(5*0 S? column diam. 15 mm) using 1,2-dichloroethane-ethanol 
(98:2, v/v) as eluant. After collection of 30 x 3 ml fractions 
the eluant was changed to 1,2-dichloroethane-ethanol (95*5* v/v) 
and 30 further 3 ml fractions were collected. The material remaining 
on the column was then eluted with methanol. Aliquots (0.1 ml) of 
each fraction was taken to determine total radioactivity. The 
fractions comprising each radioactive peak resolved by column 
chromatography were combined and the solvent removed under reduced 
pressure.
The first fractions in each case containing the partially 
resolved metabolites were individually rechromatographed on 
another Kieselgel H (5.O g) column using toluene - ethyl acetate 
(7:3? v/v) as eluant in order to obtain a better separation of the 
individual metabolites. Blank urine samples (50 ml) from each 
animal were also hydrolysed, extracted and chromatographed as 
described above.
4.2.7. Gas chromatography and combined gas chromatography - 
mass spectrometry :
Aliquots of each fraction isolated by Kieselgel H column 
chromatography of the neutral extracts were analysed by glc and 
combined gc-ms as their TflS and MO-TMS derivatives. In addition, 
aliquots of fraction No. 6 were also analysed as their acetonide- 
TMS ether derivatives. Capillary column glc was carried out by 
Masspec Analytical Services Ltd., StroUd, Gloucestershire, using 
a Carlo ESrba FL 2150 instrument fitted with an OF-1 WCOT1 column
(20 in, 0.2 mm id), with He as the carrier gas.
4*3 RESULTS
4.3.1* Radioactivity in plasma :
The levels of radioactivity in plasma after administration of 
^C-testosterone to the two horses are shown in Big. 22; plasma 
levels were very low, reaching a maximum at ahout 3 h. Only 45$ 
of the radioaotivity present in the plasma (0-8 h pool) could be 
extracted using ethyl acetate. Tic of the extract (in system S-3) 
showed that the major band of radioactivity had the same Rf value 
as authentic testosterone (Fig. 23)*
4.3*2. Bzoretion and distribution of radioactivity in crude urine 
and urine fractions t.
14 *
The urinary excretion of C from both administrations is shown 
in Big. 24* About 45$ of administered radioaotivity was excreted 
in 96 h; small amounts could still be detected at 200 h. The 
distribution of radioactivity in the crude ethyl acetate extracts 
after various hydrolytic treatments on aliquots of the 0—24 k sample 
as described in Big. 21 is shown in Thble 14*
The results indicate that only a small amount (about 4*3$) 
of the urinary radioactivity was excreted in the unconjugated form. 
Bbr the two experiments, after mixed enszyme hydrolysis treatment, 
only 22$ and 34$ respectively of the urinary radioactivity could 
be extracted from the urine and a further 48$ and 41$ respectively 
could be extraoted after hot acid hydrolysis treatment on the 
residual urine samples. However, after total acid hydrolysis treat­
ment on aliquots (50 ml) of the 24 h collection from both experi­
ments (l/77 and 13/77), 83$ and 78$ of the total urinary was 
extracted with ethyl acetate of which 64$ and 56$ remained in the 
neutral extracts respectively.
4.3.3. Purification of the crude neutral extracts by Kieselgel H 
column chromatography :
Using the solvent extraction procedure described, crude neutral 
extracts were isolated following enzymatic hydrolysis treatment, 
subsequent hot acid hydrolysis treatment on the residual urine 
after enzyme hydrolysis and also after total hot acid hydrolysis 
treatment on aliquots (50 ml) of the 0-24 h collection for both
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Fig. 24. Urinary excretion of radioactivity after intramuscular
14administration of (4 - C)testosterone to horses.
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experiments. Chromatography on Kieselgel KD of these neutral
extracts resolved six radioactive fractions in each case, the
seventh fraction was eluted with methanol. The elution patterns of 
14C from column chromatography of the extracts obtained from expt.
13/77 are illustrated in Fig. 25(a) (total acid hydrolysis);*
Fig. 25(b). (enzyme hydrolysis) and Fig. 25(c) (acid hydrolysis of
residual urine after enzyme hydrolysis treatment). Similar elution
patterns were obtained for expt. l/77* The distribution of urinary 
14C activity m  the crude extracts and in the fractions resolved 
by KieselgelH chromatography is given in Table 15*
4.3.4. Identification of the urinary metabolites by gc-ms r
Fractions al-a6, bl-b6 and cl-c6 (Fig.25) isolated by 
Kieselgel H chromatography were analysed as their trimethylsilyl 
ether or methoxime-trimethylsilylether derivatives by glc and gc-ms. 
The identities of the metabolites of testosterone present in these 
fractions were established by comparison of their retention times 
and their mass-spectra with those of authentic reference compounds 
where available and also by peak augmentation with authentic 
standards on glc using packed and capillary columns.
Fraction 1 - Fractions al, bl and cl (Fig. 25) after the formation 
of their MO-TMS derivatives proved too complex on analysis by 
gc-ms and the metabolites present in these fractions could not be 
identified. Therefore, these fractions (from expt. 13/77) were 
further purified by rechromatography on Kieselgel H (5 g) using 
toluene-ethyl acetate (7*3$ v/v) as eluant. In each case two 
radioactive fractions were resolved comprising 7$ and 2*4$ of 
the urinary activity for fraction al, 1.0$ and 0.6$ for 
fraction bl and 1.8$ and 0.8$ for fraction cl respectively. After 
the formation of their MO-TMS derivatives, none of the compounds 
present in the major fractions could be identified by gc-ms.
However, 'using SIM, an isomer of 3-hydroxy an drostanr-17-one as its 
MO-TMS derivative was detected in the minor fractions in each case. 
The mass spectra of these compounds show major ions at m/z 391 
(M*), 376(M*-15), 360(Mt-3l), 270 [m1*^ 90+31)] and 213 (Fig.26).
From the retention time data and ooinjection with reference 
steroids, the stereochemistry of this isomer was found to be 
consistent with the 3p-hydroxy~5aandros tan-17-one (n) con­
figuration.
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Fig. 25. Kieselgel H column chromatography of the neutral urinary extract 
isolated from expt. 13/77.
(a) after total acid hydrolysis of 0 - 24- h pooled urine
(b) after mixed enzyme hydrolysis of the urine
(c) after hot acid hydrolysis of the residual urine 
following mixed enzyme hydrolysis and extraction 
of the freed steroids.
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Fig. 26. Selected Ion Current Profiles of an isomer of the 
17-oxosteroid ( 5a«androstan-33-ol-17-one-.M0-*TMS ) 
isolated from horse urine extracts by Kieselgel H 
column chromatography (Fractions 1).
(a) authentic 5a-androstan-33-ol-17-one
(b) after total acid hydrolysis of 24h urine sample
(c) after mixed enzyme hydrolysis
(d) after hot acid hydrolysis of the residual urine 
from (c).
(from Houghton and Dumasia 1979)
Fraction 2 - Fractions a2, b2 and c2 (Fig, 25), after the 
formation of their MO-TMS derivatives were analysed by glc and 
go-ms. Only fractions a2 and c2 showed the presence of a major 
component which was tentatively identified as an isomer of 17- 
,hydroxyandrost-4-ene-3-one. By comparison of its retention time 
on glc and coinjection with authentic reference steroids it was 
identified as the unchanged drug testosterone (i). The mass spectrum 
of testosterone-MO-TMS ether shows a molecular ion at ra/z 389 and 
fragment ions at m/z 374(M*-15)> 358(M*-3l), 268 £m*-(90+31)] ,
129 and 125 (FLg. 27). Testo sterone could not be detected in 
fraction b2 (isolated from the enzyme hydrolysed urine extract) 
even by SIM,
Fraction 3 - Fractions a3, b3 and c3 (Fig, 25), after the formation 
of their TMS and MO-TMS ether derivatives and analysis by gc-ms, 
showed that between them they contained at least three different 
metabolites. On the basis of their molecular weights and mass 
spectral fragmentation patterns, two of these compounds were iden­
tified as isomers of 5"*androstane-3,17-diol-bis-TMS ether. The 
mass spectra of the isomers of these compounds show a base peak 
at m/z 129 and fragment ions at m/z 436 (M*),, 42l(M*-15), 346(M*-90) 
and 256[m^-(2x90)J for loss of methyl and trimethylsilanol groups 
(Fig. 28). Their stereochemistry was determined by comparison 
of their retention times and by coinjection with the bis-TMS ethers 
of the four authentic androstane-3,17P~diol isomers using capillary 
column glc (Fig.29 )• The separation of the bis-TMS ethers of 
the four 17f3-diol isomers is shown in Fig. 29(a), the peak of 
the longest retention time corresponds to that of 5a-androstane-3P* 
17|3-diol-bis-TMS, The separation of the two urinary diol isomers 
is shown in Fig. 29(h) and the chromato.graph showing coinjection 
of the metabolites and the reference steroids is illustrated in 
Fig. 29(c). The silyl derivative of one of the metabolites (R^ 26.4 
min.) was clearly separated from the bis-TMS ethers of the four 
possible isomers with a 17P-0H configuration, thus indicating 
that the configuration at C-17 in this metabolite must be a. 
Enhancement of the peak with the longest R^ showed that the 
second diol isomer must be 5a-androstane-3|3,17P-diol (IV). This 
metabolite was the only diol present in fraction c3 [FLg.25(c)] 
and was a minor component in fraction b3 ]Fig. 25(b)j •
The diol having the 17a~0H configuration is tie major meta­
bolite present in fraction b3 ^Fig.25(bJ . Using this fraction the
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Comparison of the gas chromatography retention times of 
the bis-TMS derivatives of the androstane-3,17-diol 
metabolites and those of silylated reference compounds.
a) Co-injection of 53-androstane-3a,173-diol bis-TMS, 5a- 
androstane-3a,173-diol bis-TMS, 53-androstane-33,173-diol 
bis-TMS and 5a-androstane-33,173-diol bis-TMS reference 
steroids, (b) injection of the bis-TMS derivatives of the 
androstane-3,17-diol metabolites, (c) co-injection of the 
urinary diol metabolites and the reference androstane-3, 
17-diol isomers.
(from Houghton & Dumasia 1979)
the retention time of its bis-TMS ether with the retention times 
of the bi3—TMS ethers of the four isomers of androstane—3? 17flG-diol 
using a packed column (l.51/ OV-1 on (Jas Ghrom Q, 200-240° at 2°/nri.n). 
The of the silylated metabolite corresponded to that of 5<X- 
androstane—33,17(*-diol-bis-TMS ether (ill).* This isomer ivas clearly 
separated from the other three under the glc conditions used. Bbth 
isomers were present in fraction a3 ^ Fig.25(a}jL
In addition to the two isomeric 0.^0 2 metabolites, fractions
a3, b3 and c3 (Fig. 25) each contained another metabolite which on 
the basis of its molecular weight and mass spectral fragmentation 
pattern was identified as an isomer of a dihydroxymonoketo andro— 
stane (O-^O^* ® ie derivative of this compound had a retention 
time of 12.2 min and showed a molecular ion at m/z 450 with fragment 
ions at m/z 435* 216, 215 and a base peak at m/z 129 indicating the , 
presence of a 17-0TMS. group (Fig. 30 )• The MO-TMS derivative 
(R^ 13*3 min) showed a weak molecular ion at m/z 479 and fragment 
ions at m/z 4^4* 448, 358* 174 and 158 (Fig.3l). The ion at m/z 
358 showing a loss of 121 amu from the mdecular ion is indicative 
of the presence of a carbonyl group in addition to a 17-0TMS group. 
These mass spectra were identical with those of the TMS and MO-TMS 
derivative of 33>17p-diky&c*o-5<K-androstan-l6-one. Based on these 
findings, this metabolite was identified as an isomer of 3*17- 
dihydro xy andro s t an-16-one (V).
Fraction 4 - Analysis by gc-rps of fractions a4, b4 and c4 (Fig. 25) 
as their TMS and MO-TMS derivatives showed the presence of two 
isomeric dihydroxymonoketo androstanes. The TMS and MO-TMS deri­
vatives of the minor metabolite had the same retention times and 
mass spectra as the component (V) identified in fractions a3* b3 and 
c3 and is possibly a carry over from fraction 3* The mass spectrum 
of the TMS derivative of the major metabolite (R^ 11.2 min)- had a 
molecular,ion at m/z 450 and fragment ions at m/z 435* 345* 216,
215 and 117 (base peak) (Fig.32). The MO-TMS derivative (R^ 12.3 min) 
showed a weak molecular ion at m/z 479 and fragment ions at m/z 
464, 448, 358, 268 and a base peak at 174 (Fig* 33). The origin of 
the ion at m/Z 174 has been described by Fouros and Hhrvey (1972).
As these mass spectra were identical with those of the TMS and 
MO-TMS derivatives of 33,l6oC-dihydroxy-53-androstan-17-one, 
this metabolite was identified as an isomer of 3>l6-dihydroxy- 
androstan-17-one (Vi). The stereochemistry of the urinary
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metabolites could not be determined in this case due to the lack of 
all the authentic reference isomers*
Fraction 5 - After analysis of fractions a5 and b5 (Fig*25) 
by glc and gc-ms as their TMS and MO-TMS derivatives, any metabolites 
of testosterone in these fractions could not be identified possibly 
because they are present in very small amounts.
Fraction 6 — Analysis of the TMS and MO—TMS derivatives of fractions . 
a6, b6 and c6 (Fig* 25) by gc-ms indicated the presence of two compounds, 
the mass spectra of which showed weak molecular ions at m/z 524 
fragment ions at m/z 509, 434, 344, 191 and 147 (*lg- 34). From the 
molecular weight and the mass speotral data, these metabolites were 
identified as isomerio androstane-3,l6,17-triols (Ml)* The mass 
spectra of the isomers of these compounds have been reported by 
Grote and Spiteller (1977)• The cis configuration of the C-16,17- 
hydroxyl groups in the D ring was confirmed by the fact that both 
isomers formed an acetonide. The mass spectrum of the acetonide-QMS 
derivatives (Fig. 35 ) showed ions at m/z 405 (M*-15) and 
255[m*-(15+60+90)] indicating losses of the methyl, acetrc <*:i<l and 
trimethylsilanol moieties*
4*3*5«- Studies on the steroid conjugates s
After Amberlite XAD-2 extraction of the urine samples,
Sephadex LH-20 column ohromatography was used to separate the total 
urinary steroid extracts into conjugate groups (Vihko 1966, Eriksson 
and Gfustafsson 1970)• Two major radioactive fractions were resolved, 
fraction G (between 16-45 ml of effluent) containing the free 
steroids and the glucuronic acid conjugates and fractim S (between 
51-120 ml of effluent) containing the sulphuric acid conjugates 
(Fig. 36 ). After enzyme hydrolysis of the glucuronides and solvoly- 
sis of the sulphoconjugates, crude neutral extracts were isolated 
and fractionated on Kieselgel H columns. The percentage distribution 
of urinary in the Amberlite XAJ>-2 extracts, the fraotions G and 
S obtained from Sephadex LH-20 chromatography, the crude neutral 
extracts isolated by solvent extraction after hydrolysis of the 
conjugates and the fractions G1 to G6 and SI to S6 obtained from 
Kieselgel H ohromatography of the crude extracts for both experiments 
is given in Table 16*
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Fig. 35. El - mass spectrum of the silyl ether derivative of
16,17-isopropylidenedioxy-5-androstane-3-ol,
( 5-androstane-3,16,17-triol-acetonide-TMS ether ).
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Fig. 3£ Conjugate group separation by Sephadex LH-20 
column chromatography of an Amberlite XAD-2 
extract of horse urine (Expt. 1/77, 0-24 h sample) 
into free and glucuronic acid (G) and sulphuric 
acid (S) conjugates.
XU2
1/77 13/77
A 97 94
Fraction G Fraction S Fraction G Fraction S
B 19.1 68.1 22.5 63.9
C 15.5 62.5 19.8 59.6
0 Fraction 1 1.7 12.7 1.8
■6
7.1
Fraction 2 1.0 20.3 1.1 18.8
Fraction 3 4.4 9.0 6.1 7.0
Fraction 4 - 5.8 - 4.9
Fraction 5 1.8 1.4 1.2 2.6
Fraction 6 1.0 4.7 3.6 5.7
Methanol wash 4.5 5.8 4.8 10.3
Table 16. The distribution of radioactivity* in (A) Amberlite XAD-2 
extracts of the 0-24 h urine samples, (B) the free plus 
glucuronic acid (G) and sulphoconjugate (S) fractions 
isolated by Sephadex LH-20 chromatography,(C) the crude 
neutral extracts obtained after hydrolysis of the conjugated 
and (D) fractions G1-G6, S1-S6 and the methanol washes 
isolated from kieselgel H chromatography of the neutral 
extracts.
* expressed as percentage of radioactivity present in 
the 0-24 h urine samples.
To confirm the separation of free and glucuronic acid con­
jugates (fraction G, 16-45 ml) and sulphoconjugates (fraction S, 
51—120 ml) by Sephadex LH—20, authentic 19—nortestosterone, testos­
terone glucuronide and androsterone sulphate were added to an 
Amberlite XAD-2 extract of blank urine (50 ml), The extract was 
then chromatographed on a Sephadex LH 20' column under identical 
conditions and similar fractions were isolated. After mixed enzyme 
hydrolysis, the presence in fraction G of 19-nortestosterone and 
testosterone as their MO-TMS ethers was confirmed by gc-ms. 
Similarly, following solvolysis, the presence of androsterone MO-TMS 
ether was confirmed in fraction S,
For each horse, the MO-TMS derivative of fraction SI proved 
to be extremely complex on analysis by gc-ms and the metabolites 
present in these fractions could not be identified. Testosterone 
(i) was identified only in fraction S2. 3,17-Idhydroxyandrostan-
16-one (V) was a major metabolite in fraction S3, and a minor 
component in fraction S4, 3916-Dihydroxyandrostan-17-one (Vi) was 
present only in fraction S4*
Fractions G1 and G2 contained only a small percentage of 
14the urinary C and none of the metabolites present in these 
fractions could be identified by gc-ms. In fraction G3 from both 
experiments, 5oc-androstane-3j3,17<x-diol (ill) was found to be the 
major metabolite and 5a-androstane-3|3,17(3-diol (IV) was only a 
minor component. In fraction S3* however, 5a-androstane-3f3>17f3-diol
(IV) was the major metabolite whilst 5tt-androstane-3|3,17cc-diol ( m )  
was only a minor component.
Fractions G5 and S5 again contained only a small percentage 
of the urinary "^C and the metabolites present in these fractions 
could not be identified. The two isomeric androstane-3*16,17-triols 
(VII) were identified in fractions G6 and S6.
ft
Normal pre-administration urine samples collected from both 
animals were analysed by the same experimental procedures. Using 
selected ion monitoring go-ms none of the metabolites identified 
was found in these samples.
4.4# DISCUSSION
After intramuscular administration of (4 - ^C); testosterone 
to two crossbred gelded horses, very low levels of were found 
in the plasma and 45$ of the radioactivity in the plasma (,0-8h pool) 
was present in the unconjugated fraction. About 50-55$ of the 
administered radioactivity was recovered in the urine over a period 
of 200 h, 26$ of the dose being excreted in the first 24 h and 37$ 
within 48 k after injection. This is significantly slower than in 
man where almost 90$ of the dose was excreted in the urine within 
48 h (Sandberg and Slaunwhite 195^) • Less than 5$ of the urinary 
radioactivity in the first 24 h sample was present in the unconju­
gated fraction, about 28-34$ could be extracted after mixed enzyme 
hydrolysis treatment and a further 40-50$ after hot acid hydrolysis 
treatment of the residual urine after extraction of the aglycones.
The crude extracts containing neutral steroid metabolites were 
obtained by solvent extraction, after mixed enzyme and hot acid 
hydrolysis treatments on aliquots of the 0-24 h urine collection.
Each of these extracts was further resolved by Kieselgel H chromato­
graphy into six radioactive fractions which together accounted for 
about 40$ of the urinary activity. Aliquots of each of these fractions 
were analysed by glc and gc-ms as their TMS and MO-TMS ethers and 
at least eight urinary metabolites of testosterone were identified. 
Identification of the metabolites was based upon the comparison of 
their retention times with authentic reference compounds where 
available, and co-injection to observe peak augmentation. In cases 
where no reference compounds \\rere available, identification was 
based upon the comparison of the fragmentation pattern of the unknown 
metabolite with the published mass-spectra reported in literature.
Only one 17-oxosteroid,3|3-hydroxy-5a-androstan-17-one (il) 
was identified as a minor metabolite predominantly in the acidft
hydrolysed extract. In man, the 17-oxosteroids, androsterone and 
etiocholanolone are quantitatively the most important metabolites of 
testosterone accounting for about 60$ of urinary metabolites 
(Vermeulen 1979)*
The parent steroid 17(3-hydroxy-androst-4-ene-3-one (^ ) was 
the major component isolated from the acid-hydrolysed or solvolysed 
extracts. In man, testosterone is excreted in the urine predominantly
as the glucuronide and to a very small extent as the sulpho— 
conjugate (Ebtherby and James 1972). .In contrast, only conjugation 
with sulphuric acid was found in the horse. 6f the two isomeric 
°19°2 diols, the 5®—androstane-3(3,17a-diol (ill) was the major 
metabolite isolated after enzyme hydrolysis treatment while the 
second isomer 5a-andr°s'fcane-3p,17f3-diol (IV) was present predo­
minantly in the acid hydrolysed extract isolated after removal 
of the aglyoones. Isomers of 5-androstane-3,17-diol are foun(i 
the urine of human and other animal species (Dorfman and Unger
1965). In man, the androstanediols are formed either by direct
4
reduction of testosterone by the A  -reductases and the 3-hydro- 
xysteroid dehydrogenases (hydroxylic route) or by reduction of the 
17-oxo-steroids by the 17-hydroxysteroid oxidoreductases (ketonio 
route) (Mauvais-Jarvis et al 1968a and b, Baulieu and Mauvais- 
Jhrvis 1964a and b). In the present study, therefore, the 17(3-diol 
isomer could arise either by thehydroxylio or the ketonic route.
The 17<^diol can be formed from epitestosterone via the hydroxylio 
route, but no epitestosterone was detected in the present study.
Thus it appears that the 17a-diol is formed by the ketonic pathway. 
However, in the absence of any further evidence, the presence of an 
epimerase-raediated process cannot be ruled out. The formation of 
5-estrane-3,17oc-diols has also been found to be a predominant 
pathway in the metabolism of 19-nortestosterone in ponies (Hough­
ton 1977)•
Oxygenation at C-16 was found to be an important metabolic 
pathway in the horse and metabolites containing either a 16- 
hydroxyl or a 16-oxo group were identified. All the metabolites,
3, l6-dihydroxy-5-androstane-17-one, 3,17-dihydro xy-5-androstane-
16-one (v) and isomersof 5-androstane-3,l6,17-triols (VIl) contained 
the fully saturated A ring. Although the full stereochemistry of 
none of these metabolites could be determined, the cis configuration 
of the 1^ , 17-hydroxyl groups was established by formation of the
aoetonide derivatives (Janne 1971)- These metabolites were
identified both after enzyme and hot acid hydrolysis treatments.
Both 16-oxygenated ketonic steroids and 16-hydroxylated
(LqO-, steroid triols have been isolated and identified from in 
19 3 .
vitro studies using liver preparations from animal species (Axelrod
et al 1956, Jiagarinec et al 1967, Gustafsson and Lisboa 1970), 
and in vivo from adult human urine (Janne 1971) and from urine,
faeces, and blood of infants (Shackleton et al 1970). The 16- 
oxygenation of 17oc-methlytestosterone in rabbits (Watabe et al 1970)), 
Oxandrolone (Karim et al 1973) and 4-chloro-17a-methyl-l-dehydrotes- 
tosterone (Schubert and Schuraan 1970) in man and of 19-nortestosterone 
in the horse (Houghton and Dumasia 1980) have also been reported#
The role of 16-hydroxylation of C-19 steroids in the biosynthesis of 
oestriol is also well established (Diczfalusy 1969)# Although no 
attempt was made in the present study to identify the oestrogens, a 
significant amount (about 20$) of radioactivity extracted from the 
urine after both enzyme and hot acid hydrolysis was removed from 
the ethyl acetate during alkaline washes suggesting that there was 
some conversion to phenolic compounds#
Rearrangements of the C-l6,17 ring D ketols have been observed 
■under both acid and alkaline treatments (Fishman I960, Nhmbara and 
Fishman 1962).# Under strong alkaline conditions, the l6-hydroxy-17- 
one group is isomerised to 17-hydroxy-l6-one# However, under mild 
treatment (0*1 N HaOH), the 16-hydro xy-17-one group was found to be 
stable to alkaline rearrangement (Houghton and Dumasia 1980) thus 
indicating that the 17-hydroxy-16-0ne isomer did not arise by 
n i n t  during the extraction procedure. Similar isomers of 3,17- 
dihydroxy-5-estrane-l6-one and 3,l6-dihydroxy-5-estrane-17-one have 
also been isolated from horse urine after administration of 19- 
nortestosterone (Houghton and Dumasia 1980).
On separation of the urinary steroid metabolites into their 
conjugate groups using Sephadex LH-20 chromatography, about 66$ 
of the urinary was found in the sulphate fraction (s) and about 
20$ in the glucuronide fraction (G) (Table 16 )• After hydrolysis
of the conjugate moieties and analysis of the partially resolved 
radioactive fractions from Kieselgel H chromatography, testosterone (i)
3,17-dihydroxyandrostan-l6-one (V) and 3,16-dihydroxyandrostane- 
17-one (Vi) were found only in the sulphate fraction(s). 5®- 
Androstane-3(3,17f3-diol (IV) and the two isomeric androstane-3,16,17- 
triols (VIl) were present mainly intiis fraction and 5ot~an.<ix*ost;a.ne—3p> 
17a-diol (ill)) was only a minor component. In the glucuronide 
fraction (g), 5a-androstane-33,17a-diol (ill) was the major meta­
bolite and 5a-androstane-3p,173-dlol (IV) and the two isomerio 
androstane-3,16,17-triols (VIl) were only minor components. The 
urinary metabolites of testosterone identified in the present
study are summarised in fig. 37 • It can be. concluded, therefore, that 
the pathways of biotransforraation of testosterone in the equine 
male castrate are qualitatively similar to those reported in 
literature for man. However, significant differences are present 
in the urinary exoretion of radioactivity and in the mode of 
conjugation of the metabolites.
In the metabolites where the stereochemistry of the substi­
tuent groups was identified, the reduction of the ^  and 3-oxo
groups was found to be specific for the formation of the 5a and 33
isomers. Although 5a-reduction is considered primarily to be a 
catabolic route, in recent years evidence has been mounting from
in vitro studies on ventral prostate that this route of testos­
terone metabolism may in a functional sense serve as a biosyn­
thetic step in the formation of 5tt“"reduced metabolites whioh are 
in themselves potent androgens (Wilson 1975)»
Two different but complementary methods were used to extract 
the metabolites of testosterone from horse urine : l) solvent 
extraction of the freed steroids after various hydrolysis treat­
ments directly on the urine samples, 2) initial extraction and 
group separation of the steroid conjugates from the urine followdd 
by hydrolysis and solvent extraction of the freed steroids. Studies 
on the neutral extracts isolated after direct mixed enzyme hydro­
lysis and after subsequent hot acid hydrolysis of the residual 
urine from enzyme hydrolysis showed the presence of 5<x-a,ndrostane-33f 
17a-diol (ill) only in the enzyme-hydrolysable extract and testos­
terone (i) only in the acid-hydrolysable extract. 5tt-an&ros'fcane,‘“33, 
173-diol (IV), 3P-hydroxy-5a-an<trostane-17-one (il), the isomeric 
dihydroxymonoketo androstan©3 (V and VI) and the androstane-3,16,
17-triols (VIl) were found in both the acid-hydro lysable and 
enzyme—hydrolysable fractions. The presence of these metabolites 
in either the enzyme- or acid-hydrolysed fractions may be attri­
buted to the differences in their mode of conjugation. However, 
since it has been reported that urine contains inhibitors for 
both p-glucuroni das e and aryl-sulphatases (Graef et al 1977) ^ d  
that certain steroid glucuronide and sulphoconjugates are incom­
pletely hydrolysed by Helix pomatia enzymes (Shackleton et al 
1968, Mauvais-Jarvis and Baulieu 1965, Jarrige et al 1963); the 
exact nature of the conjugation of these metabolites remained 
uncertain*. Uwing the second method, after prior separation of the
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Fig .37.Urinary metabolites of testosterone in the horse
steroid conjugates into their glucuronides (Gr) and sulphocon- 
jugates ( s ) ,  metabolites (V) and (VI) were identified only 
in fraction S. This indicated that the aryl sulphatase enzyme 
only partially hydrolysed some sulphoconjugated steroids which 
were extracted together with the aglycones thus giving a false 
profile of the mode of conjugation of some metabolites. This 
was also substantiated from the percentage of *^C extracted
from the urine after direct enzyme hydrolysis (b) T&ble 15 
and the percentage of present in the glucuronic acid 
fraction Gr (b), Table 16. It thus appears that extraction and 
fractionation of the conjugates prior to hydrolysis is a better 
method to elucidate the mode of conjugation of the sterbid 
metabolites exoreted in urine.
The fact that hot acid hydrolysis causes decomposition 
of the steroids was also confirmed from the results of this 
study. This was evident from the I in the percen­
tage of the testosterone fractions isolated by Kieselgel H 
chromatography following solvolysis (fraction S2, 20.3$ and 
18.8$, expts. l/77 and. 13/77; Table 16) and after hot acid 
hydrolysis of the residual urine from enzyme hydrolysis 
(.fraction a2, 9*3$ and 8.2$, expts.l/77 and 13/77; Table 15)*
Analysis by SIM of identical fractions isolated from 
pre-administration ^lank* urine samples from both horses 
indicated that none of the steroids identified was present in 
the urine in detectable amounts prior to administration of 
testosterone. This result indicates that in the crossbred 
gelded horse urine there is very little, if any, significant 
excretion of the 11-deoxy-C^ steroids of adrenal origin.
CHAPTER V
METABOLISM OF 1-DEHYDROTESTOSTERONE
5.1. INTRODUCTION
1-Dehydrotestosterone (173-hydroxyandrost-l,4~diene-3-one) is 
one of several synthetic anabolic steroids used parenterally in 
veterinary practice. It is generally administered to horses as a long 
acting ester 173-(10)-undecenoyloxyandrost-l,4~diene-3-one (boldenone 
undecylenate).
The evaluation of boldenone undecylenate as an anabolic agent in 
horses has been reported by Stihl (1968) and O'Connor et al. (1973) 
and its effects on the reproductive tract in young stallions were 
investigated by Carson and Thompson (1979). After intramuscular 
administration of therapetutic doses of I-dehydrotestosterone and 
boldenone undecylenate to horses, the urinary excretion of the drug 
and/or its cross-reacting metabolites was detected for several days 
by radioimmunoassay (Gondorf and Moss, 1978).
The metabolism and excretion of 1-dehydroandrostanes and related 
compounds after oral administration to man have been reported by 
Gardi and Galletti (1968) and Galletti and Gardi (1971). Between 37-4-3% 
of the dose was recovered in the first 24- h after ingestion, most of it 
in the glucuronide fraction. The main features of metabolism were the 
high excretion of ,the metabolites containing the 173-hydroxyl group 
and the almost total resistance of the 1,2-double bond to enzymatic
reduction. Other interesting features were the excretion of considerable
I 4- . „.
amounts of 63-hydroxy-A ’ -3-oxo metabolites and the stereospecific
re d u c t io n  o f  th e  AZf-3 -o xo  group to  53 ,3a  compounds.
The radioimmunoassay method used routinely in this laboratory for
the detection of anabolic steroids in horse urine utilizes an antibody
raised against 19-nortestosterone-bovine serum albumin conjugate
(G ondorf 1977 ). 1 -D e h y d ro te s to s te ro n e  shows a c r o s s - r e a c t iv i t y  o f
26.3% with this antibody. In this study, the biotransformation and
3
urinary excretion of (1,2-n- H)-l-dehydrotestosterone after i.m.
administration to a cross-bred and a thoroughbred gelded horse were 
investigated. After hydrolysis and extraction of the steroids from 
the 0-24- h urine collection, the neutral metabolites were isolated and, 
after further purification, identified by gc-ms. Due to the lack of 
authentic reference compounds, the stereochemistry of the metabolites 
could not be determined.
5.2 EXPERIMENTAL
5.2.1. Administration to animals and collection of urine samples:
Before administration of the drug, urine samples from each animal 
were collected as control specimens. Intramuscular administrations 
of a mixture of the labelled and unlabelled steroids were made to the 
two horses at single sites in the neck. The dose was dissolved in 
ethanol (0.3 ml) to which was added arachis oil (8.0 ml) containing 
benzyl alcohol (10% v/v) and cresol (0.3% v/v). The weights of the 
animals and the doses are given in Table 17.
Table 17.
3
Administration of (1,2-n- H)-l-dehydrotestosterone to horses
Expt. Animal 
No.
Body
Weight
(kg)
Dose prepared _ Dose yg/kg
(^H)yCi unlabelled
(mg)
injected
(yCi)
25/77 Nimrod 360 244 150 236.6 4-04-
26/80 Floral 560 4-27 150 4-18.0 262
Song
The housing of animals and the collection of sequential timed 
urine samples have been described. Urine samples were collected upto 
120 h after administraiton and aliquots (0.1 ml x 2) from each sample
3
were taken to determine the total H excreted.
5.2.2. Distribution of radioactivity in crude urine fractions:
Samples (50 ml; 0-24 h pooled urine) from each experiment were 
processed as shown in the flow diagram (Fig. 21) in order to determine
3
the percentages of non-conjugated, conjugated and unextractable H. 
Aliquots of the urine and ethyl acetate were removed at each stage for 
scintillation counting.
5*2.3. Isolation of the neutral metabolites:
(a) Total enzyme hydrolysis:- Samples (50 ml; 0-24 h pooled urine) 
from each experiment were adjusted to pH 4.8 and incubated with Helix 
pomatia digestive juice (0.25 ml) at 37°C for 48 h. After hydrolysis 
the urine was extracted with ethyl acetate (2 x 100 ml). The ethyl 
acetate was washed with NaOH (0.1N, 2 x 50 ml), then with brine, dried over 
anhydrous Na^SO^ and taken down to dryness under reduced pressure at 
40°C.
(b) Acid hydrolysis of the residual urine :- After mixed enzyme 
hydrolysis treatment and extraction of the freed steroids, the volume 
of the residual urine was adjusted to 50 ml with deionized water and 
conc. HC1 (7.5 ml) was added. The mixture was boiled under reflux for 
1 h, cooled and the neutral extract was isolated by solvent extraction 
as described above.
5.2.4. Studies on the steroid conjugates :
The procedures used for the extraction of steroids (from the 0-24 h 
urine sample, 50 ml), the fractionation and hydrolysis of the steroid 
conjugates and the fractionation and identification of the neutral 
steroid metabolites in each group have been described in detail in 
Sections 4.2.5., 4.2.6., and 4.2.7. (Chapter IV) . A simplified flow 
diagram is illustrated in Fig.38.
Urine (0-24- h sample, 50 ml)
Amberlite XAD-2 (50 g)
1) Urine and washes discarded
2) Radioactivity eluted with methanol
(3 x 50 ml) and combined eluate taken 
to dryness
Residue
Sephadex LH-20 (10 g) chromatography
Kieselgel H (5.0 g) column chromatography
Eluent 1) Dichloroethane-ethanol (98:2; 30x 3ml)
2) Dichloroethane-ethanol (95:5; " )
Eluted with CHCl^-Methanol (1:1 v/v, 30 x 5 ml)
Pooled fraction Nos.3-10 Pooled fraction Nos. 11-26
1) Solvent removed
2) Enzyme hydrolysis
3) Solvent extraction
1) Solvent removed
2) Solvolysis in acidified 
ethyl acetate
Neutral steroids 
(Aglycones)
Neutral steroids 
(hydrolysed sulphoconjugates)
Resolved radioactive 
fractions combined
V
Derivatization of residues (TMS, M0-TMS)
Identification by GC-MS
Fig.38. Flow diagram for the extraction, separation and hydrolysis of 
steroid conjugates and the fractionation and identification 
of freed neutral steroids.
5.2.5. Analysis of l-dehydrotestosterone-17-sulphate ester by CI-MS:
Sample (50 ml; 0-24 h pooled urine,expt.25/77) was adjusted to 
pH 4.8 and incubated with Helix pomatia digestive juice (0.25 ml) 
at 37°C for 48 h. After hydrolysis treatment the aglycones were removed 
by solvent extraction as described in Section 5.2.3.a. The radioactivity 
remaining in the residual urine was then extracted by Amberlite XAD-2 
resin and the extract was fractionated into conjugate groups on a 
Sephadex LH-20 column as described previously. Aliquots of major 
fraction (fraction S) were examined by tic before and after solvolysis 
of the conjugate moiety using Systems S-9 and S-l respectively.
The remainder of fraction (S) was further purified by Kieselgel H 
column chromatography (7.5 g; column diam. 15 mm) using 1,2-dichloro- 
ethane-ethanol-water (75:25:2 v/v) as eluant and 30 x 3 ml fractions 
were collected. The major band of radioactivity (elution volume between 
55-75 ml, fraction Nos. 18-25) was combined and after removal of the 
solvent the residual material was analysed by CI-MS using direct probe 
insertion.
5.3. RESULTS
5,3.1. Excretion and distribution of radioactivity in crude urine and 
urine fractions:
3
The urinary excretion of H from both administrations is shown in
3
Fig. 39. About 47% of the administered H was excreted in 48 h;
small amounts could still be detected at 120 h. Following the procedure 
described in Fig 21 > the distribution of radioactivity in fractions A-F 
is shown in Table 18.
The results indicate that about 13.5% of the urinary radioactivity 
was excreted in the unconjugated form. This percentage is much greater 
than that observed in the corresponding fraction after the administration 
of testosterone (Chapter IV). Of the radioactivity remaining in the urine
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Fig. 39. Urinary excretion of radioactivity after intramuscular 
administration of (l,2-n-^H)-l-dehydrotestosterone.
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about 44% could be hydrolysed after treatment with mixed enzyme 
(Helix pomatia) and a further 26% was recovered after hot acid
3
hydrolysis treatment on the residual urine. About 15% of the H- 
activity remained in the aqueous phase and could not be extracted.
5.3.2. Purification of the crude neutral extracts by Kieselgel H 
column chromatography;
Crude neutral extracts of the 0-24- h urine samples (50 ml) were
isolated by solvent extraction following a) initial mixed enzyme
hydrolysis treatment and b) subsequent hot acid hydrolysis treatment
on the residual urine after enzyme hydrolysis and extraction. The
neutral extracts were fractionated by Kieselgel H column chromatography.
3The elution patterns of the H-activity from column chromatography of 
the neutral extracts obtained from expt. 25/77 are illustrated in 
Fig.4-0a (enzyme hydrolysis) and Fig.4-0b (hot acid hydrolysis of the 
residual urine). Similar elution patterns were obtained for 
expt. 26/80. The distribution of urinary H-activity in the crude ethyl 
acetate extracts and in the fractions resolved by Kieselgel H chromato­
graphy is given in Table 19.
In addition, the neutral unconjugated extract obtained from expt. 
26/80 (Fraction B, Table 18 ) was similarly fractionated on a Kieselgel
3
H column and the distribution of urinary H-activity in the resolved 
fractions is shown in Table 20.
5.3.3. Identification of the urinary metabolites by gc-ms:
Fractions al-a5 (Fig 4-Oa) and fractions bl-b2 (Fig 4-Ob) were 
analysed as their trimethylsilyl ether or methoxime-trimethylsilyl ether 
derivatives,by glc and gc-ms. Since authentic reference compounds or 
published mass spectra of some of the metabolites of 1-dehydrotesto- 
sterone were not available, identification of the compounds as possible 
metabolites of 1-dehydrotestosterone was done manually by relating the 
key ions and fragments to the proposed structure.
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Fig. 4-0. Kieselgel H column chromatography of the neutral urinary 
extracts isolated from Expt. 25/77.
t*
a) After mixed enzyme hydrolysis of 0-24 h pooled urine
b) After hot acid hydrolysis of the residual urine following 
mixed enzyme hydrolysis and extraction of the freed 
steroids.
Table 19. The distribution of radioactivity* in the crude ethyl 
acetate extracts isolated after (a) mixed enzyme 
hydrolysis treatment and (b) subsequent hot acid 
hydrolysis treatment on aliquots of the 0-24- h urine 
samples and in fractions al - a5, bl-b2 and the 
methanol washes isolated from Kieselgel H 
chromatography of the neutral extracts.
Total mixed Acid hydrolysis of
enzyme hydrolysis the residual urine
______(a)_______   (b)________
Expt.No. 25/77 26/80 25/77 26/81
Ethyl acetate 
extract before 
NaOH wash 56.2 55.7 28.2 30.8
Ethyl acetate 
extract after 
NaOH wash 51.0 4-8.5 12.0 19.0
Kieselgel H 
Chromatography
Fraction 1 6.7 5.6 2.7 2.5
Fraction 2 11.5 8.8 5.6 8.5
Fraction 3 3.5 1.9 - -
Fraction 4- 5.0 3.9 - -
Fraction 5 2.0 2.5 - -
Methanol
wash 17.3 18.8 3.5 6.9
* expressed as percentage of the radioactivity present in the
0-24- h urine samples.
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Table 20. The distribution of radioactivity* in A) the crude 
unconjugated urine extract, B) the crude neutral 
unconjugated extract and C) fractions 1-5 and the 
methanol wash isolated from Kieselgel H column 
chromatography of the neutral extract (0-24 h 
urine sample, expt. 26/80)
A) Ethyl acetate extract
before NaOH wash 17.1
B) Ethyl acetate extract 
after NaOH wash 13.2
C) Kieselgel H Chromatography
Fraction 1 0.87
Fraction 2 0.35
Fraction 3 0.20
Fraction 4 0.60
Fraction 5 0.86
Methanol Wash 10.40
* expressed as percentage of the radioactivity present in the
0-24 h urine sample
Fraction al (Fig 40a); After the formation of the MO-TMS derivative, 
two isomers of 17-hydroxy-5-androst-l-ene-3-one (II) were detected as 
minor metabolites in this fraction by gc-ms analysis! The mass spectra 
of the MO-TMS derivatives of these compounds (Fig. 41) show a molecular 
ion at m/z 389 with fragment ions at m/z 374 (Mt-15) , 358 (Mt-31) and 
268 £mT-(90+31)] CLTid. a base peak at m/z 129 characteristic of a
17-trimethylsiloxy substituent (Horning et al, 1968). The ion at 
m/z 120 is formed from the fragmentation of the substituted A-ring 
and could arise by a mechanism analogous to that for the formation of 
the ion at m/z 122 for the corresponding A^-3-oxo compounds 
(Budzikiewicz 1972) (Scheme 1). The mass spectra of the urinary 
metabolites were identical to that of authentic 173-hydroxy-5a-androst- 
l-ene-3-one MO-TMS ether. The other compounds present in this very 
complex fraction could not be identified by gc-ms.
Fraction a2 (Fig 40a)? After the formation of the MO-TMS derivative, 
two compounds were detected in this fraction by gc-ms analysis which 
showed molecular ions at m/z 387 and fragment ions at m/z 372 (Mt^ -15),
356 (Mt-31), 266 [mT-(90+31)] and m/z 120 (base peak) (Fig.42). The 
probable mode of formation of the base peak from fragmentation of the 
substituted A-ring is shown in Scheme 2. The mass spectra of these 
compounds were identical to that of authentic 1-dehydrotestosterone- 
M0-TMS ether derivative.. By comparison of their retention times (R^ .) 
on glc and co-injections with authentic 1-dehydrotestosterQne-MO-TMS 
ether, the minor urinary metabolite (R^ 10.8 min) was identified as 173-
1-dehydrotestosterone (I). The major metabolite has a retention time 
of 10.05 min and is presumably 17a-hydroxyandrost-l,4-diene-3-one (III).
Fraction a3 (Fig.40a): After the formation of the TMS and MO-TMS ether
derivatives, three compounds were detected as possible biotransformation 
products of 1-dehydrotestosterone in this fraction by gc-ms. From their 
molecular weights and fragmentation patterns two of these compounds were 
identified as ^ Isomers of fully saturated dihydroxymonoketo androstanes,
3,17-dihydroxy-5-androstane-16-one (IV) and 3,16-dihydroxy-5-androstane-
17-one (V). Both of these metabolites were present in very minor amounts 
in this fraction. Similar saturated isomers of dihydroxymonoketo 
androstanes (Figs.30-33) have been identified in the urine after admini­
stration of testosterone (Section 4.3.4. Chapter IV).
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The molecular weight and the mass spectra of the TMS and MO-TMS 
ethers of the third compound indicated it to be a dihydroxymonoketo 
androstane (C^O^). The TMS ether derivative (Fig. 43) showed a
weak molecular ion (mT) at m/z 448, fragment ions at m/z 4-33 (Mt-15),
358 '(Mt-90), 343 [}lt-(90+15)] , 268 [nt(90+90)J, 191, 147 (base peak),
122, 121 and 109. The ions at 122, 121 and 109 are characteristic of
1 i Ll
the A -3-oxo and A V -3-oxo group in the A ring (Budzikiewicz 1972).
The ions at m/z 191 and 14-7 are characteristic of the intramolecular 
rearrangements of trimethylsiloxy groups and their genesis and 
structure have been discussed in detail by Gustafsson et al. (1968) 
and Sloan et al. (1971). The mass spectrum of the MO-TMS ether 
derivative (Fig. 44) showed a molecular ion at m/z 4-77, fragment 
ions at m/z 446 (Mt-31), 387 (Mt-90), 356£mT-(90+31)], 297^lt-( 90+90 H , 
266 £mT-(90+90+31)] , 120 (substituted A-ring) and TMS rearrangement 
ions at m/z 191 and 14-7 (base peak). The molecular weight and the 
formation of a MO-TMS derivative indicated the presence of one double 
bond and a carbonyl group in the molecule. The A^-3-oxo structure 
was assigned to the A-ring on the basis of ions at m/z 122, 121 and 
109 (Fig. 4-3) and 120 (Fig.44 ). The presence of the two adjacent 
hydroxyl groups at C-16 and C-17 in a cis configuration was confirmed 
by the formation of the acetonide derivative (Fig.4.5), The mass 
spectrum of the acetonide showed ions at m/z 329 (Mt-15, base peak)
269 (loss of CH^ and CH^COOH groups) and 122, 121, 109 (A^-oxo group 
in the A-ring). On the basis of the above evidence, the structure 
assigned to this metabolite is 16,17-dihydroxy-5-androst-l-ene-3-one (VI) 
The stereochemistry of this isomer could not be determined.
Fraction a4 (Fig 40a): After the formation of the TMS and MO-TMS
ether derivatives, aliquots of this fraction were analysed by gc-ms and 
two compounds were tentatively identified as possible metabolites of
1-dehydrotestosterone. From the molecular weight and its fragmentation 
pattern, the iiiajor metabolite was identified as an isomer of 5-androstane
3,16,17-triol (VII) (Grote and Spiteller 1977). Similar isomeric 
5-androstanetriols (Fig. 34-) have been identified in the urine after 
administration of testosterone (Section4.3.4. , Chapter IV).
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Fig. 4-5: El-mass spectrum of the acetonide derivative
of an isomer of 16,17-dihydroxy-5-androst-l-ene-3-one 
isolated from horse urine.
The TMS ether derivative of the second compound (Fig. 46) showed
a weak molecular ion at m/z 446, and fragment ions at m/z 431 (Mt-15),
356 (Mt-90), 266 [nt-(90+90)J, 122, 121, 109 (A1,4-3 -oxo or A^-3-oxo group
in the A-ring), 147 (TMS rearrangement ion) and 169 (base peak). The mass
spectrum of the MO-TMS ether derivative (Fig. 47) showed a molecular ion
at m/z 475, and fragment ions at m/z 444 (Mt-31), 385 (Mt-90),
354 ]TMt-(90+31 )J , 264^mT “(90+90+31 )J , a base peak at m/z 120 (substituted
A-ring fragment) and 147(TMSrearrangement ion). The molecular weights of
the TMS and MO-TMS derivatives and the fragmentation patterns indicated
the presence of two double bonds, a carbonyl function and two hydroxyl
groups in the molecule. The ions at m/z 122, 121 and 109 (TMS derivative,
Fig. 46) and m/z 120 (MO-TMS derivative, Fig.47) indicated the presence 
1 4of a A ’ -3-oxo group in the A-ring. The location of the two hydroxy 
functions on adjacent carbon atoms in the cis configuration was confirmed 
by the formation of the acetonide derivative of this compound. The El 
mass spectrum of the acetonide (Fig. 48) showed a molecular ion at m/z 342 
and fragment ions at m/z 327 (Mt-15), 267 (Mt-75), loss of CH^ and
CH^COOH groups) and a base peak at m/z 122 indicative of the A 3-oxo 
group. The methane Cl-mass spectrum of this compound (Fig.49) showed ions 
at m/z 383 (M +41)+, 371 (M+29)+, 3 «  (M + l)+ , 328 [(M+l) -isj+,
267 (loss of CH^COCH^ and h^O) and a base peak at 285 (loss of CH^COCH^).
On the basis of the above evidence, the structure assigned to this
metabolite is 16,17-dihydroxyandrost-l,4-diene-3-one (VIII). The stereo­
chemistry of this isomer could not be determined.
Fraction a5 (Fig. 40a): After the formation of the TMS and MO-TMS ether
derivatives and analysis by gc-ms, only one compound was detected in this 
fraction. The mass spectrum of the silyl ether of this compound showed a 
weak molecular ion at m/z 448 and fragment ions at m/z 433, 358, 268, 191, 
169, 147, 129, 122, 121 and 109. The mass spectrum of the MO-TMS derivative 
showed a molecular ion at m/z 477 and fragment ions at m/z 446, 387, 356, 
297, 266, 191, 169, 147 and 120. An isomer of this compound having a 
similar fragmentation pattern (compound VI, Figs. 43-45) has already been 
identified in Fraction a3. It was therefore concluded that this compound 
is another isomer of (VI) having different stereochemical orientation of the 
functional substituents.
No attempt was made to identify any polar metabolites possibly present 
in the methanol wash fraction isolated from the Kieselgel H columns.
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Fig. 49: Methane Cl-mass spectrum of the acetonide derivative of
an isomer of 16,17-dihydroxy-androst-l,4-diene-3-one 
isolated from horse urine.
Fraction bl (Fig. 40b): After the formation of the MO-TMS derivative
aliquots of this fraction were analysed by gc-ms. None of the components 
present in this complex fraction could be identified as metabolites of 
1-dehydrotestosterone possibly because they were present in very small 
amounts.
Fraction b2 (Fig.40b): After the formation of the MO-TMS ether, and
analysis by gc-ms, only one major component was detected in this fraction* 
The mass spectrum of this compound showed a molecular ion at m/z 387 and 
fragment ions at m/z 372, 356, 266 and 120 (base peak), and was identical 
to the mass spectrum of compound (III) (Fig. 42). On the basis of its 
retention time (R^  10.8 min) and coinjection with authentic 1-dehydrotest- 
osterone MO-TMS ether, this metabolite was identified as 178-hydroxyandrost-
l,4-diene-3-one (I). ,
The methanol washes isolated from the Kieselgel columns were not 
analysed further. Also no attempt was made to analyse fractions 1 to 5 
isolated after Kieselgel H chromatography of the neutral unconjugated 
extract (Table 20) by gc-ms, since they contained very little H-activity.
5*3.4. Studies on the steroid conjugates:
After Amberlite XAD-2 extraction of the urine samples, group separation 
of the conjugate extracts was achieved by Sephadex LH-20 column chromato­
graphy (Vihko, 1966; Eriksson and Gustafsson, 1970). Two major radioactive 
fractions were resolved, fraction G (between 16-50 ml of effluent) 
containing the free steroids and the glucuronic acid conjugates and 
fraction S (between 51-120 ml of effluent) containing the sulphoconjugates 
(Fig. 50). After enzyme hydrolysis of the glucuronides and solvolysis of 
the sulphoconjugates, crude neutral extracts were isolated and fractionated 
on Kieselgel H columns. The elution of H from column chromatography of 
the neutral extracts for expt. 25/77 is illustrated in Fig51(G) (aglycons) 
and Fig.51(s)(solvolysed steroids). Similar elution patterns were also 
obtained for expt. 26/80. The percentage distribution of the urinary 
H-activity in the Amberlite XAD-2 extracts, the fractions G and S 
obtained from Sephadex LH-20 chromatography, the crude neutral extracts 
isolated by solvent extraction after hydrolysis of the conjugates and
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Fig* 50 • Conjugate group separation by Sephadex LH-20 
column chromatography of an Amberlite XAD-2 
extract of horse urine (Expt.25/77) into 
the free and glucuronic acid (G) and sulphuric 
acid (S) conjugates.
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Fig.51. Kieselgel H column chromatography of the neutral urinary
extracts isolated from Expt. 25/77 after initial Amberlite 
XAD-2 extraction of the steroids,Sephadex LH-20 separation 
into the conjugate groups and hydrolysis of the conjugates.
(G) aglycons
(S) solvolysed steroids.
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the fractions G1-G5 and SI and S2 obtained from Kieselgel H chromatography 
of the crude extracts for both experiments is given in Table 21.
After the formation of the TMS and MO-TMS ether derivatives, aliquots 
of fractions G1-G5 and SI and S2 were analysed by gc-ms. The metabolites 
identified in the fractions G1-G5 were identical with those present in the 
corresponding fractions al-a5 (Fig. 40a). The metabolites present in 
fraction SI could not be identified; 173-1-dehydrotestosterone was 
identified as the major component in fraction S2.
Normal pre-administration urine samples collected from both animals 
were analysed by the same experimental procedures. Using selected ion 
monitoring none of the metabolites identified above was found in the blank 
urine samples.
5.3.5. Isolation, purification and identification of 1-dehydrotestosterone 
sulphoconjugate:
The results obtained in the previous two sections (5.3.3. and 5.3.4-.) 
have shown that after extraction of the free steroids and the aglycons, 
the parent steroid 1-dehydrotestosterone was the major metabolite isolated 
from the residual urine using two different methods - acid hydrolysis and 
solvolysis. An attempt was made to isolate and characterize this metabolite 
in its conjugated form.
After initial mixed enzyme hydrolysis treatment of the 0-24- h urine
sample, the freed steroids were removed by solvent extraction (57.2% of the
urinary H). The radioactivity remaining in the aqueous phase was then
extracted by Amberlite XAD-2 resin (42% of urinary H) and after removal
of the solventjWas chromatographed on Sephadex LH-20 (Fig. 52). Two
radioactive fractions were resolved, fraction A accounting for 10% and
3
fraction B accouhting for 29.7% of the urinary H activity. Fraction A 
was not analysed further.
Aliquots of fraction B were initially analysed by tic, before solvolysis 
(as the conjugates) and after solvolysis (as the freed steroids).
Examination of the tic plates under UV light at 254 nm showed only one UV
Table 21. The distribution of radioactivity* in (A) Amberlite 
XAD-2 extracts of the 0-24- h urine samples, (B) the 
free plus glucuronic acid (G) and sulphoconjugate 
(S) fractions isolated by Sephadex LH-20 chromatography, 
(C) the crude neutral extracts obtained after hydrolysis 
of the conjugates and (D) fractions G1-G5, S1-S2 and 
the methanol washes isolated from Kieselgel H chromato­
graphy of the neutral extracts.
Expt.No. 25/77 26/80
A 92.5 94.0
Fraction G Fraction S Fraction G Fraction S
B 61.1 25.1 62.3 28.7
C 50.0 23.0 46.0 26.4
D Fraction 1 4.3 3.2 5.4 2.8
Fraction 2 12.6 17.1 9.8 19.5
Fraction 3 2.8 - 2.4 -
Fraction 4 5.2 - 3.8 -
Fraction 5 2.5 - 2.8 -
Methanol Wash 22.0 2.5 19.0 3.3
* expressed as percentage of the radioactivity present in the 0-24 h 
urine samples.
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Fig. 52. Sephadex LH-20 column chromatography of an
Amberlite XAD-2 extract of the steroid conjugates 
present in the residual urine after initial mixed 
enzyme hydrolysis and solvent extraction of the 
hydrolysed steroids.
absorbing band in each case. The relative distribution of the plated 
radioactivity is shown in Fig. 53. The two major peaks containing 67.9%
(Fig.53a) and 67.5% (Fig. 53b) of the radioactivity corresponded with 
the UV absorbing band in each case. The free steroid (Fig.53b) 
was eluted from the tic plate and after derivatization (as MO-TMS ether) 
was identified as 173-hydroxyandrost-l,4-diene-3-one (I) by glc and 
gc-ms as described previously (Section 5.3.3.).
The remainder of the fraction B was further purified by Kieselgel H 
chromatography (Fig. 54) , the purified steroid conjugate isolated and 
analysed by direct insertion probe Cl-mass spectrometry using methane as 
the reagent gas. It was observed that the conjugate required high 
temperature (over 200°C) whereas authentic 1-dehydrotestosterone required 
a temperature of about 50°C for volatization adequate for obtaining mass 
spectra of the compounds. The mass spectrum of the conjugate (Fig. 55a) 
showed ions at m/z 315, 297, 287, 269, 268, 135, 122 and 121. The 
methane Cl-mass spectrum of authentic 1-dehydrotestosterone (Fig.55b) 
also showed the ions at m/z 315 (M+C2H,- ) + ,297 (loss of from the ethyl 
adduct), 287 fprotonated molecular ion (M + H)+J , 286 (Mt) (weak),
269 [(M + H)-H^o]+, 135 (base peak) and the A-ring fragments at 122 and 121.
The mechanism of the formation of the ion at m/z 135 is not clear. The 
differences in the intensities of the two ions at high mass (m/z 287 and 
269) in the spectra of the two compounds is most probably due to the 
differences in the temperature at which the compounds were volatilized 
rather than the differences in their mode of fragmentation .
Thus although the solvolysis data indicated that the major metabolite 
present in the urine after removal of the free steroids and the aglycons 
was 173-hydroxyandrost-l,4~diene-3-one sulphate conjugate, no direct mass 
spectrometric evidence could be obtained for the presence of the sulphate 
group.
5 A, DISCUSSION
After intramuscular administration of -dehydrotestosterone
to two gelded horses, about 50-55% of the radioactivity was recovered in the 
urine over a period of 100 h, 36% of the dose being excreted in the first 
24- h after injection. This recovery rate is in agreement with that reported 
after oral ingestion of some 1-dehydroandrostenes in man, where the recovery 
of the metabolites in the 2k h urine samples ranged from 37-53% of the dose
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Fig. 53 Thin-layer chromatographic profile of the radioactive 
metabolites present in 'Fraction B' (Expt. 25/77) 
isolated after Sephadex LH-20 column chromatography
(a) Before solvolysis as the conjugates
(Solvent system: Chloroform-methanol-water, 70:30:2 by vol).
(b) After solvolysis as the freed steroids 
(Solvent system: ethyl acetate)
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Fig. 5^. Isolation by Kieselgel H column chromatography 
of the major metabolite (1-dehydrotestosterone- 
1 -  sulphoconjugate) present in Fraction B 
(Expt. 25/77, isolated after Sephadex LH-20 
column chromatography).
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Fig.55a. Methane Cl - mass spectrum of 1-dehydrotestosterone- 
178-sulphoconjugate isolated from horse urine.
100 135
287
269■p
HH
315
200 300100
m/z
Fig. 55b. Methane Cl - mass spectrum of authentic 1-dehydro- 
testosterone (178-hydroxyandrost-l,4~diene-3-one).
(Galletti and Gardi 1971).
The percentage distribution of the urinary radioactivity into the
unconjugated, mixed enzyme-hydrolysable, hot acid hydrolysable and
unextractable activity is shown in Table 18. Between 10-17% of the 
3urinary H in the first 24- h was present in the unconjugated fraction.
This is in marked contrast to the excretion of radioactivity in the
14urine after administration of C-testosterone (Table 14, Chapter IV)
where less than 5% was present in the unconjugated form. After
Kieselgel H chromatography of the neutral unconjugated extract (isolated
from expt. 26/80, Table 30) it was found that most of the activity (10.4%
3of urinary H or 75% of the free fraction) was eluted from the column 
in the methanol wash. This indicates that the majority of the 
unconjugated radioactive material was p^ese/nC in the form of very 
polar compounds. These fractions were not analysed further.
Crude extracts containing the neutral steroid metabolites were 
obtained using two different but complementary methods: (1) direct 
mixed enzyme hydrolysis of the urine and solvent extraction of the enzyme- 
hydrolysed steroids followed by hot acid hydrolysis of the residual urine 
and solvent extraction of the acid-hydrolysed steroids, (2) initial 
Amberlite XAD-2 extraction of the urinary steroids, separation into 
free plus glucuronides and sulphoconjugates by Sephadex LH-20 
chromatography, hydrolysis of the conjugates and solvent extraction 
of the freed steroids. There was very good agreement between the 
percentage of activity present in the various fractions isolated by 
enzyme hydrolysis (Tables 19 and 21). However, due to the decomposition 
of the steroids under hot acid hydrolysis treatment considerable differences 
were observed in the percentages of H present in fractions b2 (Table 19) 
and the corresponding fraction S2 (Table 21) isolated after solvolysis.
These fractions were shown to contain 1-dehydrotestosterone and the 
decomposition of the steroid under acid treatment was confirmed by the 
considerable reduction in peak height of 1-dehydrotestosterone (gc 
analysis, MO-TMS derivative) isolated from a spiked blank urine sample 
before and after acid hydrolysis.
Five radioactive fractions were isolated by Kieselgel H chromatography 
of the crude neutral extracts obtained after mixed enzyme hydrolysis 
treatment and two fractions were isolated from the crude neutral acid- 
hydrolysed or solvolysed extracts. Together these seven fractions contained
about 46% of the urinary radioactivity, a further 23.5% being eluted from 
the columns in the methanol washes. Aliquots of each of the fractions 
(except the washes) were analysed by glc and gc-ms as their TMS and MO-TMS 
ether derivatives and at least ten urinary metabolites of 1-dehydro- 
testosterone were identified. Since no authentic reference compounds 
or published mass spectra of some of these compounds were available, 
identification of the metabolites (Fig. 56)was based on the molecular 
weights of the substituted steroid derivatives and manual interpretation 
of their mass spectra by relating fragment losses and key diagnostic ions 
to the proposed structure.
Previous studies on the biotransformation of synthetic steroids 
1 4containing the A 9 -3-oxo group such as 1-dehydrotestolactone (Segaloff 
et al. 1966), methandienone (Durbeck et al. 1980), 1-dehydroandrostenedione 
and related steroids (Gajletti and Gardi 1971) triamcinolone (Florini et 
at. 1961), triamcinolone acetonide (Kripalani et al. 1975) betamethasone 
(Butler and Gray 1970) and dexamethasone (Mineo 1976 and also Chapter III 
of this thesis) have shown the excretion of significant amounts of the 
unreduced A-ring metabolites in urine. The stability of the A-ring to 
enzymatic reduction is reflected in the absence of either the 3-hydroxy—
17-oxo or the C^O^ diol metabolites in the urine following administration 
of 1-dehydrotestosterone. 33-Hydroxy-5a-androstan-17-one, 5a-androstane-3/3 
173-diol and 5a-androstane-33> 17a-diol were identified in horse urine after 
administration of testosterone (Chapter IV, this thesis) and 3-hydroxyestran 
-17-one and estrane-3, 17-diol were identified in the urine after administration 
of 19-nortestosterone (Houghton 1977). In the present work the parent 
steroid 1-dehydrotestosterone (I) and its 17a-isomer (1-dehydroepitestost- 
erone) (III) were identified as the major urinary metabolites and together 
accounted for 29% of the urinary radioactivity or 11% of the 
administered dose excreted in the first 24 h. *
Epimerization of the 173-hydroxy group of synthetic anabolic steroids 
such as methandienone (Macdonald et al. 1971, Durbeck et al. 1978,
Bjorkhem et al. 1980)& 19-nortestosterone (Houghton and Dumasia 1980) 
have been reported previously. Epimerization of the tertiary alcohols is 
difficult to explain. Epimerization of the secondary steroid alcohols 
has been reported to occur in biochemical systems via a carbonyl intermediate.
0
(I) 1-DEHYDROTESTOSTERONE
0
(II) 17-HYDROXYANDROST-l-ENE-3-ONE
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5-ANDROSTAN-3,16,17-TRIOL (VIII) 16,17-DIHYDROXYANDROST •
l,4-DIENE-3-0NE
Fig.56. Urinary metabolites of 1-dehydrOtestosterone in the horse.
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Raud and Hobkirk (1967) reported the conversion of oestriol to 
16-epioestriol via the 16-oxo-oestradiol-173 intermediate in avian 
liver in vitro. A similar pathway for the epimerization of the 
173-hydroxy group of estrane-3,17fdiol via 3-hydroxyestran-17-one 
has been suggested by Houghton (1977). However as no 17-oxo 
intermediates were detected in the present work, the presence of a 
direct epimerase mediated pathway cannot be excluded.
l 1 4
Reduction of the A -group in steroids containing a A 9 -3-oxo
4structure has been reported. However unlike the A -3-oxo steroids*
reduction of the 3-ketone in compounds containing the additional A^
substituent is partially hindered by the resonance energy of the 
1 4conjugated A 9 -3-one system. In view of this, substantial amounts of 
5-dihydro isomers of 1-dehydrotestosterone (Galletti and Gardi 1971), 
methenolone acetate (Langecker 1962, Gerhards et al. 1965) and fluoro-
cortolone (Lambe et al. 1978) have been found in urine. Similarly as
4 ia result of the reduction at A , two dihydro isomersp17-hydroxy-5-
androst-l-ene-3-one (II) were identified in the glucuronide fraction
following administration of 1-dehydrotestosterone to horses. Further
reduction of the A* and the 3-oxo groups leading to the complete saturation
of the A-ring was also observed with the formation of 3,17-dihydroxy-5-
andro'stane-16-one (IV), 3,16-dihydroxy-5-androstane-17-one (V) and
5 androstane-3,16,17-triol (VII) metabolites. Identification of the
fully saturated A-ring metabolites in human urine has been reported for
some synthetic corticosteroids such as prednisolone (Caspi and Pecht 1957
and 1958, Vermeulen 1959, Vermeulen and Caspi 1958) and fluorocortolone
(Gerhards et al. 1971, Kono et al. 1973). Also after the administration
of prednisolone, reduction of the A^ bond leading to the formation and
urinary excretion of cortisol in horses has been reported by Moss and
Rylance (1967).
The most interesting feature of the biotransformation of 1-dehydro- 
testosterone in the horse was the high excretion of urinary metabolites 
containing the 17-hydroxy group (90% of the identified steroids, Fig. 56)* 
This is in agreement with results obtained from the study in the bio- 
transformation of testosterone (Fig. 37, Chapter IV) and 19-nortestosterone 
(Houghton and Dumasia, 1980) in the horse where the majority of the 
urinary metabolites of these steroids also contained the 17-hydroxy group.
In man, after administration of steroids containing a 178-hydroxyl 
group, urinary excretion of 17-oxosteroidsis quantitatively the most 
important biotransformation pathway (Fotherby and Dames 1972). However 
some inhibition of the dehydrogenation of the 178-hydroxy group was 
observed by Galletti and Gardi (1971) after administration of 1-dehydro- 
androstenes to man. These workers reported that 50% of the metabolites 
identified in the urine contained a 17-hydroxyl group. In the'horse the 
formation of 17-oxosteroids seems to be a minor route; 38-hydroxy-5a- 
androstane-17-one and an isomer of 3-hydroxyestran-17-one have been 
detected as minor metabolites in horse urine after administration of 
testosterone (Chapter IV of this thesis) and 19-nortestosterone 
(Houghton 1977) respectively.
Oxidation at C-16 was found to be the major hydroxylation pathway.
In the C^O^j metabolites with the fully saturated A-ring, both 16-hydroxy- 
steroids.(IV and VII) and 16-oxosteroids (V) were identified. In the 
metabolites containing partially reduced (VI) or the unreduced A-ring (VII) 
only 16-hydroxylated steroids were detected. However no corresponding
16-hydroxytestosterone or 16-hydroxy-dihydrotestosterone metabolites were 
detected in the urine after administration of testosterone to horses 
(Chapter IV, this thesis). Oxidation at C ^  has been reported as a 
biotransformation pathway in the metabolism of 19-nortestosterone 
(Houghton and Dumasia 1980) and testosterone in the horse. It has also 
been reported for other synthetic anabolic agents like oxandrolone 
(Karim et al. 1973) and 4-chloro-17a-methyl-l-dehydrotestosterone 
(Schubert and Schuman 1970) in man and 17a-methyltestosterone in rabbits 
(Watabe et al. 1970). In man hydroxylation at C-6 has been reported as 
the major pathway of biotransformation of 1-dehydrotestosterone 
(Galletti and Gardi 1971) and for methandienone (Ddirbeck et al. 1980).
In the horse, the formation of sulphoconjugates appears to be a 
terminal stage in the biotransformation of androgenic-anabolic steroids.
In the present study after separation of the glucuronides, the majorft
metabolite in the acid-hydrolysed/solvolysed fraction was Identified as 
1-dehydrotestosterone (I) (fraction a2 - Table 19 & fraction S2 - 
Table 21 ). This indirect approach, using solvolysis , indicated that 
1-dehydrotestosterone sulphate ester was the major urinary metabolite. 
Because sulphate ester conjugates are extremely polar and non-volatile 
compounds, they are difficult to characterize directly by mass spectrometry 
Direct probe mass spectra of steroid conjugates are virtually identical 
to the spectra of their parent compounds because of thermal or electron-
impact-induced degradation of the conjugate moiety (VandenHeuvel et 
al. 1973). Analysis of the sulphate ester salts of some xenobiotics 
and natural products after the formation of their alkyl aryl 
derivatives (Paulson et al. 1978a and b), fluoroacyl derivatives 
(Murray and Baillie 1979) and trimethylsilyl ethers (VandenHeuvel 
et al. 1973) have been reported previously. In this study after the 
isolation and purification of the conjugate, it was analysed by 
direct insertion probe CI-MS using methane as the reagent gas. The 
mass spectrum of this compound (Fig. 5 3 a )  was very similar to the 
methane Cl-mass spectrum of authentic 1-dehydrotestosterone (Fig. 55b). 
The high abundances of the fragment ions m/z 269 and 287 in the mass 
spectrum of the conjugate could possibly be attributed to the presence 
of the conjugate moiety directing the fragmentation process. Although 
no direct evidence of the presence of the sulphate ester group was 
obtained it was concluded that the parent steroid is esterified at the 
C-17 hydroxyl function.
CHAPTER VI
METABOLISM OF 19-NORTESTOSTERONE.
6.1 INTRODUCTION
The synthesis of nandrolone (19-nortestosterone; 178-hydroxy-4- 
estran-3-one) was first reported by Birch (1950) and its myotrophic 
activity demonstrated by Hershberger et al.(1953). It is marketed in 
the form of its 178-esters (cyclohexylpropionate, laurate and phenyl- 
propionate) for veterinary use.
The biotransformation of 19-nortestosterone has previously been 
studied in vivo in man (Engel et al. 1958, Ward et al. 1975), in 
rabbit (Both-Miedema et al. 1972) and in a cross-bred gelded horse 
(Houghton 1977), and in vitro by female rat liver homogenate (Kupfer 
et al. 1960). The metabolites so far identified in these studies 
include unchanged 19-nortestosterone and isomers of 3-hydroxyestran-
17-one and estrane-3,17-diol. Increased urinary excretion of 
estrogens after the administration of 19-nortestosterone and its 
esters has been reported by several workers (Engel et al. 1958,
Dimick et al. 1961, Both-Miedema et al. 1972). The in vitro aromatiz- 
ation of 19-nortestosterone by the placental aromatization system has 
been reported by Ryan (1959).
A RIA method to detect the administration of therapeutic doses of 
19-nortestosterone and its esters in horse urine has been reported by 
Dondorf and Moss (1978) and a combined gc-ms method to confirm the 
administration by the identification of its major urinary metabolite 
estran-3,17-diol has been reported by Houghton et al. (1978).
In a recent publication (Houghton and Dumasia 1980), the isolation 
and identification of some 16-oxygenated metabolites of 19-nortestosterone 
from the urine of a thoroughbred gelded horse has been reported.
Aliquots of the 0 - 24 h urine sample were hydrolysed by Helix pomatia 
enzyme treatment & after solvent extraction of the freed steroids, the 
crude neutral extracts were fractionated by Kieselgel H chromatography.
In addition to 3-hydroxyestran-17-one and estrane-3,17-diol (Houghton 
1977), 19-nortestosterone, 19-norepitestosterone, two isomers of
3,16-dihydroxyestran-17-one, 2 isomers of 3,17-dihydroxyestran-16-one 
and an isomer of estrane-3,16,17-triol were identified by gc-ms using
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a packed column.
This chapter describes further studies on the XAD-2 extraction,
conjugate group separation, hydrolysis and identification of the neutral
€aglycons and solvolysed sulphoconjugates by capillary column gc-ms. The 
urine samples were obtained from Dr.E.Houghton, aliquots of which have 
been used in the previous studies (Houghton 1977, Houghton and Dumasia, 
1980).
6.2. EXPERIMENTAL
6.2.1. Administration to animals;
14-Details of the administrations of 19-nor 4-- C testosterone to 
animals are given in Table 22.
Table 22 :
14Administration of 19-nor 4- C testosterone to horses
Expt.
No.
Animal. Body
Weight
(kg)
Unlabelled
19-NT
(mg)
1ZfC 19-NT 
injected 
yCi
Dose
injected
vg/Kg
Site of 
Administration
32/75 Caspar
(P)
340 150 25 410 rump
64/75 Shepherds
Boy
(T)
430 150 21 343 neck
26/76 Shepherds
Boy
430 150 23 344 neck
14/77 Pedro
(P) *
388 150 25 377 neck
15/77 Floral
Song
(T)
550 150 26 263 neck
(P) = pony (T) = thoroughbred
£•2.2. Studies on the steroid conjugates:
The procedures used for the extraction of steroids (from the 
0-24 h urine sample, 50 ml), the fractionation and hydrolysis of 
the steroid conjugates and the fractionation and identification of the 
neutral steroid metabolites in each group have been described previously 
(Fig. 3?).
6.2.3. Capillary column gc-ms :
Combined gc-ms was carried out using a 25 m x 0.2 mm fused silica 
capillary column (Hewlitt Packard) coated with a non-polar silicon 
phase SP 2100 (carbowax deactivated). Helium was used as a carrier 
gas (linear gas velocity 40 cm/sec) . After removal of excess 
silylation reagents under at 40°, the M0-TMS ether derivatives were 
dissolved in a few drops of CHCl^-hexane (1:1, v/v) and passed down a 
small column of Sephadex LH-20 (2 cm x 0.5 cm) to remove the excess 
methoxyl^pmine reagent. The steroid M0-TMS derivatives were recovered 
in the first 2.5 ml of effluent. Solvents were removed under ^  at 
40°C and the derivatised samples were dissolved in dodecane. A sample 
volume of l-2pl was injected onto the column (in the splitless mode) 
at 190°. The sample was injected 20 sec after closing the split valve 
and the valve was re-opened 30 sec after injection. The temperature 
was programmed upto 230° at 20°/min and then at 2°/min to a final 
temperature of 260°C which was held for 10 min. The mass spectrometer 
was operated in the repetitive scan mode with a scan time of 1 sec 
for the mass range between m/z 100-550.
6.3. RESULTS
6.3.1. Extraction, group separation, hydrolysis and fractionation 
of metabolites :
Amberlite XAD-2 extracts of the urine samples (0-24 h, 50 ml) 
were fractionated by Sephadex LH-20 column chromatography into the free 
+ glucuronides (G) and sulphoconjugates (S) (Fig. 57  ^ Expt. 32/75).
After enzyme hydrolysis of fraction G and solvolysis of fraction S, the 
neutral extracts were chromatographed on Kieselgel H columns. The 
elution of radioactivity from column chromatography of the neutral aglycons 
and solvolysed sulphoconjugates isolated from expt. 32/75 is illustrated 
in Fig. 58. Similar elution patterns were observed for the other
administrations. For the five administrations^percentage distribution
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Fig.57: Conjugate group separation by Sephadex LH-20 column
chromatography of an Amberlite XAD-2 extract of horse 
urine (Expt. 32/75) into the free and glucuronic acid 
(G) and sulphuric acid (S) conjugates.
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Fig-58. Kieselgel H column chromatography of the neutral urinary
extracts isolated from Expt. 32/75 after initial Amberlite XAD-2 
extraction of the steroids, Sephadex EH-2Q separation into 
conjugate groups and hydrolysis of the conjugates
(G) Aglycons
(S) Solvolysed steroids
of the urinary radioactivity in the Amberlite XAD-2 extracts, the 
conjugate fractions G and S before and after hydrolysis treatment 
and the fractions G1-G4 and S1-S4 obtained from Kieselgel H 
chromatography of the neutral extracts is given in Table 23.
6.3.2 Identification of the urinary metabolites by gc-ms; .
Fractions G1-G4 and S1-S4 (Table 23 ) were analysed as their 
trimethylsilyl ether and methoxime-trimethylsilyl ether derivatives 
by capillary column gc-ms. The identification of the metabolites 
was based on the molecular weights and the fragmentation patterns 
of the substituted steroid derivatives or by comparison with the 
mass spectra and retention times of the authentic reference compounds 
where available.
Fraction Gl. After derivatization as MO-TMS ethers and analysis by 
gc-ms two metabolites were detected in this fraction for each admini­
stration. The mass spectrum of the first compound (R^  6.0 min)
(Fig. 59 ) showed a very weak molecular ion at m/z 377 and fragment ions 
at 362 (Mt-15), 346 (M^-31) and a base peak at m/z 256 [Mt-(90+31)J .
From its molecular weight and fragmentation pattern this compound has 
been identified as an isomer of 3-hydroxyestran-17-one (II) (Houghton
1977). The mass spectrum of the second compound showed a molecular 
ion at m/z 375 and fragment ions at m/z 360 (Mt-15), 344 (Mt-31),
285 (Mt-90), 254 £ mT-(90+31 )J and 129 (base peak). From the mass 
spectral fragmentation pattern this compound was identified as an 
isomer of 19-nortestosterone. After comparison of the retention time 
of this metabolite (R^  6.65 min) with that of authentic 19-nortestosterone 
MO-TMS ether (R^  7.4 min) it was identified as 19-norepitestosterone (III).
Fraction G2. These fractions were analysed as their TMS ether derivatives 
by gc-ms. Using EIC profiles for the ion m/z. 242, two isomers of estrane-
3,17-diol bis*.TMS ethers having Rt of 5.7 min (minor) and 6.25 min (major) 
were detected. The mass spectra of these compounds show a weak molecular 
ion at m/z 422, and fragment ions at m/z 407 (Mt-15), 332 (Mt-90),
242 jTM^ -(90+90)J and a base peak at 129 (Houghton 1977). In addition at 
least three structural isomers of dihydroxymonoketo estranes (Rt 7.2, 8.2 
and 9.0 min) were detected in this fraction for each administration using 
EIC profiles of Ions m/z 202 and 421. The mass spectra of these compounds have
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F ig . 59. E l-m ass spectrum  o f  an isom er o f  3 -h y d ro x y e s tra n -1 7 -o n e  
(as MO-TMS e th e r )  is o la te d  from  horse u r in e
already been reported (Houghton & Dumasia 1980). From their 
fragmentation patterns, two of these compounds were identified as 
isomers of 3,17-dihydroxyestrane-16-one (V) and the third compound 
as an isomer of 3,16-dihydroxyestran-17-one (VI).
Fraction G3 After derivatization as TMS ether and analysis by 
gc-ms, four isomers of dihydroxymonoketo estranes were detected in 
this fraction for each administration and were identified as 
isomers of 3,17-dihydroxyestran-16-one (V) (2 isomers) and 3,16- 
dihydroxyestran-17-one (VI) (2 isomers). The retention times of 
three of these metabolites corresponded to those of the dihydroxy­
monoketo estranes identified in fraction G2.
Fraction G4- After derivatization as TMS ethers and analysis by 
gc-ms, four isomers of estrane-3,16,17-triol-tri-TMS ethers (VII) were 
detected in this fraction using EIC profiles of ions m/z 510 and 191. 
The Rt of these isomers were 8.3, 8.8, 9.25 and 9.5 min respectively. 
The mass spectra of these compounds (Fig. 60) show a molecular 
ion at m/z 510 and fragment ions at m/z 4-95 (Mt-15), 4-20(Mt-90),
405[fit-(90+15)] , 330 QlT-(90+90)L 241 [Tit-(90+90+89)] , 191 (base peak) 
and 14-7. The last two ions are TMS rearrangement ions (Sloan et al. 
1971 and Gustafsson et al. 1968 ), indicative of the presence of
neighbouring TMS groups on the molecule.
Fraction SI After derivatization as MO-TMS ethers and analysis by 
gc-ms, two compounds were detected and identified in this fraction.
The mass spectrum of the major metabolite showed a base peak at m/z 
375 and fragment ions at m/z 360 (Mt-15), 34-4- (mT-31), 254- (Mt-(90+31) 
and a base peak at m/z 129. The retention time and mass spectrum of 
this metabolite was identical to authentic 19-nortestosterone - MO-TMS 
ether and was therefore identified as the unchanged drug (1). The 
mass spectrdm of the other metabolite showed a weak molecular ion at 
m/z 377 and fragment ions at m/z 362 (Mt-15), m/z (Mt-31) and a base 
peak at m/z 256. The mass spectrum was identical to authentic 
19-norandrosterone - MO-TMS ether and from the above data this 
compound was identified as an isomer of 3-hydroxyestran-17-one (II).
The retention time of this metabolite was 6.1 min.
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Fraction S2 These fractions were analysed as their TMS-ether derivatives 
by gc-ms. Using EICP of ion 242 two isomers of estrane-3,17-diol bis TMS 
ethers (IV) having retention times of 5.73 min. (minor) and 6.23 min 
(major) were detected. On comparison of the retention times with authentic 
reference compounds the major isomer (R^ 6.23 min) was identified as 5a- 
estrane-33,173-diol. In addition 4 isomers of dihydroxy monoketo estranes 
were also detected by EICP of ions 202 and 421. From their mass spectra 
two isomers (Ret. times 7.25 min and 8.25 min) were identified as isomers 
of 3,17-dihydroxyestran-16-one (V). The other two isomers (Ret. times 
7.75 and 9.05) were identified as isomers of 3,16-dihydroxyestran-17-one (VI).
Fraction S3 After derivatization as TMS-ethers and analysis by gc-ms four 
isomers of dihydroxy-monoketo estranes were detected in this fraction.
The retention times of these compounds (R^ 7.25, 7.75, 8.25 and 9.05 min) 
and their mass spectra were identical to those found in Fractions S2 as 
described above.
Fractions S4 These fractions were analysed by gc-ms after the formation 
of TMS-ether derivatives. Using EICP of ions m/z 510 (Fig. 61) four 
isomers of estrane -3,16,17-triol-tri TMS ethers (VII) were detected having 
retention times of 8.4, 8.85, 9.3 and 9.6 min respectively.
6.4 DISCUSSION
14After intramuscular administration of C-19-nortestosterone to cross­
bred or thoroughbred gelded horses, greater than 60% of the administered 
radioactive dose was recovered in the urine over a period of 24 h (Houghton 
& Dumasia 1980). Of the radioactivity in the 0-24 h urine sample, greater 
than 90% was present in the conjugated fraction. In previous studies on the 
metabolism of 19-nortestosterone in a crossbred gelded pony (Houghton 1977) 
and a thoroughbred gleded horse (Houghton and Dumasia 1980), only the neutral 
steroid metabolites isolated after mixed enzyme hydrolysis treatment on 
aliquots of the 0-24 h urine samples were identified. It has been shown from 
the studies on the biotransformation of testosterone (Chapter IV) and 
1-dehydrotestosterone (Chapter V) that mixed enzyme hydrolysis treatment of 
horse urine samples fails to hydrolyse all the sulphoconjugated metabolites 
of anabolic steroids. This fact has also been demonstrated to be true in 
this study. Although the major pathway for the conjugation of the metabolites
of 19-nortestostero/ie was the formation of glucuronic acid conjugates (between
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Fig.61.The total ion current profile (A) of the TMS derivative 
of fraction S4- (expt. 6^/75) and the EICP (B) of the ion 
m/z 510 for the same fraction to detect the presence of 
isomers of estrane-3,16,17-triol (tri-TMS ethers) in 
horse urine.
50-60%), about 30% of the urinary radioactivity was excreted as the 
sulphoconjugates (Table 23).
The neutral urinary metabolites of 19-nortestosterone present in 
the glucuronide fraction (G) and the sulphoconjugate fraction (S) 
showed identical distribution patterns. In total, at least twenty- 
four conjugated metabolites accounting for between 4-7-57% of the
1 lL
urinary C in the 24- h urine sample have been found for each of the 
five adminsitrations. From these results, the pathways of bio-trans- 
formation of 19-nortestosterone in the horse can be summarised as
Zl
the reduction of the A -3-oxo group in the A-ring, epimerization of 
the hydroxyl group at C-173 to its 17a-epimer, oxidation at C-17 
with the formation of 17-oxo compounds and oxygenation at C-16. The 
structures of the urinary metabolites (Fig. 6^ ) have 
been reported previously (Houghton & Dumasia 1980).
Hydroxylation at C-16 and epimerization at C-17 appear to be 
common metabolitic pathways for the degradative metabolism of androstanes 
(C^)^and estranes (C^q ) in the horse#\chapters IV and V) For 
19-nortestosterone the reduction of the A-ring and the excretion of 
estrane-3,17a-diol glucuronide conjugates was found to be the major 
metabolic pathway. A small amount of 19-norepitestosterone was found 
in the glucuronide fraction and 19-nortestosterone and 5a-estran-38,173- 
diol were found to be present in the sulphate fraction. Isomers of 
3-hydroxyestran-17-one, 3,16-dihydroxyestran-17-one, 3,17-dihydroxyestran- 
16-one and estrane-3,16,17-triols were found in both the glucuronide 
and sulphate fractions. For testosterone the dihydroxymonoketo 
androstanes were found only in the sulphate fraction and for 
1-dehydrotestosterone they were present only in the glucuronide fraction.
(I) 19-NORTESTOSTERONE (II) 3-HYDR0XYESTRAN-17-0NE
OH OH
(III) 19-N0REPITEST0STER0NE (IV) ESTRANE-3,17-DIOL
OH
HO
(V) 3,17-DIHYDR0XYESTRAN-16-0NE (VI) 3,16-DIHYDROXYESTRAN-l
OH
Hi
(VII) ESTRANE-3,16,17-TRIOL
Fig.62. Urinary metabolites of 19-nortestosterone in the horse.
7-ONE
CHAPTER VII
DISCUSSION
7.1 The analysis of steroids in urine:
The selection of a particular biological fluid for the analysig 
of unknown substances depends on the object of the determination, the 
methods used for analysis and most of all on the disposition of the 
drug and/or its metabolites in the selected matrix.
In man, the end products of steroid catabolism are mainly excreted 
in the urine. The present study has shown that in the horse after 
intramuscular administration of dexamethasone, testosterone, 1-dehydro- 
testosterone and 19-nortestosterone between 25-60% of the administered 
dose of these steroids was excreted in the urine within 24- h. As has 
been pointed out by Klopper (1976), urine is the final catchment for 
the end products of biotransformation in several body compartments 
and yet is the only compartment from which there is no outflow or 
further transformation. Therefore the data obtained from the analysis 
of a 24- h urine collection represents a summary of the metabolic events 
of the preceding 24- h and can also be useful in determining the rate of 
excretion of the parent compound and/or its metabolites. In the present 
work aliquots of the 24 h urine collection were used for the identification 
of the metabolites in order to elucidate the pathways of metabolism of 
steroids in the horse. In forensic analysis, biotransformation studies 
have been shown to be useful in determining a suitable analyte for the 
development of urinary screening or confirmatory methods for the 
detection of drugs (Ward et al. 1977, DUrbeck et al. 1978). From the 
results of the present work, specific and sensitive methods using 
dexamethasone, testosterone and 1-dehydrotestosterone as analytes are 
being developed for the identification of these and related steroids in 
horse urine (unpublished data). Using estrane-3,17-diol as an analyte, 
a method to confirm the administration of 19-nortestosterone to horses 
has already been developed (Houghton et al. 1978).
Extraction of steroids from urine;
During the course of this study the extraction of free steroids from 
urine with various organic solvents before and after hydrolysis of the 
conjugates has been used. However steroids with a wide range of 
polarity were efficiently extracted from the urine by Amberlite XAD-2 
and recoveries ranging from 85-95% were obtained. This method of
extraction of the total urinary steroids (free and conjugated) was 
also found to be useful in the determination of the mode of conjugation 
of the metabolites of anabolic steroids excreted in horse urine 
(Chapters IV, V and VI).
The efficiency of hydrolysis of the steroid conjugates :
The use of hot acid treatment to hydrolyse steroid conjugates in 
urine was found to cause decomposition of some steroids. This was 
particularly evident from the greatly increased recovery of both testos­
terone and 1-dehydrotestosterone when a milder static solvolytic 
procedure was used. Direct enzyme hydrolysis treatment of steroid 
conjugates in urine using Helix pomatia mixed enzymes did not achieve 
complete hydrolysis of the sulphoconjugates even when excess enzyme was 
present (Chapters IV, V, VI). Whether this was due to the presence 
of some specific enzyme inhibitors in horse urine or the inability of 
Helix pomatia sulphatases to hydrolyse sulphoconjugates of functional 
groups at certain positions (Vestergaard 1978, Leunissen and Thijssen
1978) has not been ascertained. To overcome this problem, urine 
extracts were separated into glucuronide and sulphoconjugates by 
Sephadex LH-20 chromatography and the sulphoconjugates were solvolysed 
with acidified ethyl acetate (Burnstein and Lieberman 1958). Using 
this approach, better overall recoveries of the urinary metabolites were 
obtained. Occasionally failure of the solvolysis reaction was observed. 
Whether this was due to insufficient acidification of the ethyl acetate 
or the presence of impurities in the urine extracts is uncertain.
Separation of steroids by column chromatography :
Sephadex LH-20 chromatography using chloroform-methanol (1:1 v/v) 
was found to be a rapid, efficient and reproducible method for the 
separation of the urinary metabolites of anabolic steroids into their 
glucuronides and sulphoconjugates. This method was found to be very 
useful in the determination of the effects of structural modifications 
on the biotransformation and conjugation of anabolic steroids (Chapters 
IV, V and VI). Partial separation of the unconjugated metabolites of 
dexamethasone by chromatography on Sephadex LH-20 prior to their
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identification was also rapid and reproducible and this method can 
be used to isolate the fraction, containing the unchanged drug for 
developing definitive identification methods for synthetic cortico­
steroids. Using this approach, a method has now been developed to ^  
isolate by Sephadex LH-20 a fraction containing a number of parent 
synthetic corticosteroids. This fraction is then analysed by HPLC 
and combined HPLC - negative ion mass spectrometry to obtain 
unequivocal identification of the parent steroids (Houghton and 
Dumasia, unpublished results).
Kieselgel H chromatography was used in this study to separate the 
radioactive steroid metabolites. These were eluted from the column in 
order of increasing polarity by increasing the concentration of 
ethanol in the eluting solvent mixture. This method of partial 
purification of urine extracts was found to be preferable to tic 
separation of the metabolites because of the increased loading and 
resolving capacity of the columns, quantitative recovery of radioactivity 
from the silica.gel, ease of handling of the procedure and reproducibility 
of the results from day to day.
Formation of derivatives of steroids:
Because of the difficulties in the quantitative and reproducible 
formation of derivatives of synthetic corticosteroids for glc and 
gc-ms analysis, the metabolites of dexamethasone were characterized 
by microchemical reactions. These reactions were also utilized in the 
preparations of some reference compounds from authentic dexamethasone.
For the analysis of the metabolites of anabolic steroids, in general, 
two stage derivatizations were used. Normally, condensation of the 
reactive carbonyl groups with methoxime results in the formation of two 
geometric isomers (syn- and anti- derivatives), which were not 
separated under the gc conditions used. Catalysed silylation of the 
functional hydroxyls using BSA: TMCS was found to be rapid and 
convenient for gas chromatographic analysis of the steroids investigated.
The silylation reagents are volatile and the derivatized steroids 
redissolved in hexane, were stable for over three days. Purification 
of the MO-TMS derivatives to remove the excess methoxylamine reagent 
was found to be necessary for capillary column gc-ms and the 
derivatized steroids, dissolved in dodecane, were stable for over 
3 weeks.
The formation of the cyclic acetal (acetonide) derivatives was 
found to be a useful reaction in the determination of the cis 
hydroxyl functions at C^g and positions (Adlercreutz et al.
1967). Because of the stability of the cyclic acetal,.prominent 
ions at high mass were observed in the mass spectra of the steroid 
derivatives and facilitated structural elucidation.
Gas chromatography and combined gas chromatography-mass spectrometry 
of steroids
Although gas chromatography can be used as a quantitative technique, 
in the present study it was used only for the identification of the 
stereochemistry of some of the anabolic steroid metabolites by co- 
injection with authentic reference compounds where available. It was 
observed that in a series of isomers of androstanes and estranes with 
the saturated A-ring the isomer with the longest retention time had the 
33,5a configuration using the OV-1 stationary phase.
Combined gc-ms was found to be extremely useful in the study of 
the biotransformation and disposition of steroids because of the rapid 
and reliable identification of the compounds using a single analytical 
system. In the present study, in spite of the poorer resolution of 
the packed columns used in the initial gc-ms work., generally there was 
little difficulty in analysing the data obtained from each gc-ms run 
using the computer facilities.
SIM-gc-ms was found to be a valuable technique in the detection 
of small amounts of material in a complex mixture and was used to 
identify 5a-androstan-33-hydroxy-17-one as a urinary metabolite of
testosterone (Chapter IV). SIM was also used to confirm the absence, in 
normal (pre-administration) horse urine, of all the urinary metabolites 
of testosterone and 1-dehydrotestosterone that were identified in the
0-24 h urine sample after the administration of these drugs.
7.2. Biotransformation of steroids in the horse
Studies on the biotransformation of dexamethasone, testosterone,
1-dehydrotestosterone and 19-7nortestosterone have been fully described 
and the results discussed in detail in chapters III, IV, V and VI 
respectively. From the neutral metabolites of these compounds 
identified in the first 24 h urine collections, it is possible to make 
some generalizations about the pathways of biotransformation of steroids 
in the equine castrate and to speculate on the effects of certain 
factors such as structural modifications^species differences, dosages 
and castration on the metabolism of these steroids.
The metabolism of steroids in the horse proceeds by oxidation, 
reduction and epimerization (Phase I) and the metabolites are excreted 
in the urine, as conjugates with glucuronic and sulphuric acid (Phase II). 
Although these reactions are qualitatively similar to those observed for 
steroid metabolism in man and other animal species (Dorfman and Ungar 
1965), the quantitative differences observed in the rates of excretion 
and in the pathways of biotransformation of the steroids studied in 
this thesis could be attributed to species variation and to structural 
differences between the steroids.
After intramuscular administrations of the steroids at therapeutic 
dose levels, about 50% to 80% of the radioactivity was recovered in the 
urine indicating that urinary excretion is a significant pathway for 
the elimination of steroids in the horse . For the three anabolic 
steroids (administered at a dose level of 150 mg each) the elimination 
rates were 19-nortestosterone> 1-dehydrotestosterone> testosterone. The 
slower rate of elimination of testosterone in the equine castrate could 
be attributed to its higher binding at receptor sites in the target 
organs (e.g. prostate) and higher affinity for binding to sex hormone 
binding globulin (SHBG) both of which could reduce its rapid catabolism 
by removal from peripheral circulation.
The differences observed in the biotransformation of the 
endogenous sex hormone testosterone between horse (Chapter IV) and 
man can be attributed to species variation. For example, after 
administration of radiolabelled testosterone to man greater than 
80% of the dose is excreted in the urine within 24 h (Fotherby &
Games, 1972, Zumoff et al. 1971). Quantitatively, the major 
transformations are the reduction of the A-ring and oxidation at 
C-17 with the formation of androsterone and etiocholanolone.
Very little unchanged testosterone is excreted and the majority of 
the urinary metabolites are conjugated with glucuronic acid 
(Vermeulen 1979, Baulieu and Robel, 1970). In the equine castrate 
only 25% of the administered dose of testosterone is recovered in 
the urine within 24 h and a further 20-25% over the next 7 days.
The major transformations are the reduction of the A-ring, hydroxylation 
at C-16 and epimerization at C-17; oxidation at C-17 being a minor 
route. Of the administered dose, 2.3% is excreted as unchanged 
testosterone and the majority of the urinary metabolites are 
conjugated with sulphuric acid. These differences are likely to be 
due to the species variation in the relative activities of the enzymes 
involved in the various metabolic pathways.
It has been reported that in rats, castration of the adult male 
animals leads to a partial 'feminization' of steroid metabolising 
enzymes defined as a move towards a more female type of pattern of 
metabolism (Kato et al. 1968, Einarsson et al. 1973). Female rat 
livers show a greater 5a-reductase activity (Yates et al. 1958,
Stenberg 1976) and a greater capacity for sulphoconjugation (Roy 1956, 
Carlstedt-Duke and Gustafsson 1973). Thus the stereospecific 
reduction of the A-ring with the formation of the 5a,33 metabolites and 
the increased sulphoconjugation could possibly be attributed to a 
'feminization' pattern in the equine castrate. However, in the absence 
of comparative data on the metabolism of testosterone in the stallion 
and the mare this interpretation must be regarded as speculative.
For testosterone, about 60% of the urinary metabolites were 
excreted as sulphoconjugates and only about 20% were excreted as 
glucuronides. However for the two synthetic anabolic steroids^
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a major proportion of their metabolites were found to be conjugated 
with glucuronic acid (about 50% - 60%) and a minor proportion (about 
30%) with sulphate. Normally sulphation and glucuronidation are the 
two common conjugation mechanisms available for steroid detoxification 
in vivo and both reactions can often compete for the same substrate.
It has been suggested by a number of workers that sulphation has a 
lower capacity, is a readily saturable mechanism and is rate-limited 
by the availability of the sulphate ion in vivo (Bray et al. 1952a 
and b, Levy and Matsuzawa 1967, Bennet et al.'1975). For any 
substrate of these conjugating enzymes, UDP-glucuronyltransferase 
and sulphotransferase, the extent to which it is glucuronidated and 
sulphated will depend on the kinetic characteristics of both enzymes 
towards this substrate (and, therefore, upon the dose) and also on 
the availability of the co-substrates UDP-glucuronate and 3'-phospho- 
adenosine 5’-phosphosulphate. Thus, the kinetic parameters, the 
cosubstrate availability and the rate at which the substrate (steroid) 
is supplied to the enzymes are the three main rate limiting factors 
affecting conjugations. In the case of the naturally occuring steroid 
testosterone, where only 27% of the administered dose was excreted 
in the first 24 h, the increase in the percentage of sulphoconjugation 
could be attributed to the lower circulating levels of the unconjugated 
steroid metabolites. However for the synthetic steroids, 19-nortestosterone 
and 1-dehydrotestosterone, where the rate of excretion was rapid, the free 
steroid metabolites could be present in relatively large proportions in 
peripheral plasma thus causing saturation of the available co-substrate 
supply (sulphate ion) and therefore increasing the utilization of the 
alternative glucuronidation pathway.
It has also been observed that the 17a-hydroxy configuration was 
present in all the steroid aglycons where the stereochemistry was verified. 
Thus it could be that in the horse there is a stereospecific mechanism 
operating at cellular level for the phase II synthetic reactions and 
when the sulphoconjugation mechanism is saturated, epimerization to the 
17a-hydroxy configuration is an essential prerequisite for the 
conjugation with gluruconic acid. All three parent anabolic steroids 
were excreted in the urine only as sulphoconjugates. However a small
amount of 19-norepitestosterone and large amounts of 1-dehydroepi- 
testosterone were excreted as glucuronic acid conjugates. Thus the 
induction of an alternative pathway for the rapid detoxification 
and elimination of exogenous steroids in the horse could be a 
plausible explanation for the increased G-17 epimerization of the 
anabolic steroids. However in the absence of any kinetic data on 
the properties of the sulphotransferases present in horse liver 
preparations or comparative data on the relative levels of 
glucuronidation and sulphation of steroid metabolites after 
administrations at lower dose levels to horses, these interpretations 
must once again be regarded as speculative.
After the administration of therapeutic doses of dexamethasone, 
a relatively small proportion (about 8-13%) of the radioactivity was 
excreted in the urine in the form of conjugates and no metabolites 
in which the A-ring was partially or fully reduced were identified 
in the urine. Synthetic glucocorticoids are poor substrates for 
the usual enzymatic transformations especially those of the 
synthetic phase II type. In the absence of ring-A reduction,
Ye-ctac-h'dM of
oxidation at C-6 and^C-20 were found to be the major pathways of 
catabolism; oxidations at C-ll and C-17 were found to be minor routes.
These results are attributed to the stability of the A-ring to 
enzymatic reductions and are consistent with similar observations 
reported by other workers for the biotransformations of synthetic 
glucocortico^steroids (Glenn et al. 1957, Florini et al.1961, Butler 
and Gray 1970, Hague et al. 1972, Mineo 1976 and 1978).
After the administration of a large dose of dexamethasone, the 
major pathway of biotransformation appeared to be oxidation at C-21 with the 
formation of C-21 carboxylicacid metabolites excreted in-the urine as free 
compounds. * The formulation and the size of the dose had a marked 
effect on the rates of absorption, excretion and biotransformation of 
the drug. The increased oxidation at C-21 could therefore be regarded 
as a dose dependant alternative detoxification pathway leading mainly 
to the formation and elimination of highly polar water soluble
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compounds thus marking a oew: pathway for the biotransformation of 
dexamethasone in the horse.
The influence of the A"** substituent on the metabolism of the 
anabolic steroids was also apparent in the present study. After 
i.m. administrations of testosterone and 19-nortestosterone less 
than 10% of the radioactivity in the 0-24 h was excreted in the un­
conjugated form. However a slight increase in the excretion of 
the free steroids (about 15% of the urinary H) was observed after 
administration of 1-dehydrotestosterone. This could be attributed 
to the stability of the conjugated dienone A-ring structure to 
reductive metabolism and is similar to the increased urinary 
excretion of unconjugated metabolites observed after administration 
of synthetic glucucorticoids (e.g. dexamethasone). The decrease
Ll
in the reduction of the A -3-oxo group and in the oxidation of the 
C-17 hydroxy group observed in the metabolism of 1-dehydrotestosterone 
can also be attributed to to the presence of the A^-substituent.
This was evident from the increased excretion of the isomers of the 
parent steroid (11% of the administered dose), the identification 
of 1.6-hydroxy-l-dehydrotestosterone and isomers of 16,17-dihydroxy- 
5-androst-l-ene-3-one and the absence of the isomers of C^O^- 
diols and the 17-oxosteroids in the urine. The increased excretion 
of 1-dehydroepitestosterone is also attributed to the increased 
resistance of the A-ring to reduction and thus marks a novel 
mechanism for the rapid detoxification and excretion of this steroid. 
Although a number of metabolites of 1-dehydrotestosterone with partly 
or fully saturated A-ring were identified in the aglycon fraction, 
in quantitative terms this was a minor pathway in contrast to the 
metabolism of testosterone and 19-nortestosterone where the reduction
l±
of the A -3-oxo group was the major route.
Finally, using sensitive SIM-gc-ms techniques none of the 
metabolites of testosterone identified in the post-administration 
urine samples could be identified in the pre-administration samples. 
Thus it seems that in the equine castrate there is very, little ; 
urinary excretion of the metabolites of androgens of adrenal
origin.
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CONCLUDING REMARKS: '
This thesis has been mainly concerned with the determination of 
the overall excretion and identification of the neutral urinary 
metabolites of dexamethasone, 1-dehydrotestosterone, testosterone 
and 19-nortestosterone after intramuscular administrations to the 
equine castrate.
It has been shown that initial Amberlite XAD-2 extraction of 
the urinary steroids,separation of the conjugates by Sephadex LH-20 
prior to hydrolysis and the inclusion of a solvolysis step is 
essential to ensure complete extraction and hydrolysis of all the 
urinary metabolites.
Results of the analysis have shown that in general the pathways 
of biotransformation of these steroids in the horse are qualitatively 
similar to those previously reported by other workers in different 
animal species. However, the quantitative differences in the mode of 
conjugation and urinary excretion of these drugs and their metabolites 
were apparent and can be attributed to the effect of species difference 
on biochemical, pathways.
Since all the work in this thesis has been performed on the equine 
castrate similar studies in intact male and female horses in active 
training need to be carried out in order to elucidate the effects of 
sex and physiological status (exercise) on the biotransformation and 
excretion of these drugs, especially the anabolic steroids.
In conclusion, the methods described in this thesis can be used not 
only to study the qualitative and semiquantitative aspects of biotrans­
formation of steroid drugs, but also to elucidate the mode of conjugation 
of their uri/iary metabolites. These methods can also be used to determine 
the metabolic profiles of other endogenous and exogenous steroids and 
possibly other groups of drugs. Where stable and quantitative derivat­
ives of the compounds can easily be made for gas-phase analysis, 
computerized gc-ms offers the highest degree of specificity and is ideal 
for the multicomponent analysis of complex mixtures.
"But now ask the beasts, 
and they shall teach thee."
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1. After intramuscular administration o f [4 -14C]testosterone to two cross-bred gelded  
horses, 45% of the radioactivity was excreted in urine in 96 h. Small amounts of urinary 
activity could still be detected at 200 h.
2. Neutral m etabolites obtained after both enzym e and acid hydrolysis of urine samples 
have been investigated by g.I.e.—mass spectrometry.
3. 5a-Androstane-3/?,17a-diol was found only in the enzym e-hydrolysable extract 
and testosterone only [in the acid-hydrolysable extract. 5a-Androstaner3j3,17/J-diol and 
3/?-hydroxy-5a-androstan-17-one were found predominantly in the acid-hydrolysable 
extract.
Introduction
In previous publications in this series, studies related to the metabolism of 
19-nortestosterone in the horse have been reported (Houghton 1977) and a method 
to confirm the administration of 19-nortestosterone or its esters to horses has been 
developed (Houghton et al. 1978). T he metabolism of testosterone in the horse has 
now been studied with a view to developing methods to confirm the administration 
of this endogenous steroid hormone. Previous studies on the metabolism of 
testosterone have been carried out in the rat (West 1951, Ashmore et al. 1953), the 
guinea-pig (Dorfman and Fish 1940, Burnstein et al. 1955), the rabbit (West 1951, 
Taylor and Scratcherd 1967), the dog (West 1951), the cat (Archer, Scratcherd and 
Taylor 1965) and man (West, Reich and Samuels 1951, H eilm an .et al. 1956, 
Sandberg and Slaunwhite 1956, Mauvais-Jarvis, Floch and Bercovici 1968 a, 
Mauvais-Jarvis et al. 1968 b). Also in recent years there have been numerous reports 
on the metabolism of testosterone in vivo and in vitro in various tissues and glands.
M aterials and m ethods
Gas chromatography and combined gas chromatography—mass spectrometry
Analytical g .l.c. was carried out using a Perkin-Elm er F—17 gas chromatograph fitted with a coiled  
glass colum n (2m  x 6-4m m  o.d ., 2m m  i.d.) packed with 1-5% O V-1 on Gas Chrom Q. N 2 was used as 
carrier gas. Capillary colum n g.l.c. was carried out by M asspec Analytical Speciality Services L td ., 
W oodchester, Stroud, Gloucestershire, U K  using a Carlo Erba F L  2150 instrument fitted with an OV— 1 
W C O T  colum n (20 m, 0-2 mrh i.d.) w ith H e as carrier gas.
Com bined g .l.c .-m ass spectrometry was carried out using a Finnigan 4000 series gas chrom atograph- 
mass spectrometer linked to a Finnigan 6110 data system. A coiled glass colum n (1-8 m x  6-4m m  o .d ., 
2 m m  i.d.) packed with l -5% OV—1 on Gas Chrom Q was used. T he column was temperature- 
programmed from 180° to 260° at 5°/m in and H e was used as carrier gas.
Solvents and chemicals
Hexane, ethyl acetate and 1,2-dichloroethane were redistilled before use. [4 -14C]Testosterone was 
obtained from the Radiochemical Centre, Amersham, U K  (sp. activity, 53-5 Ci/m ol). Testosterone, 5a- 
androstane-3/?,17j8-diol, 5/J-androstane-3/J,17/?-diol, 5a-androstane-3a,17/?-diol, 5j8-androstane-3a,17jS- 
diol, 5/?-androstan-3a-ol-17-one, 5/i-androstan-3/?-ol-17-one, 5a-androstan-3jS-ol-17-one and 5a- 
afidrostan-3a-ol-17-one were obtained from Sigma London' Chemical Company, K ingston-upon- 
Tham es, Surrey, U K . 5a-Androstane-3j3,17a-diol, 5)3-androstane-3j3,17a-diol, 5a-androstane-3a,17a-, 
diol and 5/?-androstane-3a,17a-diol were kindly obtained from the M R C  Steroid Reference Collection.
X.B.
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IV ,0-bis-(Trim ethylsilyl)acetam ide (BSA) and trimethylchlorosilane (T M C S) were obtained from  
Pierce and Warriner (U K ) Ltd., Chester, U K . M ethoxylam ine hydrochloride was obtained from  
Eastman Kodak Ltd., Kirkby, Liverpool, U K , K ieselgel H  nach Stahl from Anderman & Co. Ltd., East 
M osley, Surrey, U K  and Silica Gel S13F  for t.l.c . from W hatman Ltd., M aidstone, Kent, U K . H elix  
pom atia  digestive juice (Industrie Biologique Frangaise) was obtained from U niscience Ltd., Cambridge, 
U K  and contained a m inim um  of 100 000 units /1-glucuronidase (Fishman) and 1 000 000 units sulphatase 
(Roy) per ml.
Administration to animals
T he purity of [4 -14C]testosterone was checked by t.l.c. and scintillation counting as previously  
described for 19-nor[4-14C]testosterone (H oughton 1977). Three solvent system s were used; ethyl 
acetate; chloroform -ethyl acetate (1:1 , v/v); chloroform -m ethanol, (4 :1 , v/v).
Intramuscular administrations were made to two cross-bred gelded horses (Horse A, 382 kg and Horse 
B 378 kg) at single sites in the neck. In each case the dose (testosterone, 150 mg; [4 -14C]testosterone 
22 pC i) was dissolved in ethanol (0-3 ml) to which was added arachis oil (8 ml) containing benzyl alcohol 
(10% ) and cresol (0-3%). (T h is solvent was kindly donated by Intervet Laboratories.)
Urine samples were collected whenever voided for up to 200 h after administration and an aliquot 
(0-1 ml) from each specimen was taken to determine the total radioactivity. Sequential blood samples were 
obtained by means o f an indwelling cannula and the total radioactivity was determined as reported 
previously (Houghton 1977).
Determination of the amount of unconjugated and conjugated metabolites
Samples (50 m l) o f pooled urine from the first 24 h o f collection were processed as shown in the flow  
diagram (figure 1) to determine the percentages o f unconjugated, enzym e-hydrolysable and acid- 
hydrolysable m etabolites. Before enzyme hydrolysis N 2 was bubbled through the urine to remove any 
residual ethyl acetate. Enzyme hydrolysis was carred out by incubating the urine at pH 5 with H elix  
pomatia  juice (0-25 ml) for 36 h at 37°. For acid hydrolysis conc. HC1 (7-5 m l) was added to the urine and 
the solution boiled under reflux for 1 h. A liquots o f the urine and ethyl acetate extracts were taken at each 
stage for scintillation counting to determine the total radioactivity.
Total acid hydrolysis
Samples (50 ml) o f pooled urine from the first 24 h o f collection were boiled under reflux with HC1 
(7-5 ml) for 1 h, and the neutral extract was isolated by solvent extraction as described in figure 1.
Isolation of metabolites fo r identification by g . l .c —mass spectrometry
Samples (50 ml) o f pooled urine were enzym ically hydrolysed and the neutral fraction 
solvent extraction as described previously.
After enzyme hydrolysis and extraction the residual urine was then acid hydrolysed and 
fraction again isolated by solvent extraction.
Column chromatography
After removal o f the solvent the neutral residues were chromatographed on Kieselgel H  (5 g; column  
diam. 15 mm) using 1,2-dichloroethane-ethanol (98 : 2, v/v) as eluant; 30 x 3 ml fractions were collected  
and the material remaining on the colum n was then eluted with methanol. An aliquot (0-1 ml) o f each 
fraction was taken to determine total radioactivity. Fractions containing resolved metabolites were 
combined and the solvent removed. Som e of the resolved metabolites were rechromatographed using 
toluene-ethyl acetate (7 : 3, v/v) as eluant.
Preparation of methoxime-trimethylsilyl derivatives  (M O -T M S )
Fractions from chromatography were dissolved in an 8% solution of m ethoxylam ine HC1 in pyridine 
(0-1 ml) and the reaction was allowed to proceed overnight at room temp. T h e pyridine was removed at 40° 
in a stream of N 2 and the residual material was dissolved in BSA  (0-1 ml) and T M C S  (0-025 ml). Silylation  
was carried out at 60° for 2 h; the silylating reagents were then removed in a stream of N 2 at 40° and the 
residue dissolved in hexane (0-1 m l) for analysis by g.l.c. and g.l.c .-m ass spectrometry. M O -T M S  
derivatives of reference steroids were also prepared by this procedure.
Preparation o f trim ethylsilyl derivatives ( T M S )
Silylation of reference steroids and fractions from the chromatography of urinary metabolites was 
carried out at 60° for 2 h using B SA  (0-1 ml) and T M C S  (0-025 ml).
isolated by 
the neutral
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Volume adjusted to 
50 ml and the pH to 
5.0.Washes: 0.1 M NaOH (2 x 25 ml) 
and saturated NaCI (1 x 25 ml). 
Washes discarded.
Volume adjusted 
to 50 ml
Washes: 0.1M NaOH (2 x 25 ml! 
and saturated NaCI (1 x 25 ml). 
Washes discarded.
Washes: 0.1M NaOH (3 x 25 ml) 
and saturated NaCI (1 x 25 ml). 
Washes discarded.
Residual urine
Residual urine
Enzyme hydrolysis
Hot acid hydrolysis
Ethyl acetate 
FRACTION E
Residual urine 
discarded
U RINE  
50 ml, 24 h pool
Ethyl acetate 
FRACTION C
Ethyl acetate 
FRACTION A
EXTR A CTIO N  
Ethyl acetate (2 x 100 ml)
EXTR A CTIO N  
Ethyl acetate (2 x 100 ml)
E XTR A CTIO N  
Ethyl acetate (2 x 100 ml)
Ethyl acetate 
Neutral unconjugated 
metabolites 
FRACTION B
Ethyl acetate 
Neutral acid-hydrolysable 
metabolites 
FRACTION F
Ethyl acetate 
Neutral enzyme-hydrolysable 
metabolites 
FRACTION D'
Figure 1. F low  diagram for the isolation o f neutral urinary m etabolites.
R esults
Urinary excretion and plasma levels of radioactivity
Plasma levels of radioactivity after administration of [14C]testosterone to the two 
horses are shown in figure 2; plasma levels were low, the maxima occurring at about 
3 h. In each animal about 45% of the administered dose was excreted in the urine in 
96 h, but small amounts of urinary 14C could still be detected at 200 h.
Amounts of unconjugated, enzyme-hydrolysable and acid-hydrolysable metabolites 
T he percentages of 14C present in fractions A -E  (figure 1) are given in table 1.
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Figure 2. Plasma concentrations o f radioactivity after intramuscular administration of 
[4 -14C]testosterone O H orse A , , A H o rse  B).
T able 1. Percentage o f 14C extracted from 24 h urine pool by the procedure shown in figure 1.
Unconjugated Enzym e hydrolysed Acid hydrolysed
Horse Fraction F raction Fraction Fraction F raction F raction
A B C D E F
A 4-3 3-4 28 22 48 ' 43
B 4-3 3-4 34 27 41 33
Total acid hydrolysis
After total acid hydrolysis of urine samples from horses A and B 83% and 78% of 
the total urinary 14C was extracted with ethyl acetate of which 64% and 56% 
remained in the neutral extract. Column chromatography of this extract resolved 
four radioactive components (fractions al-a4 , figure 3 (a)) comprising 11*8%, 8-8%,
4-7% and 3-0% of the initial urinary 14C (horse B). Of the radioactivity put on the 
column 55% was eluted with 1,2-dichloroethane-ethanol (98:2, v/v; 90ml). The 
residual activity was eluted from the column with methanol. Comparable results 
were obtained after chromatography of the corresponding neutral extract from horse 
A.
Isolation and identification of metabolites by g .l.c—mass spectrometry
Column chromatography of the neutral extract isolated after enzyme hydrolysis 
resolved two radioactive components comprising 2% and 6-7% of the initial urinary 
14C for horse A and 2-4% and 7-4% for horse B (fractions b l and b2, figure 3(b)). Of 
the activity put on the column, 42% and 37% was eluted respectively with 90 ml of 
the eluant and the remainder with methanol.
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Fraction b l after formation of the M O -T M S derivative proved extremely 
complex on analysis by g.l.c.-mass spectrometry and the metabolites present in this 
fraction could not be identified. Fraction b2 as the M O -T M S derivative showed one 
major component (R t 10-3 min) on analysis by g.l.c.-mass spectrometry (figure 4(a)). 
The mass spectrum showed a weak molecular ion at m/e 436 and fragment ions at 
m/e 421 ( M t- 1 5 ) ,  346 ( M t- 9 0 ) ,  331 (M + -(904-15)), 256 ( M t - (9 0  +  90)), 241 
(M ? —(90 +  90+15)) and 129 (base peak). T he molecular weight and fragmentation 
pattern indicated that the metabolite was an isomer of androstane-3,17-diol and this 
was confirmed by comparison of the mass spectrum with that of 5a-androstane- 
3/?,17/?-diol bis-TM S. A m inor component (i?t 10-9; figure 4(a)) also showed the 
same mass spectral characteristics and is presumably a second isomer of androstane- 
3,17-diol.
E
CL
"O
15 30 45 6 0 75 9 0
Elution volume (ml)
Figure 3. Separation by colum n chromatography o f neutral urinary extracts, obtained after (a) total acid 
hydrolysis (b) enzym e hydrolysis and (c) acid hydrolysis o f the residual urine following enzym e 
hydrolysis and extraction.
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Column chromatography of the neutral extract, isolated after acid hydrolysis of 
the residual urine following enzyme hydrolysis and extraction, resolved four 
radioactive components comprising 2-4%, 14%, 2-6% and 3-4% of the initial urinary 
14C for horse A and 3%, 10%, 3-3% and 2-5% for horse B (fractions cl-c4 , figure 
3(c)). Of the activity put on the column, 55% and 59% respectively was eluted with 
90 ml of eluant and the remainder with methanol.
Fraction cl also proved too complex for identification of metabolites by g.l.c.- 
mass spectrometry. Fraction c2 as the M O -T M S derivative showed a single major 
component on analysis by g.l.c.-mass spectrometry. T he mass spectrum and 
retention time of this compound were identical to those of testosterone M O -TM S. 
The M O -T M S derivative of fraction c3 showed five major components on analysis 
by g.l.c.-mass spectrometry (figure 4(6)). One of the major components (R t 109 min) 
showed mass spectral characteristics corresponding to those of an isomer of 
androstane-3,17-diol, only one isomer was found in this fraction. On the basis of the 
mass spectral data obtained, the other four components have not yet been identified. 
The metabolites present in fraction c4 and in the methanolic column washes are still 
being investigated.
In a further attem pt to identify the metabolites present in fractions a l, b l and cl 
(figure 3(a), (6), (c)) these fractions were rechromatographed on Kieselgel H  (5 g) 
using toluene-ethyl acetate (7 : 3,v/v) as eluant. In each case two radioactive fractions 
were resolved comprising 7% and 2-4% of the initial 14C in the urine fraction for al, 
1-0% and 0-6% for fraction b l and 1-8 and 0-8% for fraction c l. After derivatization 
(M O -TM S) and g.l.c.-mass spectrometry, none of the metabolites in the major 
fractions could be identified. Using selected ion monitoring an isomer of 3- 
hydroxyandrostan-17-one was identified as its M O -T M S derivative in the minor 
fraction in each case. Isomers of 3-hydroxyandrostan-17-one M O -T M S show major 
ions at m/e 376 (M t —15), 360 (M t — 31), 270 (M + —(90 +  31)) and 213 (figure 5 (a)). 
The selected ion chromatograms for the total acid-hydrolysed fraction, the enzyme- 
hydrolysed fraction and the acid-hydrolysed fraction obtained after acid hydrolysis 
of the residual urine from enzyme hydrolysis are shown in figure 5(6), (c), (d).
Samples of normal urine obtained from horses A and B were hydrolysed, 
extracted and the extracts chromatographed in an identical m anner to the post­
administration urine extracts. Using identical g.l.c.-mass spectrometry conditions 
none of the metabolites of testosterone identified were found in these urine extracts.
9 It 13 9 II 13 15
Retention time (min)
Figure 4. Reconstructed gas chromatograms of the m ethoxim e-trim ethylsilyl derivatives of (a) fraction 
b l ,  figure 3(b) and (b) fraction c3, figure 3(c).
Metabolism o f testosterone in the horse 275
3 5 77
(d)
376
X .X  360  
2 70X
213
Retention time (min)
Figure 5. Selected ion m onitoring to detect the presence o f 17-oxo m etabolites in extracts of urine from  
horses dosed with [14C]testosterone.
Selected ion chromatograms of m/e 213, 270, 360 and 376 for the M O -T M S  derivatives o f (a) 
5a-androstan-3/)-ol-17-one; minor fraction obtained by rechromatography of (b) fraction a l, 
figure 3(a) (c) fraction b l ,  figure 3(b) and (d) fraction c l ,  figure 3(c).
Determination of the stereochemistry of the metabolites
Fractions a3 (figure 3(a)), obtained after total acid hydrolysis, was isolated and 
purified further by chromatography using the same conditions. After silylation this 
fraction was analysed by selected ion monitoring for the ion m/e 436 corresponding to 
the molecular weight of androstane-3,17-diol bis-TM S derivatives. The use of this 
technique demonstrated the presence of two isomers of androstane-3,17-diol in this 
fraction (figure 6(a)). To determine their stereochemistry , the retention times of the 
bis-TM S derivatives of these two metabolites were compared to those of the silyl 
derivatives of the four androstane-3,17/?-diol isomers using capillary column g.l.c. 
The separation of the bis-TM S derivatives of these four 17j6-diol isomers under the 
g.l.c. conditions used is shown in figure 6(b), the peak of longest retention time 
corresponding to that of 5a-androstane-3/i,17/i-diol bis-TM S. The separation of the 
two urinary diol metabolites is shown in figure 6(c) and the chromatogram for co1 
injection of the metabolites and reference steroids is shown in figure 6(d). T he silyl 
derivative of one of the metabolites (Rt 26-4 min) was clearly separated from the bis- 
T M S derivatives of all four possible isomers with a 17/?-OH configuration, 
indicating that the configuration at C-17 in this metabolite must be a. Enhancement 
of the peak of longest retention time showed that the second diol metabolite m ust be 
5a-androstane-3/?,17/?-diol. This metabolite is the only diol present in the acid- 
hydrolysed fraction (fraction c3, figure 3(c)).
The diol metabolite of shorter retention time having the 17a-OH configuration is 
the major diol isomer present in the fraction b2 (figure 3(b)) isolated by enzyme 
hydrolysis. Using this fraction, the full stereochemistry of this metabolite was 
determined by comparing the retention time of its bis-TM S derivative with the 
retention times of the bis-TM S derivatives of the four isomers of androstane-3,17a- 
diol using a packed column (1*5% OV-1 on Gas Chrom Q, 200-240° at 2°/min). The 
retention time of the silylated metabolite corresponded to that of 5a-androstane- 
3/J,17a-diol bis-TM S. This isomer was clearly separated from the other three under 
the g.l.c. conditions used.
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24 28
Figure 6. Comparison of the gas chromatography retention times o f  the b is-T M S  derivatives o f the 
androstane-3,17-diol m etabolites and those o f silylated reference com pounds.
(a) M ass chromatogram, m/e 436, for the b is-T M S  derivatives o f the purified urinary 
androstane-3,17-diol metabolites; (b) co-injection o f 5/?-androstane-3a,17/?-diol b is-T M S , 5a- 
androstane-3a,17/?-diol b is-T M S , 5/?-androstane-3/J,17/?-diol b is-T M S  and 5a-androstane- 
3/?,17/?-diol b is-T M S , (c) injection of the b is-T M S  derivatives o f the androstane-3,17-diol 
m etabolites, (d) co-injection of the b is-T M S  derivatives o f the androstane-3,17-diol metabolites 
and reference androstane-3,17jS-diols. Injections (b), (c) and (d) were carried out on an OV—1 
W C O T  colum n, 120—230° at 4°/m in.
Using g.l.c.-mass spectrometry and selected ion monitoring the retention time of 
the M O -T M S derivative of the 3-hydroxyandrostan-17-one isomer isolated from 
urine corresponded to that of 3/?-hydroxy-5a-androstan-17-one M O -T M S derivat­
ive. The derivatized testosterone rfietabolite had a retention time corresponding to 
that of 17jS-testosterone M O -TM S.
D iscussion
Since testosterone has both androgenic and anabolic activity, its use in the field of 
human athletics and other sports as an anabolic agent would appear to be limited, as a 
large num ber of anabolic steroids have been developed with less androgenic activity. 
However, with the development of routine methods of analysis for these anabolic 
agents (Brooks, F irth  and Sumner 1975, W ard, Shackleton and Lawson 1975, 
Jondorf 1977, Jondorf anci Moss 1978, Houghton et al. 1978), the use of testosterone 
may increase in the future. The present study has therefore been carried out with a 
view to developing a method to confirm the administration of this endogenous 
steroid hormone to horses.
The anabolic effect of androgens is more pronounced in boys before puberty, 
women and the castrate than in normal men (Wynn 1968, M urad and Gilman 1975). 
This observation may be significant in the field of horse racing as 68% of the urine 
samples analysed routinely by Racecourse Security Services’ Laboratories are from 
fillies and geldings. Two cross-bred geldings were used in this study.
After intramuscular administration of [4-14C]testosterone, the rate of urinary 
excretion of 14C in the two animals studied was virtually identical. About 50% of the 
administered radioactivity was excreted within 200 h, 40% being excreted in the first
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60 h. T he amount of 14C extractable from the urine before any form of hydrolysis 
was very low (4-3%) and there was a noticeable difference in the percentages of 
neutral metabolites extracted after enzyme or hot acid hydrolysis. Also after 
extraction of enzyme-hydrolysed metabolites from urine samples, a considerable 
amount of extractable 14C (about 40%) was liberated by subsequent hot acid 
hydrolysis.
Chromatography of the neutral extract obtained after enzyme hydrolysis 
resolved two radioactive components, and by g.l.c.-mass spectrometry, two isomers 
of androstan-3,17-diol were identified in the major fraction (Fraction b2, figure 
3(6)). By comparison of their retention times on g.l.c. with those of reference steroids 
(figure 6), the two isomers have been identified as 5a-androstane-3/?,17a-diol (II) 
and 5a-androstane-3/i,17/?-diol (III). Following enzyme hydrolysis and extraction, 
the residual urine samples were subjected to hot acid hydrolysis. After extraction and 
column chromatography, testosterone (I) and 5oc-androstane-3/J,17/?-diol (III) were 
identified in this extract by g.l.c.-mass spectrometry.
Column chromatography of the neutral extract obtained after total acid 
hydrolysis of urine samples gave a major fraction (fraction a l , figure 3(a)) which was 
not present to the same extent in the enzyme-hydrolysable extract (fraction b l , figure 
3(6)) or the acid-hydrolysable extract obtained after enzyme hydrolysis (fraction c l, 
figure 3(c)). Thus part of this fraction may arise from decomposition of metabolites 
which would not have been present if enzyme hydrolysis and solvent extraction had 
previously been carried out. Using selected ion monitoring, 3/?-hydroxy-5a- 
androstan-17-one (IV) has been identified in fractions al and cl and as a trace 
component in fraction b l.
The androstanediol fraction (fraction b2, figure 3(6)) obtained after enzyme 
hydrolysis was subjected to acid treatment and some decomposition was observed. 
This may account for the difference in the percentages of diol metabolites obtained 
after total acid hydrolysis (figure 3(a)), enzyme (figure 3(6)) and enzyme followed by 
acid hydrolysis (figure 3(c)). The results suggest the 17a-diol is more susceptible to 
decomposition by acid hydrolysis than the I l f  isomer.
Under the experimental conditions used, 5oc-androstane-3/?,17a-diol has been 
identified only in the enzyme-hydrolysable fraction and testosterone only in the 
acid-hydrolysable fraction (figure 7). 5a-Androstane-3/?,17jS-diol and 3/i-hydroxy- 
5a-androstan-17-one predominate in the acid-hydrolysable fraction. The presence 
of these metabolites in either enzyme- or acid-hydrolysed fractions may be 
attributed to differences in their mode of conjugation. However, since it has been 
reported that urine contains inhibitors for both jS-glucuronidase and steroid 
sulphatases (Graef, Furuya and Nishikaze 1977) and that certain steroid sulphates 
and glucurono-conjugated 17-oxo-steroids are incompletely hydrolysed by Helix 
pomatia digestive juices (Shackleton, Livingstone and Mitchell 1968, Mauvais- 
Jarvis and Baulieu 1965), the exact nature of conjugation of the diol and 17-oxo 
metabolites remains uncertain. On the basis of the present results however the 
excreted testosterone appears to be conjugated with sulphate.
Isomers of 3-hydroxyandrostan-17-one and androstane-3,17-diol are present in 
the urine of humans and several animal species (Dorfman and Ungar 1965) and 
testosterone is a known precursor of these isomers in man (Fotherby and James 1972, 
Mauvais-Jarvis et al. 1968 b, Tam m  1967). The urinary metabolites of testosterone 
identified in the present study are summarized in figure 7. In the horses studied, both 
17/?- and 17a-androstanediols have been isolated as urinary metabolites. In man,
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androstanediols are formed from testosterone either by direct reduction by specific 
A4-3-oxosteroid reductases and 3-hydroxysteroid dehydrogenases (hydroxylic path­
way) or by oxidation of the 17/?-hydroxyl group by a 17-hydroxysteroid de­
hydrogenase to yield ketonic intermediates in metabolism (ketonic pathway) 
(Mauvais-Jarvis et al. 1968 a,b, Baulieu and Mauvais-Jarvis 1964). In the horse, 
although the 17/?-diol could arise by the hydroxylic pathway, without direct 
epimerization the 17a-diol could not. The 17a-diol could arise by the direct 
reduction of the A4-3-oxo group of epitestosterone. However, although testosterone 
has been detected in the urine, under the experimental conditions used, no 
epitestosterone was found. T hus it appears that the 17a-androstanediol is formed by 
the ketonic route. The formation of estrane-3,17a-diols has been found to be a 
predominant pathway in the matabolism of 19-nortestosterone in the horse
be specific for the formation of metabolites having a 5a,3/?-hydroxy configuration; 
some of the 5a-metabolites of testosterone possess androgenic activity, whereas the 
5/?-steroids and 17-oxosteroids are not active androgens (Baulieu 1970).
(Houghton 1977).
In the horses studied, reduction of the A4-3-oxo group of testosterone appears to
TESTOSTERONE
Acid-hydrolysable
metabolites
Enzyme-hydrolysable
metabolites
OH OH
0
Testosterone ( I) H
5a-A n d ro s ta n e -3 /3 ,1 7 a  — diol (n)
OH
HO
Trace H I
H
5a-A n d ro stan e -3 ;8 ,17 /3 -d io l (H I)
0
HO
Trace IV
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Figure 7. Urinary m etabolites o f testosterone in horse.
Metabolism of testosterone in the horse 279
Normal urines were collected from both animals before administration and a 
volume (50 ml) identical to that used in the identification of metabolites in post­
administration urine samples was analysed by the same experimental procedures. 
Using g.l.c.-mass spectrometry and selected ion monitoring none of the metabolites 
identified was found in the pre-administration urine samples. Thus in the gelding, 
identification by g.l.c.-mass spectrometry of any of the major metabolites could form 
the basis of a method to confirm the administration of testosterone.
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The above results suggest that in the lactating gland, as at lactogenesis, the roles of 
spermidine and cortisol are related. Oka & Perry (1974) proposed that spermidine is a 
mediator in the effect of glucocorticoids on milk-protein synthesis in the mouse mammary 
gland, and the inhibition of corticosteroid uptake reported here would be consistent 
with this proposition. Moreover, one of the several well-documented effects of spermi­
dine is the promotion of polyribosome aggregation (see Bachrach, 1973), a process in 
which tryptophan also appears to play a controlling role (see Munro, 1970). It is thus 
possible that tryptophan is a mediator in at least one of the effects of spermidine. In 
considering the interaction of spermidine, tryptophan and corticosteroids, it is perhaps 
pertinent to note that the latter two compounds both exhibit appreciable binding to 
plasma proteins.
The lack of an increase in the rate of protein synthesis, as assessed by the uptake of 
amino acids, may not be surprising in view of the relatively short duration of perfusion 
experiments and the fact that exogenous hormones were not administered together with 
spermidine.
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is supported by a grant from the Agricultural Research Council.
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The Urinary Excretion and Metabolism of Dexamethasone in the Horse
MINOO C. DUMASIA, MARIAN W. HORNER, EDWARD HOUGHTON 
and MICHAEL S. MOSS
Racecourse Security Services' Laboratories, Newmarket, Suffolk CB8 IDT, U.K.
and JAGADISH CHAKRABORTY and VINCENT MARKS
Department o f Biochemistry, University o f Surrey, Guildford GUI 5XH, Surrey, U.K.
The excretion and metabolism of radioactively labelled dexamethasone (9a-fluoro- 
ll/?,17a,21-trihydroxy-16a-methylpregna-l,4-diene-3,20-dione) have been studied by 
several investigators. Haque et al. (1972) reported three unconjugated polar metabolites 
in urine after dexamethasone administration in man, but did not report their identity. 
Rice et al. (1974) found dexamethasone in rat urine, together with a polar metabolite 
thought to be 6-hydroxydexamethasone. The presence of the l,4-dien-3-one and 9a- 
fluoro groups inhibits enzymic reduction of ring A (Glenn et al., 1957; Florini et al., 
1961), resulting in an increased excretion of unchanged drug and the absence of 
metabolites in which ring A is reduced.
In this work, [l,2-(n)-3H]dexamethasone was administered intravenously to three 
crossbred horses and intramuscularly to two, at doses ranging from 40 to 85/fg/kg. The 
body weights ranged from 234 to 345 kg. Urine samples were collected, whenever voided, 
for up to 96h after administration and a sample of each specimen was taken for the deter­
mination of total radioactivity. Fig. 1 shows the urinary excretion of radioactivity for all
1
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Fig. 1. Urinary excretion o f radioactivity after the administration of[3H]dexamethasone
Details are given in the text. ▼, Intramuscular injection of drug; v, intravenous 
injection.
>>
.o
•3
2
o
a.o
Methanol
cflu
COoaoU
Volume of eluate
Fig. 2. Fractionation on Sephadex LH-20 o f the XAD-2 extract o f hydrolysed urine 
For further details see the text.
five experiments. The rate of excretion and the total excretion of radioactivity appear to 
be independent of the route of administration.
For identification of metabolites in the urine, samples of pooled urine from the first 
24h of collection after the two intramuscular administrations were hydrolysed with 
Helix pomatia digestive juices (mixed glucuronidase and sulphatase) and passed through 
XAD-2 resin (Shackleton et al., 1970). The resin retained all the radioactive material, 
which was then eluted with methanol, the methanol evaporated to dryness, and the 
residual material chromatographed on Sephadex LH-20 in dichloromethane/methanol 
(49:1, v/v). This resolved four major radioactive fractions; a fifth fraction was eluted
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by methanol (Fig. 2). Portions of the first four fractions were chromatographed on silica- 
gel plates in two solvent systems; (a) ethyl acetate/dichloromethane/ethanol 
(11:7:2, by vol.) and (b) chloroform/dichloromethane/ethanol (8:1:1, by vol.). 
Fraction 1 contained 16% of the urinary radioactivity and included material provision­
ally identified as 11-dehydrodexamethasone by comparison of its retention volume on 
Sephadex and its RF values in the two t.l.c. systems with authentic 11-dehydrodexa- 
methasone.
It was similarly concluded that fraction 2, which accounted for 17.5 % of the urinary 
radioactivity, contained dexamethasone. Additional evidence for this was obtained from 
the chromatography in system (b) of the products of the following microchemical re­
actions (Butler & Gray, 1970): (i) acetylation, (ii) reduction of the C-20 carboxyl group, 
(iii) oxidation of the 11 /?-hydroxyl group and (iv) oxidative removal of the C-17 side 
chain.
Fractions 3,4 and 5 contained respectively 12 %, 12 % and 25 % of the original urinary 
radioactivity.
The oxidation of the ll/?-hydroxyl group has been demonstrated in man (Gray et al., 
1956) and in the horse (Moss & Rylance, 1967) for prednisolone and in man for beta­
methasone (Butler & Gray, 1970), and our findings indicate a similar reaction for 
dexamethasone.
It is known that the various substituents on the synthetic corticosteroids decrease 
their rate of metabolism, and the major metabolic pathway appears to involve the rela­
tively slow reactions of 6/?-hydroxylation and reduction of the ketone group at C-20 
(Bush & Mahesh, 1959; Florini et al., 1961; Butler & Gray, 1970).
Our studies on the metabolism of dexamethasone in the horse also demonstrate a high 
proportion of polar metabolites in urine, suggesting similar metabolic pathways.
We thank Racecourse Security Services Ltd., and the Horserace Betting Levy Board for 
financial support of this work.
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Effects of Phenethylamine Derivatives on the Release of Biogenic 
Amines from Synaptosomes
MAURIZIO RAITERI,* ALBERTO BERTOLLINI,* RENATA DEL CARMINE* 
and GIULIO LEVIf
*Istituto de Farmacologia, Universita Cattolica, Via della Pineta Sacchetti 644,00168 
Roma, and \Laboratorio de Biologia Cellulare, CNR, Roma 00196, Italy
Previous studies have shown that when synaptosomes are superfused in conditions in 
which re-uptake of the released neurotransmitters is prevented, D-amphetamine stimu­
lated the release of dopamine (3,4-dihydroxyphenethylamine) and of 5-hydroxytrypt- 
amine from dopaminergic and serotoninergic nerve endings respectively; however, the 
drug did not affect the release of noradrenaline from noradrenergic terminals (Raiteri 
etal., 1975). Since D-amphetamine is a potent inhibitor of noradrenaline and dopamine
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synaptosomal uptake and a modest inhibitor of the uptake of 5-hydroxytryptamine 
(Horn, 1973; Wong et al., 1973), the structural requirements for the effects on uptake 
of biogenic amines appear to be different from those on release.
In the present investigation we analysed the effects of some derivatives of /?-phen- 
ethylamine on uptake and release of [3H]noradrenaline, [3H]dopamine and 5-hydroxy- 
[3H]tryptamine in rat brain synaptosomes.
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Fig. 1. Effect o f phenethylamines on biogenic-amine release from synaptosomes
Synaptosomes, prelabelled with 3H-labelled biogenic amines, were superfused as de­
scribed in the text. The arrow indicates the time of addition of the drug. The radioactivity 
of each 1 min fraction is expressed as a percentage of the total radioactivity recovered 
(filter plus total fractions). Each curve joins the mean results of two to three experiments 
run in triplicate. The drugs were tested simultaneously on the same synaptosomal 
preparation, by using 15 parallel superfusion chambers, (a) Hypothalamus, [3H]nor- 
adrenaline release; (b) corpus striatum, [3H]dopamine release; (c) corpus striatum,
5-hydroxy [3H]tryptamine release, o, Control; ■, D-amphetamine; • ,  /?-phenethylamine; 
□, p-tyramine; a , p-hydroxyamphetamine.
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SUMMARY
The metabolism of 19-nortestosterone has been studied in four 
horses, two cross-bred and two thoroughbred. Urinary excretion and 
plasma levels were monitored in each case. Neutral urinary 
metabolites were isolated and identified by combined gas 
chromatography-mass spectrometry (GC-MS). Based upon the 
metabolism studies a method to confirm the administration of 
19-nortestosterone or its esters to horses has been developed.
INTRODUCTION
Due to the increasing use of anabolic steroid therapy in the 
veterinary field a project was undertaken in this Laboratory about 
four years ago to devise methods to detect and confirm the ad­
ministration of these drugs to racehorses. A radioimmunoassay 
method has been developed which will detect a number of anabolic 
preparations12 J and metabolism studies have been carried out with a 
view to using GC-MS methods for confirmatory analysis. The present 
paper describes the metabolism of 19-nortestosterone in the horse; 
this is the parent steroid in a number of veterinary anabolic prepara­
tions.
MATERIALS AND METHODS
The dose (19-nortestosterone, 150mg + 19-nor(4-14C) testosterone, 
22pCi in arachis oil) was administered intramuscularly to the horses at 
single sites. Urine samples were collected whenever voided for up to 
72h. after administration. The total radioactivity in each sample was 
determined using scintillation counting. Blood samples were collected 
through an indwelling cannula in the left jugular vein. A sample was 
taken before administration and then at 30min. intervals for the first 
8h. after administration; a 24h. sample was also obtained.
Urine samples (100ml; 0-24h. pool) were enzymically hydrolyzed 
and the neutral extracts were isolated by solvent extraction. These ex­
tracts were purified by column chromatography on Kieselgel H using 
chloroform as eluant. Fractions containing resolved metabolites were 
combined and analyzed by GC-MS as the trimethylsilyl derivatives.
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GC-MS was carried out using a Finnigan 4000 series gas 
chromatograph-mass spectrometer linked to a Finnigan 6110 data 
system. A coiled glass column (1.8m. x 6.4mm o.d., 2mm i.d.) packed 
with 1.5% OV-1 on Gas Chrom Q  was used. The column was 
temperature programmed from 180° to 260° at 5°/min. and He was us­
ed as carrier gas.
RESULTS
Initially two administrations were made to a cross-bred horse. 
Urinary excretion of radioactivity was virtually complete within 36h; 
there were two major neutral urinary metabolites which were iden­
tified as 3P-hydroxyestran-17-one and estrane 3,17 cx  -diol4. The 
chromatographic fractions containing these two metabolites compris­
ed 12% and 28% respectively of the initial radioactivity in the urine. 
Metabolism in one of the thoroughbred animals proved more com­
plex and chromatography of the neutral extract yielded four radioac­
tive fractions comprising 1.6, 1.7, 6.3, and 9.8% of the initial activity 
in the urine. These fractions contained isomers of 3-hydroxyestran-17- 
one, estrane-3 ,17 -d io l, 3 ,16 -d ihydroxyestran -17 -one and
3,17-dihydroxyestran-16-one. Preliminary results on the metabolism 
of 19-nortestosterone in a second cross-bred horse and a second 
thoroughbred indicate that the metabolism in these two horses is iden­
tical to that in the cross-bred horse used in the original study4. The one 
thoroughbred thus appears to metabolize 19-nortestosterone dif­
ferently from the three other animals studied.
A method to confirm the administration of 19-nortestosterone or its 
esters to horses has been developed5. This original method has now 
been modified to accommodate the selected ion monitoring facilities 
offered by the Finnigan 4000 GC-MS.
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DISCUSSION
HENION: How do you see the metabolites?
HOUGHTON: We run a standard of androstane-3, 17-diol along side 
the urine extract and spray it with a molybdophosphoric acid reagent. 
The standard has the same Rf value as the diol metabolite. 
HENION: What is the color? How do the spots appear? 
HOUGHTON: They have a blue coloration.
HENION: What do you feel is your normal detectable limit? 
HOUGHTON: I couldn't say. We've not looked into that. We've got 
a situation in the UK where if you find anything, it's positive. We've 
never really looked into any quantitative limits.
HENION: If you put on an absolute amount of 25 ng of pure diol, do 
you think you can see that?
HOUGHTON: Yes. I think we would be able to detect that sort of 
level.
HENION: The nanograms of metabolite from a 10 hour urine, how 
much do you think you are getting per milliliter of that? 
HOUGHTON: I couldn't say.
HENION: The deuteration determinations are quite nice. I can share 
with you the frustration you must have had with the isomeration. Are 
you aware of, or have you ever tried, on column GC deuteration? 
HOUGHTON: No, we haven't.
HENION: With enolizable compounds, you can inject D20  with the 
sample.
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THE METABOLISM OF 1-DEHYDROTESTOSTERONE AND-
TESTOSTERONE IN THE HORSE
E.Houghton and M.C. Dumasia 
R.S.S.Laboratories, 
Soham House, Snailwell Road, 
Newmarket, Suffolk CB8 7DT, U.K. 
SUMMARY
[l,2(n)-3H] -1-Dehydrotestosterone and [4-I4C] testosterone have 
been administered to cross-bred horses and urinary excretion and 
plasma levels of radioactivity monitored. Urinary conjugates were 
subjected to enzyme hydrolysis, solvolysis and hot acid hydrolysis 
and the metabolites liberated were isolated by solvent extraction. 
After purification by column chromatography, metabolites were iden­
tified,by combined gas chromatography-mass spectrometry (GC-MS).
INTRODUCTION
The radioimmunoassay method developed in this Laboratory2 to 
detect the administration of anabolic steroids to horses utilizes 
antibodies generated to 19-nortestosterone-BSA conjugates3.
1-Dehydrotestosterone and testosterone show cross-reactivity to this 
antibody of 26.3 % and 23 % respectively and the urinary excretion 
products of both these steroids and their esters can be detected by the 
routine radioimmunoassay procedure. In view of this metabolism 
studies have been carried out in an attempt to develop a GC-MS 
method to confirm the administration of these steroids or their esters 
to horses.
MATERIALS AND METHODS.
The doses (1 -dehydrotestosterone, 150m g +  [l,2(n)-3H j 
-1-dehydrotestosterone) and (testosterone, 150m g +  [4-14C] 
testosterone) in arachis oil were administered intramuscularly at single 
sites to cross-bred horses. Urinary excretion and plasma levels of 
radioactivity were monitored.
Urine samples (50ml, pH 5.0) were enzyme'hydrolysed by incuba­
tion with Helix pomatia digestive juices and the hydrolysed 
metabolites extracted with ethyl acetate. The residual urine was pass­
ed down an XAD-2 column and the organic material eluted from the 
column with methanol. After removal of the methanol the residual 
material was solvolysed using ethyl acetate acidified with 2M FLSCh. 
For acid hydrolysis, conc. HC1 (7.5ml) was added to the urine (50ml) 
and the solution boiled under reflux. Hydrolysed metabolites were
> again isolated by solvent extraction. Neutral extracts were 
chromatographed on Kieselgel H and resolved metabolites were 
derivatised and analysed by GC-MS.
GC-MS was carried out using a Finnigan 4000 series gas 
chromatograph—mass spectrometer linked to a Finnigan 6110 data 
system.
RESULTS
Two administrations of 1-dehydrotestosterone were made and in 
both cases urinary excretion of radioactivity was virtually complete in 
90 h. 17cx-l-Dehydrotestosterone, 17p-l-dehydrotestosterone and 
J7*hydroxyandrost-l-ene-.3-one were identified in the enzyme- 
hydrolysed extract. 17p-l-Dehydrotestosterone was the major 
metabolite present in the solvolysed extract.
Two administrations of [4-I4C] testosterone were made to crossbred 
horses and traces of radioactivity could still be detected in the urine 
for 200h*. 5cx-Androstane-3p,17o<-diol was identified as the major 
metabolite in the enzyme-hydrolysed fraction. Testosterone, 
5 cx-androstane-3p,17P-diol and 3p*hydroxy-5 cx -androstan-17-one 
were identified in the acid-hydrolysable fraction1. None of these 
metabolites could be detected in pre-administration urines from the 
two animals studied.
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METABOLISM OF DEXAMETHASONE IN THE HORSE
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SUMMARY
In veterinary practice synthetic corticosteroids are used in the treat­
ment of a variety of disorders, and using radioimmunoassay it is now 
possible to measure circulating levels and 'clearance times' of these ex­
ogenous steroids in the body fluids. However, as their metabolic fate 
in the horse is not known, we have investigated the excretion and 
metabolism of dexamethasone as being a representative example in 
common use. Crossbred geldings were used in all experiments. Timed 
sequential blood and urine samples were collected and levels of 
radioactivity were monitored by liquid scintillation spectrometry.
(l,2-(n)-3H) Dexamethasone plus 25 mg of unlabeled drug were in­
jected intramuscularly to two animals. Radioactivity in plasma was 
detected within 15 min after administration reaching a peak at approx­
imately 2h. Between 40%-50% of the administered radioactivity was 
excreted in urine in the first 24h. Aliquots of the 24h pool were used 
for the isolation and identification of metabolites.
Approximately 31% of the administered radioactivity was present 
in the unconjugated ethyl acetate extract and a further 10 % could be 
extracted from the urine after enzyme hydrolysis with about 5 % still 
remaining in the residual urine. For identification of the metabolites 
aliquots of the pool were first hydrolysed with Helix pofnatia 
digestive juices and the urine passed through XAD-2 resin. The resin 
retained all the radioactive material which was then eluted with 
methanol, the methanol was evaporated to dryness and the residual 
material chromatographed on Sephadex LH-20 columns, (CH2C12;CH 
OH, 98:2) and further purified by TLC. Using these techniques at least 
six radioactive compounds were found to be present in the 24h urine 
pool. Metabolites were identified by carrying out selective 
microchemical transformations on the isolated fractions. An aliquot of 
each fraction was acetylated, oxidised with both chromic acid and 
sodium bismuthate and reduced with sodium borohydride and the 
products of these were analysed by TLC. Reference compounds were 
synthesized from dexamethasone and their identity confirmed by 
mass spectrometry. The major metabolic transformations appeared to 
involve formation of polar unconjugated metabolites. The conjugated
fraction contained 9 cx  -fluoro-1 ip-hydroxy-androst-l,4-diene-3, 
17-dione,ll-dehydrodexamethasone and dexamethasone.
In order to obtain mass spectrometric identification of the urinary 
metabolites a second study was carried out. (l,2-(n)-3H) Dex­
amethasone plus 250 mg of the unlabeled drug was injected in­
tramuscularly to three ponies, and 65 %, 9.5 % and 13 %, respectively, 
of the administered radioactivity was excreted in the urine in 24h. For 
the three experiments 7,2 and 2.5% of the administered radioactivity 
was present in the unconjugated ethyl acetate fraction. For the animals 
where 65 % of the dose was excreted in 24h dexamethasone was iden­
tified in this fraction by C.I. mass spectrometry after initial purifica­
tion by HPLC. For the same animal, after removal of the unconjugated 
metabolites a further 40 % of administered radioactivity was extracted 
with ethyl acetate (2 x 2  vols) following enzyme hydrolysis. This 
material proved extremely polar and was not eluted from Sephadex 
LH-20 using dichloromethane methanol.
INTRODUCTION
Dexam ethasone (9 o< -fluoro-16o< -methyl-11 p,17oc ,21-tri- 
hydroxypregna-l,4-diene-3,20-dione) is one of several potent syn­
thetic glucocorticoids available to the equine practitioner. Levels of 
dexamethasone and/or its metabolites in biological fluids have been 
measured by radioimmunoassay 4 6. The excretion and metabolism of 
radiolabeled dexamethasone has been studied by several in­
vestigators3 s. This paper describes the metabolism of (l,2-(n)-3H) dex­
amethasone in crossbred gelded ponies at two dose levels. Preliminary 
report on part of this work has been published2.
In the first study, two ponies were injected intramuscularly with a 
mixture of radioactive and non-radioactive dexamethasone (250 jiCi 
± 2 5 mg) dissolved in sterile pyrogen-free saline-ethanol solution 
(9:1,v/v; 10ml). Urine samples were collected up to 96h. after ad­
ministration and aliquots from each sample were taken for determina­
tion of total radioactivity. Samples of pooled urine from the first 24 h 
of collection were used for isolation and identification of metabolites. 
Samples (100ml) were hydrolysed with 'Helix pomatia' digestive 
juices and passed through XAD-2 resin. The radioactivity was eluted 
from the resin with methanol, the methanol taken down to dryness 
and the residual material chromatographed on Sephadex LH-20 in 
dichloromethane-methanol (98:2, v/v).
Between 40%-50% of the administered radioactivity was excreted 
in the urine during the first 24h. About 31 % of the dose was present 
in the unconjugated steroid fraction, a further 10% was associated 
with the conjugate fraction and about 5% remained in the residual 
urine. Four major fractions comprising 16%, 17.5%, 12% and 12% 
of the urinary activity were resolved by Sephadex LH-20 column 
chromatography; a fifth fraction containing 25 % of the urinary activi­
ty was eluted with methanol. Portions of the first four fractions were
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'further purified by thin-layer chromatography (t.l.c.) and the radio­
active metabolites identified by microchemical reactions and analysis 
of the reaction products by t.l.c.2. Reference compounds synthesized 
from dexamethasone were similarly treated.
The following metabolites were identified: 9 cx  -fluoro-16o<- 
menthyl-11 p-hydroxyandrost-l,4-diene-3/17-dione, 9c-fluoro-16cx - 
methyl-6,11 P-dihydroxyandrost-l,4-diene-3,17-dione,ll-dehydro- 
dexamethasone, 20-dihydrodexamethasone, dexamethasone and 
6-hydroxydexamethasone.
In the second study three ponies were injected intramuscularly with 
a mixture of radioactive and non-radioactive dexamethasone 250|iCi 
±  250mg) emulsified in- sterile pyrogen-free saline containing 
Tween-80 (0.5%, v/v; 10ml).
In the first 24h, 65%, 9.5% and 13% of the administered radioac­
tivity was excreted in the urine. Before enzyme hydrolysis about 7 %, 
2 % and 2.5 % respectively of the administered radioactivity was ex­
tracted from the 0-24h urine samples at pH 8.6 using ethyl acetate. 
However after acidification of the samples to pH 4.0 with HC1, 46%, 
6% and 8.5 % respectively of the administered radioactivity could be 
extracted from the urines with ethyl acetate.
In the urine where 65% of the dose was excreted in 24h, dex­
amethasone was identified by CI-NS after isolation by Sephadex 
LH-20 and purification by HPLC. The polar material representing 
about 40% of the dose was eluted from the Sephadex LH-20 column 
and methylated with diazomethane. The methylated- extract was 
purified by silica column chromatography and three radioactive 
metabolites representing 2.8%, 13.6% and 18.5% of the ad­
ministered dose were isolated. Absolute identification of the struc­
tures of these acid metabolites could not be obtained by mass- 
spectrometry.
Results of the present study indicate that at therapeutic dose level 
(25mg), intramuscularly administered dexamethasone undergoes 
several metabolic transformations which lead mainly to metabolites 
more polar than the parent drug. Six radioactive constituents were 
detected in the 0-24h urine pool and accounted for 57.5% of the 
urinary radioactivity. Similar metabolic transformations have been 
reported for metabolism of betamethasone in man1.
Results from the high dose study indicate that absorption kinetics 
are affected by mode of administration. The low urinary excretion of 
radioactivity after administration of emulsified drug suggests slower 
absorption from the site of injection. The experiment where 65 % of 
the dose was excreted in 24h indicates that during administration at 
least some of the drug was inadvertently injected into a vein. The ma­
jor metabolic transformations in this experiment involved formation 
of C-21 acid metabolites, thus suggesting that an alternate metabolic 
pathway was used.
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DISCUSSION
MCDONALD: You were saying in the hall that you have generated 
RIA metabolites from flumethasone and dexamethasone.
DUMASIA: Not RIA metabolites, rather RIA antibodies. When we 
were developing the radiommunoassay methods, we did generate 
other antibodies; however, we have never used them. 
MCDONALD: Would you be willing to allow us to purchase some of 
your antibodies?
DUMASIA: I can't tell you anything about that. You will have to 
have a talk with the director of our laboratories - Mr. Moss. 
MCDONALD: You indicated that you identified the metabolites by 
micro-crystal tests?
DUMASIA: Microchemical reactions, yes. These microchemical reac­
tions are acetylation of the primary hydroxyl group at C-21, sodium 
bismuthate oxidation of the C-17 side chain to form 17-oxo steroids, 
reduction of the 20-oxo group to form 20-dihydro compounds, and 
chromic acid oxidation of the secondary lip-hydroxyl group to form
11-oxo compounds. When you convert any of these functional groups 
on the original molecule and then run the product on TLC, its RF 
value will alter. Identification was based on taking authentic stan­
dards, which we synthesized in our own laboratory, and the unknown 
extracts, which were eluted from the LH-20 column, through the 
above procedures and running the products on TLC.
MCDONALD: Is dexamethasone a problem in England? Are they 
using it illegally?
DUMASIA: We get all sorts of stories about it being used, but we 
have never been able to prove it by radioimmunoassay. The 
metabolism is so complex and the excretion is so rapid, that if it is ad­
ministered about 3 hours before collection of the urine sample, you 
might be able to detect it. On the other hand, if it is given 24 hours 
before collection of the urine sample, I'm afraid you would not be able 
to detect it.
MCDONALD: Have you reported a medication violation on dex­
amethasone as of yet, even with all your work you've done with your 
microchemical reactions and with your RIA?
DUMASIA: No. W e won't be able to do that unless we have absolute 
identification of the drug. That means using GC/MS. W e have yet to 
develop the techniques using GC/MS. W e are thinking of using a 
metabolite of dexamethasone as an analyst for GC/MS methods, and 
we probably might go for some of the acid metabolites. I don't know. 
This work was done about six weeks ago. We have just discovered 
these acid metabolites.
HENION: You have used the 14 C and tritium radioactive tracer 
technique quite productively. Have you considered, or do you plan to 
use, since you have the available hardware, the technique of stable 
isotope dilution which has some advantages?
DUMASIA: We have considered that. The use of stable isotopes in 
metabolism studies involves the synthesis of the labeled compounds 
and we haven't yet gone over the problems involved in the synthesis 
of these compounds. These labeled compounds are not readily 
available commercially.
HENION: They are becoming more available. The A ring, which is 
known to stay intact through the mass spectrometer, will allow us to 
use this in the near future.
HOUGHTON: Could I make a comment with reference to the use of 
stable isotopes, particularly deuterated analogs. They could effect the 
metabolism quite drastically. In certain cases that have been reported 
in the UK, I think it was the phosphoramides, where the introduction 
of a deuterium atom completely altered the metabolism. I think the 13 
C analogs would be extremely expensive and probably this would 
deter their use.
MAYLIN: Will you state again the metabolites you did find? 
DUMASIA: Please show the last slide. This slide sums up the six 
urinary metabolites of dexamethasone identified in horse urine. Dex­
amethasone, 11-oxodexamethasone, 20-dihydrodexamethasone, 
17-oxodexamethasone, 6-hydroxydexamethasone and 6-hydroxy-17- 
oxodexamethasone. And finally we have the proposed structures of 
the acid metabolites.
LAMBERT: Would your method differentiate between 6 cx -and  
6p-hydroxycortisone metabolites?
DUMASIA: If we can analyse them by GC/MS using either 
trimethylsilyl or MO-TMS derivatives, we might be able to. It is the 
basic lability of the side chain which hinders the analysis of these 
steroids. There have been many attempts to stabilize the C-17 side 
chain by using cyclic bororiates, siliconides, acetonides, and' other 
derivatives. As yet no one has been able to produce a very stable 
structure. When you try to silylate these steroids, you get a multi­
plicity of products, even under standard conditions. Therefore, unless
we can get an absolute quantitative derivatization, we really cannot 
use this method.
LAMBERT: I was thinking more of the older methods where you us­
ed microchemical reactions on the hydroxyl group and then examined 
using thin layer chromatography.
DUMASIA: We can do a lot of work and find out systems in which 
the o< - and the 0- will migrate differently. It has been done with cor­
tisol; 6 -hydroxy and 6p-hydroxy-cortisol can be separated. I'm sure, if 
we can synthesize 6 o< - and 6p-hydroxycortisone, it can be done. It 
would be a lot of work and a lot of expense.
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1. T h e m etabolism  o f 19-nor[4-14C] testosterone in a thoroughbred horse has been  
studied and neutral urinary m etabolites obtained after enzym e hydrolysis have been 
investigated by g .l.c .-m ass spectrometry.
2. 3-H ydroxyestran-17-one, 17a- and 17/1-19-nortestosterone, estrane-3,17-diol (two 
isom ers), 3,16-dihydroxyestran-17-one (two isomers), 3,17-dihydroxyestran-16-one (two 
isomers) and estrane-3,16,17-triol were identified in the neutral urinary extracts.
Introduction
In a previous publication in this series, the metabolism of 19-nortestosterone in a 
cross-bred pony was reported (Houghton 1977). Two neutral urinary metabolites 
were isolated and, using g.l.c.-mass spectrometry, were identified as isomers of 3/1- 
hydroxyestran-17-one and estrane-3,17a-diol. T he metabolism of 19-nortesto- 
sterone has now been studied in a thoroughbred horse and some 16-oxygenated 
metabolites have been identified. Oxygenation at C-16 appears to be a major 
metabolic route in the horse used in this study.
M aterials and m ethods
Gas chromatography and combined gas chromatography-mass spectrometry
Analytical g.l.c. was carried out using a Perkin-Elmer F—17 gas chromatograph fitted with a coiled  
glass colum n (2 m x 6-4m m  o .d ., 2 m m  i.d.) packed with 1-5% O V -1 on Gas Chrom Q. N 2 was used as 
carrier gas and the colum n was temperature programmed from 180 to 260°C at 2°/min.
Com bined g.l.c .-m ass spectrometry was carried out using a Finnigan 4000 series gas chrom atograph- 
mass spectrom eter linked to a Finnigan 6110 data system. A coiled glass colum n (1-8 m  X 6-4m m  o.d ., 
2 m m  i.d.) packed with 1‘5% OV—1 on Gas Chrom Q was used. T h e  colum n was temperature 
programmed from 180 to 260°C at 5°/niin and H e was used as carrier gas.
Solvents and chemicals
Ethyl acetate and 1,2-dichloroethane were redistilled before use. 19-Nortestosterone, deutero- 
m ethanol (C H 3O D ) and deuterium oxide w ere obtained from Sigma London Chemical Com pany, U K . 
19-N or[4-14C]testosterone was obtained from CEA, France (sp. activity, 4 0 -50  Ci/m ol).
Samples o f 3/?,17/?-dihydroxy-5a-androstan-16-one and 3/?,16a-dihydroxy-5/?-androstan-17-one 
were gifts from Professor D r G . Spiteller, U niversity o f Bayreuth, FR Germany.
Adm inistration to animals
19-N ortestosterone was recrystallized from m ethanol-water before use and the purity o f 19-nor[4- 
14C]testosterone was checked using t.l.c. as described previously (H oughton 1977).
T w o intramuscular administrations were made to a thoroughbred horse (body weight 430 kg) at single  
sites in the neck, w ith a period o f eight m onths between the two injections. T h e  preparation of the dose 
(19-nortestosterone, 150 mg; 19-nor[4-14C]testosterone, 22/iC i), the collection of urine and plasma 
samples and the m onitoring of radioactivity in these samples were carried out as reported before 
(H oughton 1977).
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Enzym e hydrolysis o f urinary conjugates and extraction of neutral metabolites '
T h e m ethods used for the determination o f the percentage of conjugated metabolites, the enzym e 
hydrolysis o f conjugates in urine and the extraction o f neutral urinary metabolites were identical to those 
described previously (H oughton 1977). Enzyme hydrolysis was carried out by incubation of the urine 
with H elix pom atia  digestive juices and hydrolysed m etabolites were isolated by solvent extraction using  
ethyl acetate (2 x 2 vols., l x l  vol.). T h e  com bined ethyl acetate extracts were washed w ith 0-1 M N aO H .
Chromatography o f neutral urinary metabolites
T h e neutral extracts from urine (0 -24  h pool, 100 m l) were chromatographed on K ieselgel H  (25 g; 
colum n diam. 30 m m) using chloroform as eluant; 5 m l fractions were collected. Neutral extracts from  
urine (50 ml) were chromatographed on K ieselgel H  (5g; colum n diam. 15 m m) using 1,2- 
dichloroethane—ethanol (98 :2, v/v) as eluant; 3 m l fractions were collected and after elution of 90 m l the 
concentration of the ethanol was increased to 5%. In each case an aliquot (0-1 ml) o f each fraction was 
taken for scintillation counting and resolved radioactive fractions were com bined and the solvent 
removed.
D erivatization  of fractions isolated by column chromatography
T o  prepare trim ethylsilyl (T M S) derivatives, aliquots o f the fractions from chromatography were 
dissolved in iV ,0-bis-(trim ethylsilyl)acetam ide (BSA; 0-1 ml) and trimethylchlorosilane (TM C S; 
0-025 m l), and the reaction was allowed to proceed at 60°C for 2 h . T h e silylating reagents were then 
removed in a stream of N 2 at 40°C and the residue dissolved in hexane (0-1 ml).
For the preparation of m ethoxim e-trim ethylsilyl derivatives (M O -T M S ) aliquots o f the isolated 
fractions were dissolved in.an 8% w /v soln o f m ethoxylam ine HC1 in pyridine (0-1 ml) and the reaction 
allowed to proceed at room tem p, overnight. T h e  pyridine was removed at 40°C in a stream o f N 2 and the 
residual material silylated as described above. T M S  and M O -T M S  derivatives o f reference steroids were 
also prepared by these procedures. T h e  derivatized fractions, from colum n chromatography, and 
reference steroids were analysed by g.l.c. and g .l.c .-m ass spectrometry.
Deuteration of fractions isolated by column chromatography
A n aliquot (equiv. to 15 m l urine) o f the fraction isolated from colum n chromatography was dissolved  
in deuteromethanol (0-5 ml) and N aO D  (0-5 m l, prepared by addition of N a to D 20 )  was added. T h e  soln  
was allowed to stand at room temp, for 2 h, then diluted with D 20  (1 ml) and the deuterated products 
isolated by solvent extraction (redistilled chloroform, 3 x 2 ml). T h e com bined chloroform extracts were 
dried (anhydrous N a2S 0 4), the solvent removed and the residual material silylated and analysed by g.l.c. 
and g .l.c .-m ass spectrometry.
3/),17/J-Dihydroxy-5a-androstan-16-one (1 0 pg) and 3/l,16a-dihydroxy-5/)-androstan-17-one (20 gg) 
were deuterated as described above; the deuterated products were derivatized and analysed by g .l.c .-m ass  
spectrometry.
A lk a li treatment o f fractions isolated by column chromatography
A n aliquot (equiv. to 15 m l urine) o f the fraction isolated by chromatography was dissolved in 
m ethanol (0-5 m l) and treated with alkali (N a +  H 20 )  under the conditions used for deuteration. T he  
products were isolated by solvent extraction and were analysed, after silylation, by g .l.c.-m ass  
spectrometry.
R esults
Urinary excretion and plasma levels of radioactivity
T he rates of urinary excretion of radioactivity following the two administrations 
of 19-nor[14C]testosterone were very similar, but there was a difference in the total 
radioactivity excreted (75% and 87%).. In each case the urinary excretion of 
radioactivity was virtually completed within 36 h. Plasma levels of radioactivity were 
low, the maximum level being obtained after about 2 h.
Hydrolysis o f urinary conjugates and extraction of neutral metabolites
Extraction of urine samples before hydrojysis showed that >  90% of the 14C- 
metabolites was either conjugated or not extractable into ethyl acetate. After enzyme 
hydrolysis of urinary conjugates, 58% of the 14C was extracted with ethyl acetate, 
and after washing with NaOH (0-1 m ) 48% remained in the neutral extract.
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* Figure 1. Separation by colum n chromatography of neutral urinary extracts.
(a) Extract o f urine (100m l); K ieselgel H  (25 g); eluant, CHC13. (6) Extract o f urine (50m l)  
Kieselgel H  (5 g); eluant, C H 2C l2 :EtO H  (90m l 9 8 :2 , v /v , follow ed by 90m l 9 5 :5 , v/v).
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Chromatography of neutral urinary metabolites
Column chromatography on Kieselgel H  (25 g) of the neutral extracts from 
enzyme-hydrolysed urine (100 ml) resolved four radioactive components (figure 
1 (a)). These fractions, a l-a4 , accounted for 1-6%, 1-7%, 6-3% and 9-8% respect­
ively of the initial urinary radioactivity. Of the activity put on the column, 40% was 
eluted with chloroform (400 ml); the remaining activity was eluted with methanol.
Chromatography of the neutral extracts from enzyme-hydrolysed urine (50 ml) 
using Kieselgel H (5 g) and 1,2-dichloroethane-ethanol (90 ml, 98 : 2, v/v followed 
by 90m l, 95 :5 , v/v) as eluant showed six radioactive components (figure 1 (b)). 
These fractions (b l-b6) accounted for 3-9%, 9-6%, 2-9%, 7-5%, 4-5% and 9-3% of 
the initial activity in the urine. In this case, of the activity put on the column 69% was 
eluted with 180 ml of the eluant.
Comparative chromatographic data were obtained for the neutral extracts of 
urines from both administrations.
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Identification of metabolites by g.l.c.-mass spectrometry
Fraction a l was analysed both as the T M S and M O -T M S derivatives, and an 
isomer of 3-hydroxyestran-17-one (II) (Houghton 1977) was shown to be present.
Fraction a2 was initially analysed as the M O -T M S derivative, using selected ion 
monitoring for ions m/e 375, 344, 254 and 129. These are characteristic ions in the 
mass spectrum of 19-nortestosterone M O -TM S. T he selected ion chromatogram is 
shown in figure 2. Co-injection of the derivatized fraction with 19-nortestosterone 
M O -T M S enhanced the series of peaks of longer retention time (i?j9-5min). To 
confirm the results obtained by selected ion monitoring, full mass spectra were also 
obtained.
Fraction a3 was analysed as the T M S derivative and was shown to contain an 
isomer of estrane-3,17-diol as the major component. T he mass spectra of isomers of 
estrane-3,17-diol bis-TM S shows significant peaks at m /e332 (M "f— 90) and 242 
(M 7 —(90 +  90)). Mass chromatograms for m/e 242 and 332 of this derivatized 
fraction indicated the presence of a trace amount of a second isomer of this diol.
Fraction a4 was rechromatographed on Kieselgel H  (5 g) using 1,2- 
dichloroethane-ethanol (98 : 2, v/v) as eluant. Two fractions were resolved a4(I) and 
a4(II) which were analysed by g.l.c.-mass spectrometry as the T M S and M O -TM S 
derivatives. T he less polar of the fractions (fraction a4(I)) on analysis by g.l.c.-mass 
spectrometry as the T M S derivative (figure 3 (a)) showed a major- component (R t 
11 ’8 min) and two minor components (R t 10-85 and 11-35 min). T he mass spectra of 
the components having retention times of 10-85 and 11-8 were identical; the mass 
spectrum is shown in figure 4 (a). T he mass spectrum of the component with 
retention time of 11-35 min is shown in figure 4(6). T he more polar of the two 
fractions (fraction a4(II)) on analysis by g.l.c.-mass spectrometry as its TM S 
derivatives (figure 3 (6)) showed a major component (R t 10-3 min) and three m inor 
components (Rt 10-85, 11-35 and ll-8m in). T he mass spectrum of the major 
component was identical to that shown in figure 4(6).
375
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Figure 2. Selected ion m onitoring to detect the presence o f 17a- and 17)S-19-nortestosterone in fraction
a2 (figure 1 (a)).
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Figure 3. Reconstructed gas chromatograms of the T M S  derivatives o f (a ) fraction a4(I), ([b) fraction 
a4(II) and (c) fraction a4(II) after treatment with alkali.
Fractions a4(I) and a4(II) were also analysed by g.l.c.-mass spectrometry as 
their M O -T M S derivatives. T he mass spectra of the four components present in 
these fractions showed in some cases weak molecular ions at m/e 465 with, in all cases, 
low intensity peaks at ?w/e450 (M* — 15) and m /e434 (M+ —31). T he ion m /e419 
(M+ —15-31) also occurred in the spectra in some cases. O ther significant ions were 
at m /e344, 254, 201, 174, 158 and 133.
Fractions a4(I) and a4(II) were also deuterated and the deuterated products 
analysed by g.l.c.-mass spectrometry as the TM S derivatives. After deuteration and 
silylation, fraction a4(I) showed only two components, one major and one minor. 
T he mass spectra of these two components showed weak molecular ions at m/e 439, a 
shift of 3 a.m.u. when compared to the spectrum shown in figure 4(a), indicating 
uptake of three deuterium atoms. There were corresponding shifts in the m/e values, 
of some of the fragment ions. Analysis by g.l.c.-mass spectrometry of the silylated, 
deuterated product from fraction a4(II) also gave two components w ith g.l.c. 
retention times identical to those isolated from fraction a4(I). T he mass spectra were- 
identical to the mass spectrum of the major deuterated component isolated from 
fraction a4(I).
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Figure 4. M ass spectra o f the T M S  derivatives of («) the major com ponent in fraction a4(I) and (b) the
major com ponent in fraction a4(II).
Fraction a4(I) had R t 11-8 min (figure 3 («)); fraction a4(II) had R t 10-3 m in (figure 3(b)).
3/?,17/i-Dihydroxy-5a-androstan-16-one and 3/?,16a-dihydroxy-5j6-androstan- 
|17-one were deuterated and the deuterated products analysed, as their TM S 
derivatives by g.l.c.-mass spectrometry. T he products from both compounds gave 
the same mass spectrum with a weak molecular ion at m/e 45 3 again indicating uptake 
of three deuterium atoms.
After alkali treatm ent of fraction a4(II) and derivatization, analysis by g.l.c.- 
mass spectrometry showed a significant decrease in the concentrations of the 
components with retention times of 10-3 and 11-35 min and a corresponding increase 
in the concentration of those with retention times of 10-85 and 11-8 min (figure 3 (c)). 
After alkali treatm ent of fraction a4(I) there was a significant decrease in the 
concentration of the component with retention time of 11-35 min.
Analysis of fractions b l—b6 by g.l.c.-mass spectrometry
Fraction b l contained an isomer of 3-hydroxyandrostan-17-one and the two 
isomers of 19-nortestosterone; estrane-3,17-diol was shown to be present in fraction 
b2. Fractions b2, b3 and b4 as their T M S derivatives contained, between them, two 
isomers with mass spectra identical to that shown in figure 4(a) and two with mass 
spectra identical to that in figure 4(6). Fraction b6, again as the T M S  derivative, 
showed a major component the mass spectrum of which had a molecular ion at 
m/e 510 and significant fragment ions at m/e 420, 330, 191 and 147. The molecular 
weight and fragmentation pattern indicated that this metabolite was an isomer of
3,16,17-estranetriol. T he fragmentation pattern was very similar to that of cor­
responding compounds in the androstane series (Grote and Spiteller 1977).
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D iscussion
After administration of 19-nor[4-14C]testosterone to a thoroughbred horse, the 
rate of excretion of urinary 14C was similar to that previously reported in a crossbred 
pony (Houghton 1977); the metabolism however, appeared to be significantly more 
complex. T he thoroughbred and the crossbred pony are different breeds within the 
species Equus caballus. For the pony, chromatography of the neutral extract isolated 
from enzyme-hydrolysed urine resolved only two radioactive components, account­
ing for 12% and 28% of the initial activity in the urine. In the thoroughbred animal 
four radioactive components were resolved using the same eluant (figure 1 (a)). T he 
fractions a l—a4 accounted for T 6 ,L 7, 6-3 and 9-8% respectively of the initial activity 
in the urine (equiv. to 1:0, T l, 4-1 and 6-4% dose). As in the case of the pony, more 
than 90% of the metabolites was either conjugated or not extractable in ethyl acetate. 
Using g.l.c.-mass spectrometry, the metabolites identified in the pony urine, 
isomers of 3-hydroxyestran-17-one (II) and estrane-3,17-diol (III), have also been 
identified in the present study.
In addition to these two metabolites, 17a- and 17j8-19-nortestosterone have been 
detected (fraction a2) using selected ion monitoring (figure 2). Co-injection of the 
derivatized fraction (M O -TM S) with 17/?-19-nortestosterone M O -T M S revealed 
that 17a-19-nortestosterone was the predominant isomer.
Four structural isomers (mol. wt. 436 as T M S derivatives; 465 as M O -T M S 
derivatives) have also been identified (fraction a4). These isomers were partially 
resolved by rechromatography of fraction a4 and on analysis by g.l.c.-mass 
spectrometry as the T M S derivatives, two had the mass spectrum shown in figure 
4 (a) and the other two that shown in figure 4(6). T he molecular weights indicated 
that these metabolites were isomers of dihydroxy mono-keto estranes. T he presence 
of the mono-keto function was confirmed by their analysis as M O -T M S derivatives.
Comparison of the mass spectra of their T M S derivatives (figure 4(a) and (6)) 
with literature spectra for the corresponding compounds in the androstane series 
(Gustafsson and Lisboa 1970) indicated that two of the metabolites in fraction a4 
were isomers of 3,17-dihydroxyestran-16-one (IV; mass spectrum, figure 4 (a)) and 
the other two were isomers of 3,16-dihydroxyestran-17-one (V; mass spectrum, 
figure 4(6)). In order to confirm these structures the two fractions isolated by 
rechromatography of fraction a4 were deuterated under alkaline conditions. U nder 
these conditions protons on carbon atoms adjacent to carbonyl groups can be 
exchanged. T hus in the case of the 16-keto compound (IV) three deuterium  atoms 
should be incorporated into the molecule (2 at C -15 and 1 at C-17) and in the case of 
th*e 17-keto compound only one (at C-16). Analysis of the deuterated products by 
g.l.c.-mass spectrometry as the T M S derivatives showed that three deuterium  
atoms were incorporated into each of the four metabolites. This confirmed that two 
of the metabolites were isomers of 3,17-dihydroxyestran-16-one (IV) but indicated 
that the other two were not isomers of the 17-keto compound (V). However, as the 
mass spectra of all the deuterated products were virtually identical, this suggested 
the possibility that isomerization had occurred under the conditions used. T he 
confirmation that isomerization had occurred was obtained by deuteration of 
3j8,17/?-dihydroxy-5a-androstan-16-one and 3/?,16a-dihydroxy-5/?-androstan-17- 
one under the same alkaline conditions. In each case a trideuterated product was 
formed and the mass spectrum of the deuterated product of 3/l,16a-dihydroxy-5/?- 
androstan-17-one was identical that formed from .the 16-keto compound. Alkali 
treatm ent of the two fractions isolated by rechromatography of fraction a4 and
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analysis of the products by g.l.c.-mass spectrometry as the TM S derivatives also 
indicated a conversion of the two isomers of 3,16-dihydroxyestran-17-one (R t 10-3 
and 11*35 min) to the 16-keto isomers (R t 10*85 and 11*8min; figure 3(6) and (c)).
been reported previously (Johnson, Gastambide and Pappo 1957, Fishman 1960, 
N am baraand Fishman 1962). T he fact that 3/?,16a-dihydroxy-5/i-androstan-17-one 
in ethyl acetate was stable to alkaline washing (0*1 M  NaOH) indicated that the two 
isomers of 3,17-dihydroxyestran-16-one did not arise by isomerization during the 
isolation procedure.
A variation in the elution volume of the metabolites was noticed when different 
batches of chloroform were used as eluant for column chromatography and this 
variation was attributed to varying amounts of ethanol added to the chloroform as 
stabilizer (the chloroform was not distilled before use). T o standardize the elution 
conditions, the neutral urinary extracts were chromatographed on Kieselgel H using 
1,2-dichloroethane—ethanol as eluant; although this resulted in a decrease in 
resolution, metabolites I—IV could still be identified in fractions b l—b4 (figure 1 (6)) 
using g.l.c.-mass spectrometry. W ith this eluant there was no inter-column variation 
in elution volume and an additional metabolite was eluted from the column (fraction
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Figure_6. Histogram s from the colum n chromatography of enzym e-hydrolysed 0 -2 4  h urine extracts 
showing the elution o f 14C metabolites and the % o f urinary 14C in each fraction follow ing  
administration of 19-nor[4-14C]testosterone to four horses.
Column diam. "30 mm; Kieselgel H  25 g; eluant, 1,2-dichloroethane-ethanol (96 :4 , v/v).
N eutral extracts o f urine (100 ml) from
(a) the thoroughbred horse used in the present study;
(b) a second thoroughbred horse;
(c) a cross-bred horse (H oughton 1977);
(d) a second cross-bred horse.
b6; figure 1 (b)) which was identified as an isomer of 3,16,17-estranetriol (VI) using 
g.l.c.-mass spectrometry. T he radioactive component in fraction b5 has not as yet 
been identified.
T he structures of the urinary metabolites of 19-nortestosterone identified in this 
study are given in figure 5. T he metabolism is considerably more complex than that 
reported previously, the emphasis in this animal being towards metabolites of 19- 
nortestosterone oxygenated at C-16. 16-Oxygenated metabolites of testosterone 
have been isolated from human urine (Janne and Vihko 1969), by incubation of 
testosterone with rat liver homogenates in vitro (Gustafsson and Lisboa 1970), and 
from horse urine after administration of testosterone (M. C. Dumasia and E. 
Houghton, unpublished).
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In view of the difference in the metabolism of 19-nortestosterone in the two 
horses studied, a re-investigation of the metabolism in the horse used previously 
(Houghton 1977) has been undertaken using more sensitive mass spectrometric 
techniques and the metabolism of this anabolic steroid has been studied in a second 
thoroughbred and a second cross-bred horse. Preliminary analysis of the data from 
the chromatography of neutral extracts for the four horses studied (figure 6 (a)-(d)) 
indicates that there is a greater tendency towards the formation of 16-oxygenated 
metabolites in the thoroughbred horse used in the study described in this paper. Also 
for this particular horse the amount of estrane-3,17-diol isolated from the urine, 
following enzyme hydrolysis and solvent extraction, was significantly less than that 
isolated from the other three horses (fractions 2; figure 6 (a)—(d)). T he percentages of 
the administered dose excreted in 24 h for the four horses were 78, 60, 77 and 67 
respectively.
A detailed analysis by g.l.c.-mass spectrometry of the urinary metabolites of 19- 
nortestosterone for the four horses is in progress and a comparison of the metabolism 
will be reported in due course.
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Book R eview s
Topics in Antibiotic Chemistry, Volum e 3. Mechanisms of Action of N alidixic A c id  and its Congeners: and  
N ew  f-L actam  Antibiotics. Edited by P. G. S a m m e s , (Ellis H orwood, 1980.) [Pp. 203.] Price £18 .50 .
T h i s , the third volum e of a continuing series on antibiotics, is directed to the synthetic urinary tract 
antiobiotics, nalidixic acid and its congeners, and to novel natural antibiotics containing the /Mactam  
function, a them e w hich is further developed in the next volum e. T he section on nalidixic acid and its 
congeners, oxolinic acid, pyrom idic acid, p ipem idic acid, etc., written by John Sm ith and his colleagues o f  
the School of Pharmacy, London, is concerned primarily w ith the bactericidal effects, as specific and 
reversible inhibitors o f bacterial D N A  synthesis, and the bacteriostatic effects, as inhibitors o f R N A  
synthesis, both of which seem  dependent on the role o f these acids as metal chelating agents. T h e section  
on /M actam antibiotics is written by R. D . G. Cooper o f L illy  Research Laboratories, Indianapolis, and 
primarily concerns three new families of /Mactam antibiotics, the clavulanic acid derivatives, the 
carbapenem derivatives, and the nocardicins. T h e biosyntheses, m echanism s of action, and structure— 
activity relationship o f the antibiotics o f these three series are critically reviewed and, in addition, the 
synthesis and structure-activity relationships o f the unnatural 1-oxacephalosporins are described. T h e  
text is w ell illustrated w ith structural formulae and the tabulation of biological and clinical data, all 
com bining to make a m ost valuable treatise in the continuing high tradition o f this series.
Topics in Antibiotic Chemistry, Volum e 4. The Chemistry and Antimicrobial A c tiv ity  o f N ew Synthetic  
f-L a c ta m  Antibiotics. Edited by P. G . Samm es (Chichester: Ellis H orwood, 1980.) [Pp. 241 +  37.] Price 
£25-00.
T h is  is the fourth volum e in this useful series, w hich has dealt w ith  the am inoglycosides, daunomycin, 
nalidixic acid and now, in the present volum e, w ith the /M actam antibiotics. T h is group of antibiotics, 
w hich includes the closely related penicillin  and cephalosporin families, is that in w idest clinical use, and 
consequently, that in highest production. T h e occasion is ripe for this review, as in the last decade great 
advances have been m ade in the total chemical synthesis o f these com pounds and this has occurred at the 
sam e tim e as the discovery o f many new types o f /Mactam structure.
In this volum e the m odern synthetic approaches to a w ide range o f /Mactam antibiotics, including the 
natural penicillins and cephalosporins, the unnatural penams and cepham s, the epi-penicillins and 
, -cephalosporins, and various C -substituted analogues, are described in the context o f their biological 
activities, highlighting desirable new biological features, including resistance to enzym ic deactivation, 
which is the major disadvantage o f the naturally occurring m embers o f this valuable group of antibiotics.
A lthough am ong the safest o f all antibiotics, the /Mactams still present difficulties concerning the 
efficacy on oral administration, and hypersensitivity reactions in clinical practice. W ith the aim of solving  
these problems research has recently been directed to the chem ical m odification of the natural /1-lactams, 
and to the preparation o f new /Mactam antibiotics by total synthesis, and the results o f this work of the last 
decade form the substance o f the present monograph.
T h e contributors to the present volum e are Frederic A. Jung, W illiam  R. Pilgrim , J. Philip  Poyser, 
and Patrice J. Siret, all o f I.C .I. Pharma S .A ., Reims, France, who have made substantial contributions to 
the synthesis of the numerous m odified penicillins and cephalosporins now used in m edicine or currently 
undergoing clinical trial. T h e contents o f the volum e are arranged to include the total synthesis o f the 
natural penicillins and cephalosporins, new system s obtained by sem i-synthetic m odifications, and 
modification of the natural penicillin and cephalosporin system s. T h e volum e is w ell illustrated,
: excellently produced and has a bibliography of over five, hundred references.
Progress in Drug M etabolism, Volum e 3. Edited by J. W . B r id g e s  and L . F. C h a s s e a u d . (Chichester, N ew  
York: John W iley, 1979.) [Pp. 340 and 332.]. Price £19-25.
T h is  is the latest volum e in a review series aimed at providing up-to-date critical accounts o f various 
aspects o f drug m etabolism  and xenobiochem istry, to keep the reader with interests in this field more 
easily informed on the many and diverse recent developm ents. Volum e 1 was devoted to m ass 
spectrometric m ethods, bioactivation, epoxides, clinical aspects o f enzym e induction, and drug 
interactions w ith serum proteins, and Volume 2 dealt w ith stable isotopes, ion-pair extraction, 
bioavailability, placental transfer, metabolism in cell culture, and glucuronidation. T h e major them es of  
V olum e 3 are physico-chem ical m ethodology and insecticide m etabolism . T h e application o f n.m .r. 
spectroscopy to drug m etabolism  (Ian Calder, U niversity o f M elbourne), and high-pressure liquid  
chromatography (D . A. Schooley and G. B. Quistad, Zoecon Corporation, Palo Alto) com prise the
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chapters on m ethodology. T h e latter, w ith its emphasis on applications to pesticide analysis, forms a link 
with the chapters on insect m etabolism  of xenobiotics (Gerry Brooks, A R C , U niversity o f Sussex) and 
mammalian m etabolism  o f pyrethroid insecticides (David H utson, Tunstall Laboratories, Shell, 
Sittingbourne) w hich com prise the section on insecticide m etabolism . T h e remaining chapters in this 
volum e are concerned w ith drug analysis in biological fluids (W. Reiss and colleagues, Ciba-G eigy, Basel) 
and w ith epoxide hydratase (Franz Oesch, U niversity o f M ainz). T h e chapter on high-pressure liquid  
chromatography and its application to pesticide analysis is the major work o f this volum e and is an 
excellent, lavishly documented work o f reference which should prove o f inestim able value to anyone 
working in the pesticide field. This, the latest volume in this review series, maintains the high standards of 
the preceding volum es and, m oreover, perhaps because o f the developm ent o f two major themes in place 
o f the pot-pourris o f earlier reviews, it would seem  to be o f that greater value and significance to the reader.
M ammalian M etabolism of P lant Xenobiotics. By R. R. S c h e l in e . (London: Academic Press, 1978.) 
[Pp. 502 +  11.] Price £28-00.
T in s  treatise on the animal m etabolism  of plant anutrient chem icals is a unique contribution to the 
literature o f xenobiotic m etabolism . Over the years a great number o f publications in this field have 
appeared, scattered throughout a diverse range o f scientific works and journals, and the present volume 
has been com piled to collect this fragmented information to provide a com prehensive survey o f this field. 
T h e major pathways o f mammalian m etabolism  of plant xenobiotics are outlined in the introductory 
chapter o f the book, and this is follow ed by a series o f chapters dealing with the individual metabolic fates 
of the various classes o f plant com pounds. T h e book is w ell illustrated w ith structural formulae o f the 
plant xenobiotics d iscussed, and w ith diagrams o f metabolic pathways. It w ill undoubtedly be regarded as 
the standard work o f reference in this field and w ill be o f particular interest and help to toxicologists, plant 
biologists and agricultural chem ists.
Encyclopaedia o f Antibiotics, by J o h n  S. G l a s b y , 2nd edition (John W iley and Sons, Chichester and N ew  
York, 1979.) [Pp. 467.] £24-00.
T h is  encyclopaedia appeared in its first edition in 1976. T h e discovery of many new antibiotics since that 
time, and the elucidation or revision of the chemical structures o f antibiotics previously described, has 
necessitated the publication o f a com pletely new edition of this valuable work. T h is new edition contains 
information on som e two thousand antibiotics, from Aabom ycin to Zygosporin G . T h e monograph of 
each antibiotic described, contains information on its chem ical formula and structure, physicochemical 
properties, biological source, m ethods o f preparation and purification, m icrobiology and toxicity, 
together with a selection o f the m ore important references. T h e  definition o f antibiotics, as included in this 
encyclopaedia, is the w idest one, namely, substances produced by, or derived from, living organisms 
which, at low concentrations, are capable o f inhibiting the life processes o f m icro-organisms or of 
malignant tumours. T h e volum e is superbly produced and is undoubtedly the foremost work o f reference 
in this important field o f m edicine and biology.
Selective Toxicity. By A d r ie n  A l b e r t . 6th edition (London: Chapman and H all, 1979.) [Pp. 576 +  86.] 
Price £15-00.
F ir s t  published in 1951, this classic treatise on the physicochem ical basis o f therapeutics and toxicology, 
has long been accepted as one o f the standard works in the field o f m edicinal chem istry and 
xenobiochem istry. T h is, the sixth edition, has been com pletely revised by the author, and contains a 
number o f new chapters and expanded treatments. Part One o f  the book, com prising the nucleus o f a 
course on selective toxicity, has a new chapter on the Correlation o f Structure w ith Biological Action, 
dealing w ith  the concept of biological receptors in its w idest aspects. In Part T w o  of the book, in which  
earlier topics are dealt w ith in greater depth, the chapters on Comparative Cytology and 
Pharmacodynamics have been extensively restructured, and new sections have been added on 
psychotherapeutic agents and their receptors, and the repair o f membranes by biologically active agents. 
Other new subjects or new  treatments include the enkephalins and endorphins, antiviral chemotherapy, 
m icrotubule inhibitors, H am m ett and T aft sigma values, and the Singer and N icolson m odel o f  
m embranes. N ow  with over 2000 references, and a text liberally illustrated with chemical formulae and 
figures and tables o f  biological data, this book w ill continue to retain its premier position as a text for 
molecular toxicologists, pharmacologists and biologists, and as an outstanding work o f reference.
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Forthcom ing Events 
Im pact o f chlorinated dioxins and related com pounds  
on the environm ent
Rome, Italy, 22—24 October 1980
T he International Association of Environmental Analytical Chemistry together 
w ith the International Society of Toxicological and Environmental Chemists, is 
organizing a workshop on chlorinated dioxins and related compounds.
T his meeting will be problem-oriented and will include all aspects of analytical 
chemistry, environmental chemistry, human toxicology as well as case studies such 
as the story of chlorodibenzodioxins and related compounds in effluents from 
incineration processes. Key areas will be treated by over 30 invited speakers. 
Emphasis will be placed on discussion and exchange of information possibly 
supported by a poster session.
T he preliminary programme and registration form can be obtained from: 
Professor D r O. Hutzinger, University of Amsterdam, Nieuwe Achtergracht 166, 
Amsterdam, T he Netherlands.
First International Sym posium  on Chromatography in  
B iochem istry, M ed icin e and Environm ental R esearch
Venice, Italy, 16—17 June 1981
and  
Eighth International Sym posium  on M ass Spectrom etry in  
Biochem istry, M ed icin e and Environm ental R esearch
Venice, Italy, 18—19 June 1981
Organized by the Italian Group for Mass Spectrometry in Biochemistry and 
Medjcine and the International Scientific Centre.
Scope
Both Symposia will discuss all the latest aspects of the relevant technique and its 
area of application, including biochemistry, medicine, toxicology, drug research, 
forensic science, clinical chemistry, and pollution. T he Symposia will consist of 
presentations from eminent invited speakers and free communications. Part of the 
Mass Spectrometry Symposium will be devoted to ‘Metabolism-directed design o f 
drugs’.
Contributed papers
Those wishing to present a communication (lasting up to 20 minutes, including 
discussion) are requested to submit the title and an abstract of no more than 200 
words, in English, before 31 January 1981. Notification of acceptance will be sent 
before 31 M arch 1981. Facilities will be available for poster communications.
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For further details of both Venice Symposia, please contact
D r Alberto Frigerio,
Instituto di Ricerche ‘M ario N egri’,
Via Eritrea 62,
20157 Milan,
Italy.
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Production and Properties of Antisera to Dexamethasone-Protein Conjugates
B y M in eo  C. D u m asia , D o n a ld  I. C hapm an, M ic h a e l  S. M oss and C a th y  O ’C o n n o r  
Racecourse Security Services’ Laboratories, Soham House, Snailwell Road, 
Newmarket, Suffolk CBS IDT, U.K.
(Received 5 March 1973)
Antibodies to dexamethasone 21-hemisuccinate conjugated to bovine serum albumin were 
produced in rabbits. Antisera diluted 1:3000 bound 50% of 90pg of [l,2-3H]dexametha- 
sone. The cross-reaction of the antisera with other synthetic and natural corticosteroids 
was measured.
In recent years the technique of radioimmunoassay 
has been developed as a very sensitive method for the 
determination of small amounts of steroids in bio­
logical fluids. The antisera produced to date have 
been mainly to protein conjugates of naturally occur­
ring steroids. The highly potent, synthetic, anti­
inflammatory steroids are used widely in both human 
and veterinary medicine. Determination of these 
steroids by g.l.c. is difficult because of the labile C-17 
side chain. Radioimmunoassay appears to offer a 
suitable technique for the determination of these 
compounds, and this paper describes the production 
and properties of antisera to protein conjugates of 
dexamethasone (9a-fluoro-l 1/3,17,21 -trihydroxy-16a- 
methylpregna-1,4-diene-3,20-dione.)
Materials and methods
Animals. Male lop-ear rabbits, weighing about 
4kg, were obtained from Goodchild and Bros., 
Crawley, Sussex, U.K. They were fed ad libitum on 
rabbit pellets from C. Hitchcock Ltd., Bures, Suffolk, 
U.K., and they were allowed free access to water.
The rabbits were bled by incision of a marginal ear 
vein and the blood was collected into glass bottles 
containing heparin (250 units/ml of blood). The blood 
was centrifuged within 1 h of being collected and the 
plasma stored at —20°C.
Chemicals. Bovine serum albumin (crystallized) 
was obtained from BDH Chemicals Ltd., Poole, 
Dorset, U.K.; Freund’s complete adjuvant was ob­
tained from Difco Laboratories, Detroit, Mich., 
U.S.A., and Tween 80 (polyoxyethylene sorbitan 
mono-oleate) from George T, Gurr Ltd., London 
S.W.6, U.K. Dexamethasone was a gift from Merck 
Sharp and Dohme Research Laboratories, Rahway, 
N.J., U.S.A., and [l,2-3H]dexamethasone (22Ci/ 
mmol) was obtained from The Radiochemical Centre, 
Amersham, Bucks., U.K. All reagents were of A.R. 
grade.
The following trivial names of steroids are used: 
aldosterone (11 /8,21 -dihydroxy-3,20-dioxopregn-4-
en-18-al), beclomethasone dipropionate (9a-chloro- 
11)3 - hydroxy -16/8 - methyl -17,21 - dipropionyloxy- 
pregna-l,4-diene-3,20-dione), betamethasone (9a- 
fluoro - 11)3,17,21 - trihydroxy - 16/8 - methylpregna-
1.4-diene-3,20-dione), chlormadinone acetate (17- 
acetoxy-6-chloropregna-4,6-diene-3,20-dione), corti­
costerone (1 l/S,21-dihydroxypregn-4-ene-3,20-dione), 
cortisol (1 l/3,17,21-trihydroxypregn-4-ene-3,20- 
dione), cortisone (17,21-dihydroxypregn-4-ene-3,ll,-
20-trione), equilenin [3-hydroxyoestra-l,3,5(10),6,8- 
pentaen-17-one], fludrocortisone (9a-fluoro-l 1/8,17,-
21-trihydroxypregn-4-ene-3,20-dione), flumethasone 
(6a,9a-diflu oro-11/8,17,21 -trihydroxy- 16a-methyl- 
pregna-l,4-diene-3,20-dione), fluocinolone (6a,9a- 
difluoro -11/3,21 - dihydroxy - 16a, 17a- isopropyl- 
idenedioxypregna-1,4-diene-3,20-dione), fluocorto- 
lone (6a-fluoro-l 1 /8,21 -dihydroxy-16a-methylpregna-
1.4-diene-3,20-dione), fluorometholone (9a-fluoro- 
11/8,17 - dihydroxy - 6a - methylpregna -1,4 - diene- 
3,20-dione), fluperolone acetate (21-acetoxy-9a- 
fluoro - 11/8,17 - dihydroxy - 21 - methylpregna - 1,4- 
diene-3,20-dione), fluprednisolone (6a-fluoro-l 1/8,17,- 
21-trihydroxypregna-l,4-diene-3,20-dione), flurand- 
renolone (6a-fluoro-l l/8,21-dihydroxy-l6a,17a-iso- 
propylidenedioxypregn-4-ene-3,20-dione), parameth- 
asone acetate (21-acetoxy-6a-fluoro-ll/8,17-dihyd- 
roxy-16a-methylpregna-l,4-diene-3,20-dione), pred­
nisone (17,21 -dihydroxypregna-l,4-diene-3,ll,20- 
trione), progesterone (pregn-4-ene-3,20-dione), testo­
sterone (17/8-hydroxyandrost-4-en-3-one) and tri­
amcinolone (9a-fluoro-l l/8,16a,17,21-tetrahydroxy- 
pregna-1,4-diene-3,20-dione).
Preparation o f dexamethasone 21-hemisuccinate. 
Dexamethasone 21-hemisuccinate was prepared by a 
method similar to that used by Erlanger et al. (1959) 
for deoxycorticosterone 21-hemisuccinate (21-hyd- 
roxypregn-4-ene-3,20-dione 21-hemisuccinate). The 
compound was recrystallized from aqueous methanol 
to give white needles, m.p. 137-139°C. The yield was 
33 % of theoretical. The purity and identity of the 
compound were confirmed by t.l.c., i.r. spectroscopy 
and n.m.r. spectroscopy.
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Preparation o f dexamethasone-protein conjugate. 
Dexamethasone 21-hemisuccinate was conjugated to 
bovine serum albumin by the mixed-anhydride 
method of Erlanger et ah (1959). The conjugate was 
purified by dialysis against water and then freeze- 
dried. U.v. spectroscopy indicated a ratio of 6mol of 
dexamethasone to 1 mol of bovine serum albumin, 
assuming a molecular weight of70000 for the protein. 
Acidic hydrolysis of the conjugate and t.l.c. of the 
hydrolysate confirmed the presence of covalently 
bound dexamethasone.
Injection o f rabbits. The dexamethasone-protein 
conjugate (4mg) was dissolved in 0.9% NaCl (1ml) 
and homogenized with Freund’s complete adjuvant 
(1 ml) and aq. 1 % (v/v) Tween 80 (1 ml). Each of five 
rabbits received the equivalent of 4mg of conjugate. 
A third of the homogenized conjugate was injected 
intramuscularly into each hind-leg and the final third 
was injected subcutaneously into five sites along the 
back. A sixth rabbit was used as a control. Booster 
doses of 2 mg of conjugate, homogenized as described 
above, were administered similarly to each rabbit at 
monthly intervals after preliminary immunization. 
Blood was collected 10 days after each booster dose 
had been given.
Detection and titre o f antibodies. The ability of the 
sera from immunized rabbits to bind dexamethasone 
was compared with that from a non-immunized 
rabbit. Serial dilutions of plasma in O.lM-phosphate
buffer, pH6.6 (Tulchinsky & Abraham, 1971), were 
prepared from 1:100 to 1:25 600.
The titre of the antibodies was checked by two 
different, complementary, methods. The first method 
was based on that of Tulchinsky & Abraham (1971) 
in which the unbound steroid was adsorbed on char­
coal, the bound radioactive steroid being measured 
in a Packard Tri-Carb model 3320 liquid-scintillation 
spectrometer. The efficiency of counting was 31 %. 
The second method was based on that of Arnold & 
James (1971), in which the bound steroid was pre­
cipitated with (NH4)2S04, the unbound radioactive 
steroid being measured by liquid-scintillation count­
ing.
Determination o f specificity. The specificity of the 
antisera to dexamethasone was tested by cross­
reaction of other steroids. Various amounts (20- 
1000g) of the steroid to be tested were dissolved in 
ethanol and treated with a 1:800 dilution of plasma 
from rabbit C, bleed 2, referred to below as plasma 
C2. The unbound steroid was adsorbed on charcoal 
and the bound radioactive dexamethasone was meas­
ured as described above.
Results and discussion
The rabbits lost weight and developed large 
abscesses at the sites of injections. Although these
100
1:16001:4001:100 1:6400 1:25600
Plasma dilution
-cta3oX3
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O
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dexamethasone (pg)
Fig. 1 .Percentage ofl4000d.p.m. (90pg) o f [1,2-3 H]dexamethasone bound by (a) various dilutions ofrabbit antisera 
and (b) 1:800 dilution o f  antiserum {plasma C2) in the presence o f non-radioactive dexamethasone
For experimental details see the text. The antisera used in (a) were: □, plasma B2; 
a , plasma E3; • ,  plasma Fx.
i, plasma C2; a ,  plasma D j;
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Table 1. Cross-reaction o f antisera raised against 
dexamethasone-protein conjugates with other steroids
For experimental details see the text. The percentage 
cross-reaction is expressed as (x/y) x 100, where x  is 
the mass of non-radioactive dexamethasone and y  is 
the mass of cross-reacting steroid required to produce 
50 % inhibition of the binding of [l,2-3H]dexametha- 
sone by the antisera. Antiserum (plasma C2) was 
diluted 1:800. Negligible (<1 %) cross-reaction was 
given by fluocortolone, fluocinolone acetonide, flu- 
prednisolone, fluorometholone and triamcinolone, 
and zero cross-reaction by chlormadinone acetate, 
flurandrenolone acetonide and prednisone; the 
natural steroids aldosterone, corticosterone, cortisol, 
cortisone, equilenin, progesterone and testosterone 
also gave zero cross-reaction.
Steroid Cross-reaction (%)
Dexamethasone 100
Paramethasone acetate 19
Flumethasone 11
Beclomethasone dipropionate 5
Betamethasone 4
Fludrocortisone 2
Fluperolone acetate 2
abscesses were initially sterile, they became infected 
when they ruptured. The abscesses healed and the 
rabbits put on weight after they had been treated and 
injections of conjugate had been stopped. Haning 
et al. (1972) reported that three of six sheep died while 
being immunized with aldosterone hemisuccinate 
conjugated to bovine serum albumin. There appear to 
have been very few reports of adverse reactions of 
animals to immunization with steroid-protein con­
jugates. Whether this is due to such reactions not 
occurring or to their not being reported is not 
known.
Three of the five rabbits produced a reasonable 
concentration of antibodies to the dexamethasone- 
protein conjugates. The two methods of detecting 
antibodies gave very similar results. The percentage 
of dexamethasone bound was dependent on plasma 
dilution. With the characoal method, the plasma from 
the three rabbits bound 50% of the 14000d.p.m. 
(90pg) of the [l,2-3H]dexamethasone when diluted 
1:1900 (plasma B2), 1:3100 (plasma C2) and 1:1600 
(plasma Fi). The plasma from the control rabbit 
(plasma A2) bound only 3 % at a dilution of 1:3000. 
The percentage of [l,2-3H]dexamethasone bound 
fell to 25% at dilutions of 1:5100 (plasma B2),
1:5700 (plasma C2) and 1:4200 (plasma Fx), whereas 
the amount bound by the control remained the same 
on dilution to 1:6000 (Fig. la).
The concentrations of antibodies produced are 
comparable with those raised to conjugates of 
natural corticosteroids such as corticosterone (Under­
wood & Williams, 1972), deoxycorticosterone 
(Arnold & James, 1971; Rose & Newsome, 1972) and 
deoxycortisol (17,21-dihydroxypregn-4-ene-3,20- 
dione) (Abraham et al, 1972), but are lower than 
those often raised to natural protein hormones 
(Kirkham & Hunter, 1971).
A plasma dilution of 1:800 was chosen for antisera 
from rabbit C (plasma C2) for assessing the specificity. 
Addition of increased amounts of non-radioactive 
dexamethasone progressively lowered the percentage 
of radioactive dexamethasone bound.
The standard curve is linear over the range 25- 
200pg of dexamethasone and should enable this 
amount of steroid to be measured (Fig. lb).
The cross-reaction of the antisera with other syn­
thetic and natural corticosteroids is given in Table 1.
Cross-reaction of the antisera with synthetic corti­
costeroids ranged from zero to 19% (as defined in 
Table 1). However, the most important fact is that 
none of the natural steroids examined exhibited any 
cross-reaction. This means that this antisera can be 
used to measure dexamethasone in biological fluids 
provided that any of the steroids with appreciable 
cross-reaction have not been administered as well.
Attempts to correlate immunological cross-reaction 
with structure of the steroids indicated that stereoiso­
merism was important. Conversion of a 16a-methyl 
group into a 16jS-methyl group (betamethasone) 
diminished the cross-reactivity from 100 to 4%. 
Antiserum raised to 17j8-oestradiol behaves in a 
similar way when 17a-oestradiol is tested (Midgley & 
Niswender, 1970). Our antiserum was very sensitive 
to changes in the D-ring of the steroid, and 
appreciable cross-reaction (>10%) occurred only 
when both 17a-hydroxyl and 16a-methyl groups were 
present (compare dexamethasone with betamethasone 
and triamcinolone). The antisera also ‘recognized’ 
changes in the B-ring of the steroid, because the 
addition of a 6a-fluoro atom (flumethasone) dimi­
nished the cross-reaction from 100 to 11 %.
We thank Dr. G. Ayrey, Mr. R. Dunlop and Dr. H. R. 
Morris for obtaining the n.m.r. spectra and for help in 
interpreting them.
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Studies related to the metabolism of anabolic 
steroids in the horse: the identification of 
some 16-oxygenated metabolites of testosterone 
and a study of the phase II metabolism.
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1) Isomers of 3,17-dihydroxyandrostan-16-one,
3,16-dihydroxyandrostan-17-one and 
androstane-3,16,17-triol have been identified 
as urinary metabolites of testosterone.
2) Following XAD-2 extraction of urine samples, 
Sephadex LH-20 chromatography was used to 
separate the extract into conjugate groups. 
Metabolites obtained after hydrolysis of the 
conjugates have been investigated by g.l.c.-* 
mass spectrometry.
3) Testosterone, 3,17-dihydroxyandrostan-16-one 
and 3,16-dihydroxyandrostan-17-one were 
found only in the sulphate fraction.
5o-Androstane-3(?,170-diol and two isomeric 
androstane triols were present mainly in 
this fraction and 5a-androstane-30,17ft-diol 
was a minor component. In the glucuronide 
fraction 5a-androstane-30,17a-diol was the 
major metabolite present and 5a-androstane-30, 
170-diol and the two isomeric triols were 
minor components.
Introduction
14
In a previous publication on the metabolism of (4- C)testosterone 
in the horse, the isolation and identification of testosterone and its 
reduced C^gO^ metabolites 33-hydroxy-5a-androstan-17-one, 5a-androstane- 
-33,170-diol and 5a-androstane-33>17a-diol have been reported (Houghton 
and Dumasia 1979). Other investigators have also reported the isolation 
and identification of the reduced C^g02 metabolites of testosterone 
after its administration to animals and man (West 1951, Burnstein et 
al. 1955, Archer, Scratcherd and Taylor 1965, Taylor and Scratcherd 1967, 
Mauvais-Jarvis et al. 1968).
This paper describes the isolation and identification of some
saturated, 16-oxygenated ketonic and non-ketonic metabolites of
14(4- C)testosterone from horse urine. Steroids of this type have 
previously been identified in adult human urine (Jdnne 1971) and in the 
faeces and cord blood of infants (Shackleton et al. 1970). Preliminary 
results on the nature of conjugation of testosterone and its C O±j Z
metabolites were based on observations using enzyme (Helix pomatia) and 
hot acid hydrolysis (Houghton and Dumasia 1979). In the present study, 
in order to obtain more explicit information, urinary .conjugates isolated 
by Amberlite XAD-2 extraction, were separated into conjugate groups on 
Sephadex LH-20 columns and after hydrolysis the C O  and C O  metabolit
J- \J  C* 1 \7 O
present in the glucuronide and sulphate fractions were identified by g.l. 
mass spectrometry. '
Materials and Methods
Gas chromatography and combined gas chromatography-mass spectrometry.
Analytical g.l.c. was carried out using a Perkin-Elmer F-17 gas 
chromatograph fitted with a coiled glass column (2 m x 6.4 mm o.d.,
2 mm i . d . )  packed w ith  1.5% 0V-1 on Gas Chrom Q. was used as c a r r ie r
Combined g.l.c.-mass spectrometry was carried out using a Finnigan 
4000 series gas chromatograph-mass spectrometer linked to a Finnigan 6110 
data system. A coiled glass column (1.8 m x 6.4 mmo.d., 2 mm i.d.) 
packed with 1.5% 0V-1 on Gas Chrom Q was used. The column was 
temperature-programmed from 180° to 260° at 5°/min and He was used as 
carrier gas.
Solvent and chemicals
Amberlite XAD-2 resin was purchased from BDH Chemicals, Ltd., Poole 
Dorset, U.K., Sephadex LH-20 from Pharmacia Fine Chemicals, London, U.K. 
and p-toluene sulphonic acid, testosterone glucuronide sodium salt, 
androsterone sulphate sodium salt and 19-nortestosterone from Sigma London 
Chemical Co., Kingston-upon-Thames, Surrey. Helix pomatia digestive 
juice (Industrie Biologique Francaise) was purchased from Uniscience Ltd. 
Cambridge, U.K. and contained a minimum of 100,000.units of 
3-glucuronidase (Fishman) and 1,000,000 units sulphatase (Roy) per ml. 
Other solvents and chemicals were obtained as previously described 
(Houghton and Dumasia 1979).
Administration to animals
Before administration of the drug urine samples from each animal
were collected as control specimens. The intramuscular administration 
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of (4- C ) testosterone to two cross-bred gelded ponies and the 
collection of timed sequential urine samples after its administration 
have been reported previously (Houghton and Dumasia 1979).
Isolation of urinary metabolites
Samples (50 ml) of pooled urine from the first 24 h of collection 
were adjusted to pH 4.8 and incubated with Helix pomatia digestive juice 
(0.25 ml) at 37°C for 48 h. After hydrolysis the urine was extracted
with ethyl acetate (2 x 100 ml). The ethyl acetate was washed with NaOH 
(0.1 M, 2 x 50 ml), then dried over anhydrous Na£S0^ and evaporated to- ' 
dryness under reduced pressure at 4-0°. Ethyl acetate was used in order 
to isolate the more polar metabolites, though it was recognised that 
its hydrophilic nature may prevent complete resolution of ’free’ and
- i<
. 1conjugated1 material.
After mixed enzyme hydrolysis and extraction, the volume of the 
residual urine was adjusted to 50 ml with deionised water and cone. HC1 
(7.5 ml) was added. The mixture was boiled under reflux for 1 h, cooled 
and the neutral extract was isolated by solvent extraction as described 
above. Aliquots of the urine and ethyl acetate were taken at each stage 
to determine the total radioactivity.
Total acid hydrolysis (acid hydrolysis without prior enzymic treatment).
Samples (50 ml) of pooled urine from the first 24- h of collection 
were boiled under reflux with conc. HC1 (7.5 ml) for 1 h, and the neutral 
extract was isolated as described above.
Studies on steroid conjugates
Samples (50 ml) of pooled urine (0-24- h) were passed down a column 
of Amberlite XAD-2 resin (50,0 g; column diam; 30 mm) (Bradlow 1968).
After washing the column with deionised water (2 x 50 ml), the material 
remaining on the column was eluted with methanol (3 x 50 ml) and the 
methanol was evaporated under reduced pressure at 40? The residual material 
was dissolved in chloroform - methanol (1:1, v/v; 2 ml) made 0.01M with 
respect to NaCl and fractionated on a Sephadex LH-20 column (10.0 g; 
column diam. 20 mm) prepared in and eluted with the same solvent mixture 
(VihkO 1966, Eriksson and Gustafsson 1970). Fractions (30 x 5 ml) were 
collected and the material remaining on the column was eluted with methanol 
An aliquot (0.1 ml) of each fraction was taken to determine the total 
radioactivity. Fractions containing the resolved metabolites were 
combined and the solvent removed under reduced pressure at 40°.
Hydrolysis of the steroid conjugates isolated by Sephadex LH-20 
chromatography.
The fraction containing the glucuronic acid conjugates was 
dissolved in 0.5 M sodium acetate buffer, pH 4.5 (50 ml) and incubated 
with Helix pomatia digestive juice (0.25 ml) at 37° for 48 h. After 
hydrolysis the neutral extract was-isolated as described above.
The fraction containing the sulphuric acid conjugates was. 
dissolved in methanol (1.0 ml) and solvolysed at 37° for 24 h in ethyl • 
acetate (50 ml) acidified with 2M ^SO^ (Vihko 1966). After solvolysis 
the ethyl acetate phase was washed with aqueous saturated NaHC03 
solution until it was alkaline and then with saturated NaCl solution 
(1 x 50 ml). The ethyl acetate was dried over anhydrous Na2S04 and 
evaporated to dryness under reduced pressure at 40^.
19-Nortestosterone (1 mg), testosterone glucuronide (Na salt)
(1 mg) and androsterone sulphate (Na salt) (1 mg) were added to an 
Amberlite XAD-2 extract of a pre-administration urine sample (50 ml) 
and the extract was chromatographed on a Sephadex LH-20 column, using 
the above conditions. The glucuronide and sulphate fractions were 
isolated and after hydrolysis, an aliquot (- 1/6) of each fraction was 
derivatised (M0-TMS) and analysed by g.l.c.-mass spectrometry.
Kieselgel H column chromatography
*
The neutral extracts were fractionated on Kieselgel H (5.0 g; 
column diam. 15 mm) using 1,2-dichloroethane-ethanol (98:2, v/v) as 
eluant. After collection of 30 x 3 ml fractions the eluant was changed 
to 1,2-dichloroethane-ethanol (95:5, v/v)/ and 30 further 3 ml fractions 
' were collected. The material remaining on the column was eluted with
5 -
methanol. An aliquot (0.1 ml) of each fraction was taken to determine 
total radioactivity. Fractions containing the resolved metabolites 
were combined and the solvent removed under reduced pressure at 40°. 
Aliquots from each fraction were analysed by g.l.c. and g.l.c.-mass 
spectrometry as their trimethylsilyl (TMS) and 0-methyloxime- 
trimethylsilyl (MO-TMS) derivatives (Houghton and Dumasia 1979).
Preparation of O-isopropylidene-trimethylsilyl (acetonide-TMS) 
derivatives (Bailey 1967).
The urine extracts were dissolved in dry acetone (2 ml) containing 
p-toluene sulphonic acid (2 mg). Anhydrous CaClg (50 mg) was added 
and the reaction mixture was shaken for 4 h. After centrifugation, 
the supernatant was decanted into a glass tube and the solvent removed 
in a stream of N2 at 40°. The residual material was dissolved in 
benzene (10 ml), and the solution was washed with NaOH (1M,1 x 2 ml) 
and then with deionised water (1 x 2 ml). The benzene was dried over 
anhydrous NagSO^ and evaporated to dryness. Silylation of the 
acetonides was carried out at 60° for 2h using N,0-bis-(trimethyl- 
silyl)acetamide (0.1 m) and trimethylchlorosilane (0.025 ml).
Results
Isolation of urinary metabolites
Using the solvent extraction procedure described neutral extracts 
of 0-24 h urine samples were isolated following enzyme hydrolysis, hot 
acid hydrolysis of the residual urine from enzyme hydrolysis and totkl 
acid hydrolysis. Chromatography on Kieselgel H of these neutral 
extracts resolved six radioactive fractions in each case (figures la» 
lb, und lo, llorno U). Siniil.ur olulion pulLurnu wort) obtuined for
- 6 -
Horse A. The distribution of urinary activity in the extracts 
and in the fractions from Kieselgel H chromatography is given in 
table 1.
, (Insert figure 1 and table 1)
I d e n t i f i c a t io n  o f  m e ta b o lite s  by g . l .c . -m a s s  sp e c tro m e try
33-Hydroxy-5a-androstan-17-one (II, figure 3) has already been 
identified as a component in fractions al, bl and cl (figure 1), and 
testosterone (I) as a major component in fractions a2 and c2. 
5a-Androstane-33,17a-diol (III) was identified in fractions a3 and 
b3 and 5a-androstane-33?173-diol (IV) in fractions a3 and c3 and as a 
trace component in fraction b3 (Houghton and Dumasia 1979).
In addition to the two isomeric diol metabolites, fractions
a3, b3 and c3 (figure 1) each contained another metabolite which on 
the basis of its molecular weight and mass spectral fragmentation 
pattern was identified as an isomer of a dihydroxymonoketo androstane. 
The TMS derivative of this compound had a retention time of 12.2 min 
and showed a molecular ion at m/z 450 with fragment ions at m/z 435, 
216, 215 and 129 (base peak). The MO-TMS derivative (R^ 13.3 min) 
showed a weak molecular ion at m/z 479 and fragment ions at m/z 464, 
448, 358, 174 and 158. These mass spectra were identical' with the 
mass spectra of the TMS and MO-TMS derivatives of 33>17 3-dihydroxy-5a- 
-androstan-16-one. Based on these findings, this metabolite was 
identified as an isomer of 3,17-dihydroxyandrostan-16-one (V).
Analysis by g.l.c.-mass spectrometry of fractions a4-, b4 and c4 
(figure 1), as their TMS and MO-TMS derivatives showed the presence
aSal a2
a4 a6
r^2 b6
cl c2 c3 I c4 c5
c6
figure 1* Fractionation by Kieselgel H column chromatography of 
neutral urinary extracts from Horse B, obtained after 
(a) total aoid hydrolysis (b) enzyme hydrolysis and
to
(c) acid hydrolysis of the residual urine following 
enzyme hydrolysis and extraction*
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of two isomeric dihydroxymonoketo androstanes. The TMS and MO-TMS
derivatives of the minor metabolite had the same retention times and
mass spectra as the component identified in fractions a3, b3 and’c3.
The mass spectrum of the TMS derivative of the major metabolite
(R, 11.2 min) had a molecular ion at m/z 450 and fragment ions at
t
m/z 435, 216, 215 and 117 (base peak). The MO-TMS derivative
(R^ _ 12.3 min) showed a weak molecular ion at m/z 479 and fragment
ions at m/z 464, 448, 358 and 174. As these mass spectra were 
identical with the mass spectra of the TMS and MO-TMS derivatives of 
30,16a-dihydroxy-53-androstan-17-one, this metabolite was identified 
As an isomer of 3,16-dihydroxyandrostan-17-one (VI).
The metabolites of testosterone in fractions a5 and b5 could not 
be identified by g.l.c.-mass spectrometry possibly because' they were 
present in very small amounts.
Analysis of the TMS and MO-TMS derivatives of fractions a6, b6 
and c6 (figure 1), by g.l.c.-mass spectrometry showed the presence of 
two compounds, the mass spectra of which .showed weak molecular ions at 
m/z 524 and fragment ions at m/z 509, 434, 344, 191 and 147, From the 
molecular weight and the mass spectral data these metabolites were 
identified as isomeric androstane-3,16,17-triols (VII) (Grdte and 
Spiteller 1977). The cis configuration of the C16,17-hydroxyl groups 
in the D-ring was confirmed by the fact that both isomers formed an 
acetonide. The mass spectrum of the acetonide-TMS derivatives showed 
ions at m/z 405 (M* - 15) and 255 (M^ - (15 + 6 0 + 9 0 ) ) .
Studies on the steroid conjugates
After Amberlite XAD-2 extraction of the urine, Sephadex LH-20 
column chromatography was used to separate the methanol extracts into
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conjugate groups (Vihko 1966, Eriksson and Gustafsson 1970). Two 
major fractions were resolved, fraction G (between 16-45 ml of effluent) 
containing the glucuronic acid conjugates and fraction S (between
51-120 ml of effluent) containing the sulphuric acid conjugates
V'
(figure 2). After enzyme hydrolysis of the glucuronides and solvolysis 
of the sulphates the neutral extracts were isolated and chromatographed 
on Kieselgel H columns. The percentage distribution of urinary C m  
the Amberlite XAD-2 extracts, the fractions G and S from Sephadex LH-20 
chromatography,.the neutral extracts isolated after hydrolysis of the 
Conjugates and the fractions G1 to G6 and SI to S6 obtained following 
Kieselgel H chromatography of the netural extracts is given in table 2.
(Insert figure 2 and table 2)
To confirm the separation, using Sephadex LH-20, into free plus
glucuronic acid conjugates (fraction G, 16-45 ml) and sulphate conjugates
(fraction S, 51-120 ml), these fractions were isolated following
Chromatography of an XAD-2 extract containing 19-nortestosterone,
testosterone glucuronide and androsterone'sulphate. After enzyme
hydrolysis, the presence in fraction G of 19-nortestosterone and
testosterone, as the MO-TMS derivatives, was confirmed using g.l.c.-
mass spectrometry. Similarly, following solvolysis, the presence of
/
androsterone as the MO-TMS derivative was confirmed in fraction S.
For each horse, the MO-TMS derivative of fraction SI proved to be 
extremely complex on analysis by g.l.c.-mass spectrometry and the 
metabolites present in these fractions could not be identified. 
Testosterone (I) was identified only in fraction S2. 3,17-Dihydroxy-
androstan-16-one (V) was a major metabolite in fraction S3 and a minor 
component in fraction S4. 3,16-Dihydroxyandrostan-17-one (VI) was
present only in fraction S4.

Figure 2. Separation by Sephadex LH-20 column chromatography of an 
Amberlite XAD-2 extract of urine (Horse A) into glucuronic 
acid (G) and sulphate (S) conjugates.
Horse A Horse B
A , 97 94
Fraction G Fraction S Fraction G Fraction S
B 19.1 68.1 22.5 63.9
C 15.5 62.5 19.8 59.6 :
D Fraction 1 1.7 12.7 1.8 7.1
Fraction 2 1.0 20.3 1.1 . 18.8
Fraction 3 4.4 9.0 6.1 7.0
Fraction 4 - 5.8 - • 4.9
! Fraction 5 1.8 !. 4 1.2 2.6
Fraction 6 1.0 4.7 • 3.6 5.7
!: ' * Methanol wash 4.5 5.8 4.8 10.3
Table 2. Percentage distribution of urinary 14C in (A) the Amberlite 
XAD-2 extract of urine samples (B) the glucuronic acid (G) 
and sulphate (S) fractions isolated by Sephadex LH-20 
chromatography of the Amberlite XAD-2 extracts (C) the 
neutral extracts obtained after hydrolysis of the conjugates 
and (D ) the fractions G1-G6 and S1-S6 isolated by Kieselgel 
H chromatography of the neutral extracts.
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Fractions G1 and G2 contained only a small percentage of the 
urinary and none of the metabolites present in these fractions 
could be identified by g.I.e.-mass spectrometry. In fraction G3 
from both horses, 5a-androstane-.33,17a-diol (III) was a major metabolite 
and 5a-androstane-3p,17p-diol (IV) was only a minor component. In 
fraction S3, however, 5a-androstane-3$,173-diol (IV) was a major 
metabolite whilst 5a-androstane-33,17a-diol (III) was only a minor 
component.
Fractions G5 and S5 again contained only a small percentage of the 
Urinary '^C, and the metabolites present in these fractions could not 
be identified. The two isomeric androstane-3,16,17-triols (VII) were 
identified in fractions G6 and S6.
Normal pre-administration urine samples collected from both 
animals were analysed by the same experimental procedures. Using g.l.c.- 
mass spectrometry and selected ion monitoring none of the metabolites 
identified was found in these samples.
Discussion
The isolation and identification of testosterone (I), 3f3-hydroxy- 
*-5a-androstan-17-one (II), 5a-androstane-33,17o-diol (III) and 5a- 
-iandrostane-33,173-diol (IV) as urinary metabolites of (4-^C)testosterone 
iafter its administration to cross-bred gelded ponies have already been : 
described (Houghton and Dumasia 1979), These metabolites were identified 
by g.I.e.-mass spectrometry following hydrolysis of the steroid 
conjugates, solvent extraction and chromatography of the neutral extracts 
on Kieselgel H using 1,2-dichloroethane-ethanol (98:2, v/v) as eluant.
Two additional metabolites have now been identified in the chromatographic
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fractions a3, b3 and c3 and a4, b4 and c4 (figure 1) eluted from 
the column using this eluant. On the basis of the mass spectral 
data, these two metabolites have been identified as isomers of
3,17-dihydroxyandrostan-16-one (V) and 3,16-dihydroxyandrostan- 
-17-one (VI).
14 .
: In addition, two further fractions containing C activity
were eluted from the column when, after the elution of 90 ml of 
eluant, the proportion of the ethanol was increased from 2% to 5% 
(fractions a5 and b5 and a6, b6 and c6, figure 1). The metabolites 
^present in fractions a5 and b5 could not be identified, however, 
two isomers of androstane-3,16,l7-triol (VII) were identified as 
components of fractions a6, b6 and c6. The cis configuration of 
the Cl6,17-hydroxyl groups was confirmed by the formation of the 
acetonide derivative.
All the saturated cig03 steroid metabolites identified from the 
24 h urine samples after both enzyme and hot acid hydrolysis were 
oxygenated at C16; no unsaturated 16-oxygenated metabolites were 
identified. 16-Hydroxylated ketonic C19 steroid sulphates have been 
reported in human urine (Jhnne and Vihko 1969) and 5-androstane- 
>-3,16,17-triols are frequently found in biological fluids (Laatikainen 
1970, JUnne 1971, Brooksbank et al. 1972). 16-0xygenated metabolites 
Of 19-nortestosterone have also been identified in thoroughbred horse 
urine (Houghton and Dumasia (1980).
Studies on extracts of urine after mixed enzyme hydrolysis and 
after subsequent hot acid hydrolysis of the residual urine from enzyme 
hydrolysis showed the presence of 5a-androstane-38-17a-diol (III) only 
in the enzyme-hydrolysable extract and testosterone (I) only in the 
acid-hydrolysable extract. 5a-Androstane-3S.173-diol (IV),
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3p-hydroxy-5a-androstane-17-one (II), the isomeric dihydroxymonoketo 
androstanes (V and VI) and the androstane-3,16,17-triols (VII) were 
found mainly in the acid hydrolysable extract.
When the urinary steroid metabolites were separated into the 
conjugate groups, using Sephadex LH-20 chromatography, about 66% of. 
the urinary 14C was present in the sulphate fraction, and about 20% 
in the glucuronide fraction (table 2). From the results obtained by 
extraction of the urine following enzyme hydrolysis (table 1), it is 
clear that incubation of the urine with Helix pomatia digestive juice 
only partially hydrolysed some of the sulphuric acid conjugates thus 
giving a false profile of the metabolites. Hot acid hydrolysis of the 
urine was unsatisfactory because it caused some decompositions of the 
steroids giving low recoveries; this was evident from the considerable 
difference in the percentage of the testosterone fraction isolated by 
column chromatography following solvolysis (20.3% and 18.8%, fraction S2, 
Horses A and B, table 2) and by hot acid hydrolysis of the residual 
urine from enzyme hydrolysis (9.3% and 8.2%, fraction 2, Horses A and B, 
table 1).
After hydrolysis of the conjugates and analysis of the individual 
fractions from chromatography, testosterone (I), 3,17-dihydroxyandrostan- 
-16-one (V) and 3,16-dihydroxyandrostan-17-one (VI) were found only in 
the sulphate fraction. 5a-Androstane-3$,173-diol (IV) and the two 
isomeric androstane-3,16,17-triols (VII) were present mainly in this 
fraction and 5a-androstane-3p,17a-diol (III) was a minor component. In 
the glucuronide fraction 5a-androstane-38»17a-diol (III) was the major 
metabolite and 5a-androstane-33,173-diol (IV) and the two isomeric 
androstane-3,i6,17-triols (VII) were minor components. The urinary 
metabolites of testosterone identified in the present study are 
summarised in figure 3.
12 -
(Insert figure 3)
After administration of (4-14C)testosterone to the horse, 25% 
of the administered dose was excreted in 24 h, 37% being excreted • '
in 48 h. This is significantly slower than the excretion of administered 
testosterone in man, where 90% of the dose is excreted in 48 h (Fotherby 
and James 1972). In the horse the majot proportion of the urinary 
metabolites are 17-hydroxy compounds whereas in man the major urinary 
metabolites are the 17-oxo steroids, androsterone and etiocholanOlone,
A study of phase II metabolism in the horse indicates that the 
178-hydroxy metabolites are conjugated mainly with sulphate and the 
l7ft-hydroxy metabolites with glucuronic acid; the major portion of the 
urinary metabolites (66%) are excreted as sulphate conjugates. This 
Again contrasts with the metabolism in man where the urinary metabolites 
of testosterone are essentially conjugated with glucuronic acid 
(Baulieu and Robel 1970).
OH
h i
ii
H0‘
H
0
OH
IV
HO
HO
lA A H
VII
OH 
^ OH
HO
Urinary metabolites of (4-^C)testosterone in the horse. 
(I) Testosterone, (II) 33”-hydroxy-5a-androstan-17-one,’ 
(III) 5a-androstane-33>17a-diol, (IV) 5a-androstane-33» 
-173-diol, (V) 3,17-dihydroxyandrostan-cl6-One,
(VI) 3,16-dihydroxyandrostan-17-one and (VII) androstane- 
-3,16,17-triol.
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